# 2025年11月8日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. ESR1突变型转移性乳腺癌中与elacestrant治疗结局相关的临床和基因组学因素

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201834](https://pubmed.ncbi.nlm.nih.gov/41201834)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41201834
**DOI：** 10.1158/1078-0432.CCR-25-3033

### 第一部分 原文与翻译

**英文原标题：** Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer.

**英文摘要原文：**
PURPOSE: ESR1 mutations mediate resistance to antiestrogen therapy in hormone receptor-positive metastatic breast cancer (MBC). Elacestrant, an oral selective estrogen receptor degrader, improves progression-free survival over standard endocrine therapy in ESR1-mutant MBC. We assessed real-world elacestrant use and clinical-genomic factors associated with outcomes.

EXPERIMENTAL DESIGN: This study used the GuardantINFORM database, linking >42,000 real-world breast cancer cases with sequencing and claims data. We included patients with activating ESR1 mutations detected <6 months before elacestrant initiation (January 2023-March 2024). Outcomes of time-to-treatment-discontinuation (TTD), time-to-next-treatment (TTNT), and overall survival were estimated with Kaplan-Meier and Cox regression analysis, adjusting for clinical variables.

RESULTS: We identified 756 patients (76% with prior CDK4/6 inhibitor and 38% prior chemotherapy exposure), and 742 (98.2%) were evaluable for outcomes. Median TTNT was 6.4 months, and TTD was 4.6 months. In those with ≤1 prior lines of metastatic therapy, TTNT was 8.8 months, compared to 6.0 months in the third-line setting. Prior fulvestrant exposure trended toward shorter treatment duration (HR 1.19, 95% CI 0.91-1.56). Higher ESR1 polyclonality (≥4 alterations; 11% of patients) correlated with shorter TTNT of 5.2 months (HR 1.44, 95% CI 1.01-2.06), but efficacy was consistent across ESR1 alleles (e.g., Y537S, D538G). Disease with dual ESR1 and PI3K-pathway mutations (PIK3CA, AKT1, PTEN) had a median TTNT of 5.2 months.

CONCLUSIONS: In ESR1-mutant MBC, elacestrant treatment durations support the routine use of elacestrant monotherapy in appropriately selected patients. For patients with concurrent ESR1 and PI3K-pathway mutations, single-agent activity was comparable to outcomes observed in phase III studies.

**中文摘要译文：**
目的：在激素受体阳性的转移性乳腺癌（MBC）中，ESR1突变介导了对雌激素拮抗剂治疗的耐药性。Elacestrant是一种口服选择性雌激素受体降解剂，在ESR1突变的MBC中，其无进展生存期优于标准内分泌治疗。我们评估了elacestrant的真实世界使用情况以及与治疗结局相关的临床基因组学因素。

实验设计：本研究使用了GuardantINFORM数据库，该数据库关联了超过42,000例真实世界乳腺癌病例的测序和诊疗数据。我们纳入了在elacestrant治疗开始前（2023年1月至2024年3月）不到6个月内检测到ESR1激活突变的患者。采用Kaplan-Meier和Cox回归分析评估了至治疗中止时间（TTD）、至下一次治疗时间（TTNT）和总生存期，并对临床变量进行了校正。

结果：我们共确定了756名患者（其中76%既往接受过CDK4/6抑制剂治疗，38%接受过化疗），其中742名（98.2%）可进行结局评估。中位TTNT为6.4个月，中位TTD为4.6个月。在既往接受过≤1线转移性治疗的患者中，TTNT为8.8个月，而在三线治疗的患者中为6.0个月。既往使用氟维司群的经历有缩短治疗持续时间的趋势（HR 1.19, 95% CI 0.91-1.56）。较高的ESR1多克隆性（≥4个变异；占11%的患者）与较短的TTNT（5.2个月）相关（HR 1.44, 95% CI 1.01-2.06），但疗效在不同的ESR1等位基因（如Y537S, D538G）之间保持一致。同时存在ESR1和PI3K通路突变（PIK3CA, AKT1, PTEN）的患者，中位TTNT为5.2个月。

结论：在ESR1突变的MBC中，elacestrant的治疗持续时间数据支持在适当选择的患者中常规使用elacestrant单药治疗。对于同时存在ESR1和PI3K通路突变的患者，其单药治疗的活性与III期研究中观察到的结局相当。

### 第二部分 AI 大师评价

本研究基于一个大型真实世界数据库，旨在评估口服SERD药物elacestrant在ESR1突变转移性乳腺癌患者中的实际疗效，并探索相关的临床和基因组学影响因素。研究的关键发现证实了elacestrant在真实世界中的临床价值，尤其在治疗线数靠前的患者中获益更佳，同时创新性地揭示了ESR1多克隆性是其疗效的负向预测因子。这项研究为elacestrant的临床应用提供了重要的真实世界证据，对其精准用药和患者筛选具有指导意义。

---

## 2. lncRNA LISRR组装癌症特异性核糖体，抑制黑色素瘤抗肿瘤免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201478](https://pubmed.ncbi.nlm.nih.gov/41201478)
**期刊：** The Journal of experimental medicine
**PMID：** 41201478
**DOI：** 10.1084/jem.20251507

### 第一部分 原文与翻译

**英文原标题：** The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumor immunity.

**英文摘要原文：**
Gains of chromosome 12p11.21, encoding for the cancer-specific lncRNA LISRR, correlate with poor survival across different cancers. In melanoma, LISRR is upregulated in immunotherapy-resistant patients to contribute to the generation of drug-tolerant cells by activating an immune-suppressive translational program, affecting the synthesis of PD-L1 and of the glycocalyx. Accordingly, downregulation of LISRR initiates robust immune responses and resensitizes to immunotherapy ex vivo and in vivo. The use of glycans to evade immunity exhibits shared characteristics with the testis, where defects in the glycocalyx cause infertility. Mechanistically, we showed that LISRR affects the ribosome core composition and recruits deleted in azoospermia-associated protein 1 to polysomes to prime the integrated stress response. Our study reveals the contribution of lncRNAs to the generation of cancer-specific ribosomes and identifies an RNA-based strategy to overcome resistance to immune checkpoint blockade.

**中文摘要译文：**
编码癌症特异性lncRNA LISRR的12号染色体p11.21区域扩增，与多种癌症的不良生存率相关。在黑色素瘤中，LISRR在免疫治疗耐药患者中表达上调，通过激活一个免疫抑制性的翻译程序，影响PD-L1和糖萼的合成，从而促进耐药细胞的生成。因此，在体外和体内实验中，下调LISRR的表达可引发强有力的免疫应答，并恢复细胞对免疫治疗的敏感性。利用聚糖逃避免疫的机制与睾丸组织有相似之处，在睾丸中，糖萼缺陷可导致不育。机制研究表明，LISRR影响核糖体的核心组成，并将无精子症缺失相关蛋白1（DAZAP1）招募至多聚核糖体，从而启动整合应激反应。本研究揭示了lncRNA在癌症特异性核糖体生成中的作用，并提出了一种基于RNA的策略，以克服对免疫检查点阻断疗法的耐药性。

### 第二部分 AI 大师评价

该研究旨在阐明长链非编码RNA (lncRNA) LISRR在介导黑色素瘤免疫治疗耐药中的关键作用及其分子机制。研究发现，LISRR通过重塑核糖体核心组分，组装出“癌症特异性核糖体”，进而激活一个免疫抑制性的翻译程序并启动整合应激反应，最终导致肿瘤免疫逃逸。这项工作的创新之处在于首次揭示了lncRNA可调控核糖体异质性以影响肿瘤免疫微环境，并将LISRR确定为一个极具潜力的治疗靶点，为克服免疫检查点抑制剂耐药提供了全新的RNA层面干预策略。

---

## 3. 揭示结直肠癌中增殖性肿瘤细胞与细胞毒性T细胞的效应及特征

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201451](https://pubmed.ncbi.nlm.nih.gov/41201451)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41201451
**DOI：** 10.1158/1078-0432.CCR-25-2026

### 第一部分 原文与翻译

**英文原标题：** Unraveling the effects and characteristics of proliferating tumor and cytotoxic T cells in colorectal cancer.

**英文摘要原文：**
PURPOSE: The prognostic role of tumor proliferation in colorectal cancer (CRC) has been unclear, while T cell proliferation has been associated with favorable outcome. We investigated characteristics and prognostic significance of proliferating tumor and cytotoxic T cells.

EXPERIMENTAL DESIGN: Two independent CRC cohorts comprising 1839 patients were analyzed using multiplex immunohistochemistry for MKI67 (Ki-67), CD8, and CK. Densities and spatial localization of MKI67+ and MKI67- cytotoxic T cells and tumor proliferation rate were assessed via digital image analysis. Single-cell RNA sequencing data from 62 colon cancers were used to characterize proliferating and non-proliferating cells.

RESULTS: High MKI67+ tumor cell percentage was associated with better cancer-specific survival, an anti-tumorigenic immune microenvironment, downregulation of epithelial mesenchymal transition, and upregulation of MYC signaling. In the larger cohort, the multivariable HR for high vs. low proliferation rate was 0.60 (95%CI 0.43-0.83). MKI67+CD8+ T cells exhibited high expression of effector molecules such as GZMB and IFNG and stronger association with favorable prognosis than MKI67-CD8+ T cells. The multivariable HR for high vs. low MKI67+CD8+ T cell density was 0.49 (95%CI 0.35-0.70). However, spatial analysis of tumor cell-T cell co-localization indicated comparable prognostic significance for both subsets when considering their proximity to tumor cells.

CONCLUSIONS: Tumor cell proliferation is a marker for better prognosis in CRC. Although proliferating cytotoxic T cells demonstrate stronger prognostic value than non-proliferating cytotoxic T cells, spatial proximity to tumor cells diminishes this difference. These findings provide new insights into the interplay between tumor proliferation, immune response, and patient outcomes in CRC.

**中文摘要译文：**
目的：肿瘤增殖在结直肠癌（CRC）中的预后作用尚不明确，而T细胞增殖则与良好预后相关。我们旨在研究增殖性肿瘤细胞和细胞毒性T细胞的特征及其预后意义。

实验设计：本研究使用多重免疫组织化学技术对包含1839名患者的两个独立结直肠癌队列进行了分析，检测指标包括MKI67 (Ki-67)、CD8和CK。通过数字图像分析评估了MKI67+和MKI67-细胞毒性T细胞的密度、空间定位以及肿瘤增殖率。同时，利用来自62例结肠癌的单细胞RNA测序数据对增殖和非增殖细胞进行了表征。

结果：高比例的MKI67+肿瘤细胞与更佳的癌症特异性生存期、抗肿瘤免疫微环境、上皮间质转化下调以及MYC信号通路上调相关。在较大的队列中，高增殖率与低增殖率相比，其多变量风险比（HR）为0.60（95%CI 0.43-0.83）。MKI67+CD8+ T细胞高表达效应分子（如GZMB和IFNG），且与良好预后的关联性强于MKI67-CD8+ T细胞。高密度与低密度MKI67+CD8+ T细胞的多变量风险比（HR）为0.49（95%CI 0.35-0.70）。然而，对肿瘤细胞与T细胞共定位的空间分析表明，当考虑其与肿瘤细胞的邻近性时，两种T细胞亚群（增殖性与非增殖性）具有相当的预后意义。

结论：在结直肠癌中，肿瘤细胞增殖是预后较好的标志物。尽管增殖性细胞毒性T细胞比非增殖性细胞毒性T细胞表现出更强的预后价值，但与肿瘤细胞的空间邻近性削弱了这一差异。这些发现为理解结直肠癌中肿瘤增殖、免疫应答和患者结局之间的相互作用提供了新的见解。

### 第二部分 AI 大师评价

本研究通过对大规模结直肠癌（CRC）队列的多重免疫组化和单细胞测序分析，旨在阐明增殖性肿瘤细胞与细胞毒性T细胞的预后价值。其核心发现颠覆了传统认知，即高肿瘤增殖率在CRC中反而与更佳的生存率和抗肿瘤免疫微环境相关。研究进一步揭示，尽管增殖性（MKI67+）CD8+ T细胞本身预后价值更强，但其与非增殖性T细胞在肿瘤邻近区域的预后作用差异不大，凸显了空间位置的关键性。这些发现为理解肿瘤增殖与免疫应答的复杂互作提供了新视角，对CRC患者的风险分层和免疫治疗策略具有重要的临床启示价值。

---

## 4. 对三阴性乳腺癌中耐药持久性细胞的表征揭示了跨越不同治疗和患者的共同持久性程序

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201442](https://pubmed.ncbi.nlm.nih.gov/41201442)
**期刊：** Cancer research
**PMID：** 41201442
**DOI：** 10.1158/0008-5472.CAN-25-0995

### 第一部分 原文与翻译

**英文原标题：** Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.

**英文摘要原文：**
UNLABELLED: Acquisition of resistance to anticancer therapies is a multistep process initiated by the survival of drug-tolerant persister cells. Accessibility of drug-tolerant persister cells in patients is limited, which has hindered understanding the mechanisms driving their emergence. In this study, using multiple patient-derived models to isolate persister cells, we showed that these cells are transcriptionally plastic in vivo and return to a common treatment naïve-like state upon relapse, regardless of treatment. Hallmarks of the persister state in triple-negative breast cancer (TNBC) across treatment modalities included high expression of basal keratins together with activation of stress response and inflammation pathways. These hallmarks were also activated in HER2+ breast and lung cancer cells in response to targeted therapies. Analysis of gene regulatory networks identified AP-1, NF-κB, and IRF/STAT as the key drivers of this hallmark persister state. Functionally, FOSL1, an AP-1 member, drove cells to the persister state by binding enhancers and reprogramming the transcriptome of cancer cells. On the contrary, cancer cells without FOSL1 had a decreased ability to reach the persister state. By defining hallmarks of TNBC persistence on multiple therapies, this study provides a resource to design effective combination therapeutic strategies that limit resistance.

SIGNIFICANCE: Elucidation of the features of the drug-tolerant persister state in triple-negative breast cancer reveals shared programs across patients and treatments that offer opportunities to prevent persistence and delay tumor recurrence.

**中文摘要译文：**
无标签: 对抗癌疗法的耐药性获得是一个多步骤过程，起始于耐药持久性细胞的存活。在患者中，耐药持久性细胞的可及性有限，这阻碍了对其出现机制的理解。本研究利用多种源自患者的模型分离持久性细胞，结果表明这些细胞在体内具有转录可塑性，并且在复发时会回到一种共同的、类似治疗前初始的状态，无论接受何种治疗。在三阴性乳腺癌（TNBC）中，跨越不同治疗方式的持久性状态的标志性特征包括基底角蛋白的高表达，以及应激反应和炎症通路的激活。这些标志性特征在HER2+乳腺癌和肺癌细胞中响应靶向治疗时也被激活。基因调控网络分析确定了AP-1、NF-κB和IRF/STAT是这种标志性持久性状态的关键驱动因素。功能上，AP-1成员FOSL1通过结合增强子和重编程癌细胞的转录组，驱动细胞进入持久性状态。相反，缺乏FOSL1的癌细胞进入持久性状态的能力下降。通过明确TNBC在多种治疗下的持久性标志，本研究为设计限制耐药性的有效联合治疗策略提供了资源。

意义: 阐明三阴性乳腺癌中耐药持久性状态的特征，揭示了跨越患者和治疗的共同程序，这为预防持久性并延缓肿瘤复发提供了机会。

### 第二部分 AI 大师评价

本研究通过分析多种患者来源的三阴性乳腺癌模型，旨在揭示耐药持久性细胞的共同特征。研究关键发现，无论采用何种治疗方法，这些细胞都会进入一种由AP-1（特别是FOSL1）、NF-κB等通路驱动的、具有转录可塑性的共同“持久性状态”。这项工作的创新之处在于识别了跨越不同疗法和患者的共享耐药机制，为开发针对FOSL1等靶点的联合疗法以预防治疗抵抗和肿瘤复发提供了坚实的理论基础和新的策略方向。

---

## 5. ESR1激活突变赋予ER阳性乳腺癌代谢脆弱性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201246](https://pubmed.ncbi.nlm.nih.gov/41201246)
**期刊：** Cancer research
**PMID：** 41201246
**DOI：** 10.1158/0008-5472.CAN-25-1339

### 第一部分 原文与翻译

**英文原标题：** ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.

**英文摘要原文：**
Endocrine therapy (ET) is the standard of care for estrogen receptor-positive (ER+) breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. Here, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of the acyl-CoA synthetase long-chain family member 4 (ACSL4), which has a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. While ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective estrogen receptor degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction.

**中文摘要译文：**
内分泌治疗（ET）是雌激素受体阳性（ER+）乳腺癌的标准治疗方案。在未经治疗的ER+乳腺癌中，编码雌激素受体的基因（ESR1）的配体结合域点突变很少见，但在内分泌治疗耐药的情况下变得普遍。本研究发现，ESR1突变使乳腺癌暴露出与脂质代谢相关的关键脆弱性。特别是，诱导ER组成性激活的ESR1突变驱动了异常的脂质生物合成和脂质摄取，同时伴随着酰基辅酶A合成酶长链家族成员4（ACSL4）的表达增加，ACSL4在脂肪酸活化中起关键作用，并已被证明与铁死亡易感性增加相关。虽然ER+乳腺癌细胞表现出对铁死亡的抵抗性，但ESR1突变的存在使肿瘤细胞对铁死亡的诱导变得敏感。重要的是，铁死亡诱导剂增强了选择性雌激素受体降解剂氟维司群和艾拉司群的疗效，这两种药物是携带ESR1突变的乳腺癌的标准治疗药物。这些研究结果在临床前模型和患者来源的材料中均得到了验证，为内分泌治疗耐药的情况确定了一种联合治疗方法，并确立了ACSL4作为识别易于发生铁死亡的ER+乳腺癌的重要生物标志物。

### 第二部分 AI 大师评价

本研究旨在探索ER+乳腺癌中常见的ESR1激活突变如何导致代谢脆弱性，从而为内分泌治疗耐药提供新的解决方案。研究发现，这些突变通过上调ACSL4蛋白，重塑了肿瘤细胞的脂质代谢，意外地使其对铁死亡（ferroptosis）变得敏感。该研究的创新之处在于，它将内分泌耐药机制与铁死亡联系起来，并验证了铁死亡诱导剂与标准疗法（如氟维司群）联合应用的协同抗癌效果。这项发现不仅为ESR1突变的晚期乳腺癌患者提供了一种极具潜力的联合治疗新策略，还提出了ACSL4可作为预测该疗法敏感性的生物标志物，具有重要的临床转化价值。

---

## 6. 基于GPC3的环状RNA疫苗通过激活适应性免疫反应抑制肝细胞癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201153](https://pubmed.ncbi.nlm.nih.gov/41201153)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41201153
**DOI：** 10.1097/HEP.0000000000001605

### 第一部分 原文与翻译

**英文原标题：** GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.

**英文摘要原文：**
BACKGROUND AIMS: Messenger RNA (mRNA) vaccine is a promising approach for cancer therapy. However, the development of mRNA cancer vaccine encounters several challenges including mRNA instability, inefficient delivery systems and potential biosafety concerns. Addressing these issues requires optimizing mRNA design, developing novel delivery vectors and enhancing immune responses. We aimed to develop a circular RNA (circRNA)-based cancer vaccine targeting tumor-associated antigen Glypican-3 (GPC3), a promising target in hepatocellular carcinoma (HCC), to improve antigen stability and anti-tumor immune responses.

APPROACH RESULTS: We designed a circRNA-based vaccine encoding GPC3 for HCC and evaluated the therapeutic efficacy and safety of the circGPC3 vaccine. The circGPC3 vaccine was demonstrated sustained antigen production, overcoming the inherent limitations of traditional mRNA vaccines and resulting in more potent and durable anti-tumor immune responses. Additionally, we incorporated Toll-like receptor-Ⅳ (TLR4) agonist as an adjuvant to further enhance immune responses. CircGPC3 vaccine plus TLR4 agonist effectively suppressed tumor progression in HCC. We employed multiplex immunofluorescence, single-cell sequencing, spatial transcriptomics and mass cytometry to characterize the tumor microenvironment (TME) in mice following combination therapy and to elucidate the mechanism. Mechanistically, circGPC3 vaccine significantly enhanced immunoproteasome-mediated antigen presentation and strengthened the interaction between cDC1 and CD8+T cells through MHC-I pathway, therefore facilitating a more effective initiation of adaptive immune responses and reprogramming TME.

CONCLUSIONS: The circGPC3 cancer vaccine was demonstrated superior efficacy compared to mRNA cancer vaccine. When further combined with a TLR4 agonist, it disrupted immune tolerance in HCC, offering a promising translational treatment strategy for HCC.

**中文摘要译文：**
背景与目的：信使RNA（mRNA）疫苗是一种有前景的癌症治疗方法。然而，mRNA癌症疫苗的开发面临mRNA不稳定性、递送系统效率低下以及潜在的生物安全问题等多重挑战。解决这些问题需要优化mRNA设计、开发新型递送载体并增强免疫反应。我们旨在开发一种靶向肿瘤相关抗原磷脂酰肌醇蛋白聚糖-3（GPC3）的环状RNA（circRNA）癌症疫苗，GPC3是肝细胞癌（HCC）中一个有前景的靶点，以提高抗原稳定性并增强抗肿瘤免疫反应。

方法与结果：我们设计了一种编码GPC3的circRNA疫苗用于治疗HCC，并评估了circGPC3疫苗的治疗效果与安全性。结果表明，circGPC3疫苗能够持续产生抗原，克服了传统mRNA疫苗的固有局限性，从而引发了更强效、更持久的抗肿瘤免疫反应。此外，我们引入了Toll样受体-Ⅳ（TLR4）激动剂作为佐剂，以进一步增强免疫反应。circGPC3疫苗联合TLR4激动剂能有效抑制HCC的肿瘤进展。我们采用多重免疫荧光、单细胞测序、空间转录组学和质谱流式细胞术等技术，来描绘联合治疗后小鼠的肿瘤微环境（TME）特征并阐明其作用机制。机制上，circGPC3疫苗显著增强了免疫蛋白酶体介导的抗原呈递，并通过MHC-I通路加强了cDC1与CD8+ T细胞间的相互作用，从而促进了适应性免疫反应的更有效启动并重塑了肿瘤微环境。

结论：circGPC3癌症疫苗显示出优于mRNA癌症疫苗的疗效。当进一步与TLR4激动剂联用时，它能打破HCC的免疫耐受，为HCC提供了一种有前景的转化治疗策略。

### 第二部分 AI 大师评价

本研究旨在解决传统mRNA癌症疫苗的不稳定性问题，创新性地开发了一种基于环状RNA（circRNA）的肝细胞癌（HCC）疫苗。研究团队通过靶向GPC3抗原，并联用TLR4激动剂作为佐剂，成功证实了该疫苗在小鼠模型中能诱导更持久、更强效的抗肿瘤免疫反应。其核心机制在于增强了免疫蛋白酶体介导的抗原呈递和CD8+ T细胞的激活。这项工作不仅为HCC提供了一种极具转化潜力的治疗新策略，也凸显了circRNA技术在肿瘤免疫治疗领域的广阔应用前景。

---

## 7. 仿生有机纳米酶作为肿瘤疫苗靶向抑制氨诱导的T淋巴细胞死亡以增强乳腺癌免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201121](https://pubmed.ncbi.nlm.nih.gov/41201121)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41201121
**DOI：** 10.1002/advs.202518037

### 第一部分 原文与翻译

**英文原标题：** Biomimetic Organic Nanozyme as Tumor Vaccines for Targeted Suppression of Ammonia-Induced T Lymphocyte Death to Augment Breast Cancer Immunotherapy.

**英文摘要原文：**
Ammonia-induced T lymphocyte death (AITD) offers a new perspective on immune regulation after the activation of CD8 T cells. However, the use of a single AITD inhibitor is constrained by multiple factors in the immunosuppressive tumor microenvironment and requires combination strategies to achieve breakthroughs. Herein, a rationally designed organic nanozyme (IR-IHpd) is presented, integrating anthocyanin-based near-infrared photodynamic therapy (NIR-PDT) and Hemin-derived peroxidase (POD)-like catalytic activity. Under 780 nm laser irradiation, it generates ROS through Type I/II photodynamic mechanisms while catalyzing HO into cytotoxic ·OH, establishing an uninterrupted ROS generation. Co-encapsulated with CB-839 in DSPE-Hyd-PEG and coated with dendritic cell (DC) membranes to form a biomimetic system (DMIC), this system targets both tumors and T cells. After intravenous administration, the DMIC nanozyme system efficiently accumulates in tumor tissues, tumor-draining lymph nodes, and spleens, where NIR irradiation induces tumor immunogenic cell death while promoting DCs maturation and T cell activation. The DMIC also functions as a tumor vaccine, capable of directly activating T cells and preventing tumor occurrence. Furthermore, the released CB-839 reduces intracellular ammonia levels in T cells, thereby enhancing anti-tumor immunity. This pioneering work achieves targeted AITD inhibition for the first time, integrating NIR-PDT, metabolic modulation, and immune activation to advance nanozyme-based immunotherapy.

**中文摘要译文：**
氨诱导的T淋巴细胞死亡（AITD）为CD8+ T细胞激活后的免疫调节提供了新视角。然而，在免疫抑制性的肿瘤微环境中，单一AITD抑制剂的使用受多种因素限制，需要联合策略以实现突破。在此，我们提出了一种合理设计的有机纳米酶（IR-IHpd），它整合了基于花青素的近红外光动力疗法（NIR-PDT）和源自血红素的过氧化物酶（POD）样催化活性。在780纳米激光照射下，它通过I/II型光动力机制产生活性氧（ROS），同时催化H₂O₂生成具有细胞毒性的·OH，从而建立了一个不间断的ROS生成系统。该纳米酶与CB-839共封装于DSPE-Hyd-PEG中，并包裹树突状细胞（DC）膜形成仿生系统（DMIC），此系统能同时靶向肿瘤和T细胞。静脉注射后，DMIC纳米酶系统能高效地在肿瘤组织、肿瘤引流淋巴结和脾脏中富集，在此处近红外光照射可诱导肿瘤的免疫原性细胞死亡，同时促进DC成熟和T细胞活化。DMIC还可作为肿瘤疫苗，能够直接激活T细胞并预防肿瘤的发生。此外，释放的CB-839能降低T细胞内的氨水平，从而增强抗肿瘤免疫力。这项开创性工作首次实现了对AITD的靶向抑制，整合了NIR-PDT、代谢调控和免疫激活，推动了基于纳米酶的免疫治疗发展。

### 第二部分 AI 大师评价

本研究旨在开发一种新型仿生纳米酶，通过靶向抑制氨诱导的T淋巴细胞死亡（AITD）来增强乳腺癌免疫治疗。研究团队构建了一个多功能仿生系统（DMIC），巧妙地将近红外光动力疗法、代谢抑制剂（CB-839）和树突状细胞膜伪装技术融为一体。其关键发现是，该系统不仅能有效杀伤肿瘤细胞、激活免疫应答，还能作为肿瘤疫苗直接激活T细胞，并通过降低T细胞内氨水平来逆转免疫抑制。这项工作的创新性在于首次实现了对AITD的靶向干预，并将光疗、代谢调控与免疫激活相结合，为克服肿瘤免疫抑制微环境提供了极具潜力的多功能治疗新策略。

---

## 8. 替代BPA：结构替代物BPAF与孕酮受体结合，提升乳腺癌风险

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201099](https://pubmed.ncbi.nlm.nih.gov/41201099)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41201099
**DOI：** 10.1002/advs.202502444

### 第一部分 原文与翻译

**英文原标题：** Replacing BPA: Structural Substitutes BPAF Binding to the Progesterone Receptor Elevates Breast Cancer Risk.

**英文摘要原文：**
As the global production of bisphenol analogs (BPs) surges to replace regulated bisphenol A (BPA), their pervasive environmental presence and uncharacterized breast cancer risk raise critical public health concerns. Herein, the environmental risks of BPs are deciphered by linking their structural affinity for the progesterone receptor (PR), a master regulator of breast cancer, to oncogenic outcomes across experimental tiers. Molecular simulations reveal that environmental BPAF and BPB exhibited stronger binding to the PR-ligand binding domain (LBD) than BPA. Chemical assays confirm persistent PR-LBD structural changes after BPs exposure, mimicking endocrine disruption patterns. The cellular thermal shift assay also confirms the interaction between the PR and BPs. In vitro, BPAF and BPF boost PR expression at human-relevant concentrations. In addition, BPAF elevates PR expression, and the enhanced migratory and invasive capacities are effectively suppressed by the PR inhibitor. Toxicological Prioritization Index-based risk stratification, weighted by the binding affinity of BPs to the PR and cellular toxicity, ranks BPAF as the highest-risk analog. Alarmingly, low-dose BPAF exposure (30 µg kg) accelerates mammary tumor growth in mice, paralleling PR upregulation in tumor tissues. This study underscores that substituting BPA with structurally akin analogs merely shifts, rather than mitigates, environmental health risks.

**中文摘要译文：**
随着全球范围内用于替代受规制的双酚A（BPA）的双酚类类似物（BPs）产量激增，其在环境中的广泛存在以及尚未明确的乳腺癌风险，引发了严重的公共卫生关切。本研究通过将BPs与乳腺癌关键调控因子——孕酮受体（PR）的结构亲和力，同多层次实验中的致癌结果相关联，从而阐释了BPs的环境风险。分子模拟研究揭示，环境中的BPAF和BPB与PR配体结合域（LBD）的结合能力强于BPA。化学分析证实，暴露于BPs后，PR-LBD发生持续的结构变化，模拟了内分泌干扰的模式。细胞热位移测定也证实了PR与BPs之间存在相互作用。在体外实验中，与人体暴露相关的浓度下，BPAF和BPF能促进PR的表达。此外，BPAF能提高PR的表达，而其增强的细胞迁移和侵袭能力可被PR抑制剂有效抑制。基于毒理学优先指数的风险分层（通过BPs与PR的结合亲和力及细胞毒性进行加权）将BPAF列为风险最高的类似物。令人警惕的是，低剂量BPAF暴露（30微克/千克）可加速小鼠乳腺肿瘤的生长，并伴随肿瘤组织中PR的上调。本研究强调，使用结构相似的类似物替代BPA，仅仅是转移了环境健康风险，而非减轻风险。

### 第二部分 AI 大师评价

本研究旨在探讨双酚A（BPA）的结构替代物（特别是BPAF）是否通过与孕酮受体（PR）相互作用而带来乳腺癌风险。研究综合运用了分子模拟、细胞生物学实验及动物模型等多层次方法，揭示了BPAF比BPA具有更强的PR结合能力，并能在体内外促进肿瘤进展。该研究的创新之处在于系统性地阐明了BPA替代物的潜在致癌机制，强调了化学品替代策略中“从一种风险转向另一种风险”的严重问题，对环境化学品安全评估和公共卫生政策制定具有重要的警示价值。

---

## 9. 肝癌的免疫微环境：从分析到靶向

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201063](https://pubmed.ncbi.nlm.nih.gov/41201063)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41201063
**DOI：** 10.1002/advs.202518487

### 第一部分 原文与翻译

**英文原标题：** The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.

**英文摘要原文：**
Despite advancements in early detection and treatment, liver cancer (LC) remains highly recurrent due to its complex immunosuppressive tumor microenvironment (TME), leading to poor prognosis in advanced stages. Nanomedicines (NMs) offer novel therapeutic strategies for reversing the immunosuppressive TME in LC. This review systematically analysed the diverse mechanisms contributing to immunosuppressive TME formation and explored the potential of smart responsive NMs in targeted drug delivery, immune remodeling, and multimodal therapy. The immunosuppressive TME in LC arises from abnormal physiological conditions, extracellular matrix (ECM) deposition, dysfunction of antigen-presenting cells, exhaustion of T cells, infiltration of immunosuppressive cells, metabolic reprogramming, and microbiota influences. Smart NMs can overcome delivery barriers through passive targeting and ligand-directed active targeting to LC cells via receptors, as well as to immunosuppressive cell populations. NMs can respond to endogenous and exogenous stimuli, enabling precise spatiotemporal drug release. This feature enables integration of chemotherapy, immunotherapy, and physical therapies. Additionally, NMs can reprogram the TME by remodeling physiological conditions, inhibiting ECM deposition, regulating metabolism, inducing immunogenic cell death, and modulating microbiota-derived metabolites. Although toxicity and clinical translation still require further optimization, smart NMs offer a paradigm shift for LC therapy through an integrated "targeted delivery-immune reprogramming" strategy.

**中文摘要译文：**
尽管早期检测和治疗已取得进展，但由于其复杂的免疫抑制性肿瘤微环境（TME），肝癌（LC）仍然具有高复发性，导致晚期患者预后不良。纳米药物（NMs）为逆转肝癌中的免疫抑制性TME提供了新的治疗策略。这篇综述系统地分析了导致免疫抑制性TME形成的多种机制，并探讨了智能响应性纳米药物在靶向药物递送、免疫重塑和多模式治疗中的潜力。肝癌的免疫抑制性TME源于异常的生理条件、细胞外基质（ECM）沉积、抗原呈递细胞功能障碍、T细胞耗竭、免疫抑制细胞浸润、代谢重编程以及微生物群的影响。智能纳米药物可以通过被动靶向和配体介导的主动靶向，经由受体靶向肝癌细胞及免疫抑制细胞群体，从而克服递送障碍。纳米药物能够响应内源性和外源性刺激，实现精准的时空药物释放。这一特性使其能够整合化学疗法、免疫疗法和物理疗法。此外，纳米药物还可以通过重塑生理条件、抑制ECM沉积、调节代谢、诱导免疫原性细胞死亡以及调节微生物群来源的代谢物来重编程TME。尽管其毒性和临床转化仍需进一步优化，但智能纳米药物通过一种整合的“靶向递送-免疫重编程”策略，为肝癌治疗提供了一种范式转变。

### 第二部分 AI 大师评价

这篇综述深刻剖析了肝癌免疫抑制性微环境的复杂成因，并前瞻性地探讨了智能纳米药物作为解决方案的巨大潜力。文章系统性地总结了纳米药物如何通过靶向递送和多模式治疗策略重塑肿瘤微环境，为克服肝癌治疗瓶颈提供了清晰的路线图。该研究不仅对基础科研具有指导价值，更为开发新型肝癌免疫疗法带来了重要启示，尽管其临床转化挑战依然存在。

---

## 10. 肠道中性神经酰胺酶缺乏通过GD3触发调节性T细胞应答以保护宿主免受肠道炎症

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201002](https://pubmed.ncbi.nlm.nih.gov/41201002)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41201002
**DOI：** 10.1002/advs.202512681

### 第一部分 原文与翻译

**英文原标题：** Intestinal Neutral Ceramidase Deficiency Triggers Regulatory T Cell Response via Gd3 to Protect the Host from Intestinal Inflammation.

**英文摘要原文：**
Sphingolipids play a crucial role in gut inflammation. Neutral ceramidase (NcDase) serves as a pivotal regulator of ceramide, the central intermediate in sphingolipid metabolism. The contribution of intestinal epithelial cells (IEC) NcDase to colitis is not well understood. Here, a protective mechanism by which IEC NcDase deficiency (Asah2) and its-related gangliosides prevent dextran sulfate sodium (DSS)-induced colitis in mice is described. Asah2 mice display reduced susceptibility to DSS-induced colitis and increase regulatory T (T) cells compared to Asah2 littermates. Deletion of IEC NcDase induces the upregulation of sialyltransferase ST8SIA1 and promotes the sialic-acid-containing ganglioside GD3 production. Siglec-E is a sialic-acid-binding lectin expresses predominantly on myeloid cells. Mechanistically, it is identified that GD3 is a functional ligand for Siglec-E on macrophages and found that GD3/Siglec-E interaction induced a rapid metabolic rewiring of macrophages that involved the production of IL-33, which contributes to the generation of ST2Foxp3 T cells. Finally, deletion of ST8SIA1 or administration of dietary GD3 induces or reduces mucosal inflammation, respectively. This work defines a critical role for ganglioside GD3 in the induction of colonic T cells and identifies an activating pathway that follows engagement of Siglec-E.

**中文摘要译文：**
鞘脂在肠道炎症中扮演着至关重要的角色。中性神经酰胺酶（NcDase）是鞘脂代谢核心中间产物——神经酰胺的关键调节因子。肠上皮细胞（IEC）中的NcDase对结肠炎的作用尚不明确。本研究描述了一种保护性机制，即肠上皮细胞NcDase缺乏（Asah2）及其相关的神经节苷脂可预防葡聚糖硫酸钠（DSS）诱导的小鼠结肠炎。与同窝对照小鼠相比，Asah2缺陷小鼠对DSS诱导的结肠炎易感性降低，并且调节性T（Treg）细胞增加。肠上皮细胞NcDase的缺失会诱导唾液酸转移酶ST8SIA1的上调，并促进含唾液酸的神经节苷脂GD3的产生。Siglec-E是一种主要在髓系细胞上表达的唾液酸结合凝集素。机制上，本研究确定了GD3是巨噬细胞上Siglec-E的功能性配体，并发现GD3/Siglec-E的相互作用诱导了巨噬细胞的快速代谢重编程，进而涉及IL-33的产生，这有助于ST2+Foxp3+ Treg细胞的生成。最后，敲除ST8SIA1或通过饮食补充GD3分别会诱导或减轻黏膜炎症。这项工作明确了神经节苷脂GD3在诱导结肠Treg细胞中的关键作用，并揭示了一条由Siglec-E参与的激活通路。

### 第二部分 AI 大师评价

本研究旨在探究肠道上皮细胞中性神经酰胺酶（NcDase）缺乏对结肠炎的影响及其潜在机制。研究通过构建NcDase基因敲除小鼠模型，发现NcDase缺乏能上调神经节苷脂GD3的合成，GD3作为信号分子与巨噬细胞上的Siglec-E结合，进而诱导IL-33产生并促进保护性调节性T细胞（Treg）的分化，最终减轻肠道炎症。该研究创新性地揭示了一条连接鞘脂代谢与肠道免疫调节的“NcDase-GD3-Siglec-E-Treg”新通路，不仅深化了对肠道稳态维持机制的理解，也提示了饮食补充GD3作为治疗炎症性肠病的潜在策略，具有重要的科研与临床转化价值。

---

## 11. 精准设计的固体自乳化纳米疫苗通过双重调控树突状细胞和T细胞实现强效抗肿瘤免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199675](https://pubmed.ncbi.nlm.nih.gov/41199675)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41199675
**DOI：** 10.1002/advs.202512139

### 第一部分 原文与翻译

**英文原标题：** Designer Solid Self-Emulsifying Nanovaccines Enable Dual Modulation of Dendritic Cells and T Cells for Potent Antitumor Immunity.

**英文摘要原文：**
Peptide-based cancer vaccines offer favorable safety and stability profiles but are limited by rapid clearance and poor immunogenicity. Here, a ≈20 nm solid self-emulsifying (SSE) nanovaccine platform that co-delivers peptide antigens and an oligonucleotide adjuvant containing the 5'-C-phosphate-G-3' (CpG) motif is reported. This formulation elicits T-cell responses 40 fold higher than those of conventional emulsified vaccines and even achieves complete tumor regression at low doses. Apolipoprotein E (ApoE) adsorbed on SSE vaccines enhances lymph node targeting and dendritic cell internalization. Furthermore, SSE is internalized by T cells and promotes lipid raft formation, thereby further sensitizing T cells to activation. These findings reveal a dual mechanism of immune regulation through the simultaneous engagement of dendritic cells and T cells. The SSE platform offers a clinically translatable strategy for potent cancer immunotherapy and provides mechanistic insights into nanoparticle-immune cell interactions that may guide the design of next-generation nanovaccines.

**中文摘要译文：**
基于多肽的癌症疫苗具有良好的安全性和稳定性，但受限于其快速清除和低免疫原性。本研究报道了一种约20纳米的固体自乳化（SSE）纳米疫苗平台，该平台能够共递送多肽抗原和含有5'-C-磷酸-G-3'（CpG）基序的寡核苷酸佐剂。该制剂所诱导的T细胞反应强度是传统乳化疫苗的40倍，并且在低剂量下即可实现肿瘤的完全消退。吸附在SSE疫苗表面的载脂蛋白E（ApoE）能够增强其淋巴结靶向性和树突状细胞的内化效率。此外，SSE还能被T细胞内化并促进脂筏的形成，从而进一步增敏T细胞的活化。这些发现揭示了一种通过同时作用于树突状细胞和T细胞来实现免疫双重调控的机制。该SSE平台为实现强效的癌症免疫治疗提供了一种具有临床转化潜力的策略，并为纳米颗粒与免疫细胞相互作用的机制研究提供了新见解，可能指导下一代纳米疫苗的设计。

### 第二部分 AI 大师评价

本研究旨在解决多肽癌症疫苗免疫原性低的核心痛点。研究人员巧妙地设计了一种固体自乳化纳米疫苗（SSE）平台，共递送抗原与CpG佐剂。其核心发现是该平台不仅能通过ApoE吸附高效靶向并激活树突状细胞，还能直接被T细胞内化以增强其活化，实现了对免疫应答“启动”和“效应”两个阶段的双重调控。这一创新策略显著提升了抗肿瘤免疫效果，为开发新一代高效癌症疫苗提供了极具临床转化价值的新思路和理论依据。

---

## 12. 铁硫蛋白FDX1通过线粒体核酸释放触发肿瘤内在免疫，从而调控透明细胞肾细胞癌（ccRCC）的铁死亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199656](https://pubmed.ncbi.nlm.nih.gov/41199656)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41199656
**DOI：** 10.1002/advs.202518323

### 第一部分 原文与翻译

**英文原标题：** Fe-S Protein FDX1 Triggers Tumor-Intrinsic Innate Immunity via Mitochondrial Nucleic Acids Release to Orchestrate Ferroptosis in CCRCC.

**英文摘要原文：**
Activation of cytosolic nucleic acid-sensing pathways represents a promising strategy to convert immunologically "cold" tumors into inflamed ones. Iron-sulfur (Fe-S) enzymes are critical regulators of innate immunity and nucleic acid sensing, yet their roles in cancer remain poorly defined. Here, ferredoxin-1 (FDX1), a mitochondrial Fe-S protein frequently downregulated in clear cell renal cell carcinoma (ccRCC), is identified as a dual regulator of ferroptosis and antitumor immunity. FDX1 overexpression triggers mitochondrial permeability transition pore opening, leading to cytosolic release of mitochondrial DNA (mtDNA) and double-stranded RNA (mt-dsRNA). This reveals an independent function of FDX1 as a tumor-intrinsic immunity activator linked to mitochondrial stress signaling. These damage-associated molecular patterns (DAMPs) engage cytosolic nucleic acid sensors-specifically cGAS and RIG-I/MDA5-triggering TBK1 phosphorylation and a robust type I interferon response that occurs prior to overt ferroptosis. This innate immune cascade reshapes the tumor microenvironment by enhancing MHC I/II antigen presentation, recruiting CD8+ T cells, and suppressing tumor growth and metastasis in orthotopic syngeneic models. These findings uncover a previously unrecognized antitumor axis through which FDX1 synergizes with mitochondrial nucleic acid release with ferroptosis to promote immunogenic inflammation and T cell infiltration in ccRCC, offering novel therapeutic opportunities targeting mitochondrial-immune crosstalk.

**中文摘要译文：**
激活胞质核酸感应通路是将免疫学‘冷’肿瘤转化为‘热’肿瘤的一种有前景的策略。铁硫（Fe-S）酶是先天免疫和核酸感应的关键调节因子，但其在癌症中的作用仍不明确。本研究发现，线粒体铁硫蛋白铁氧还蛋白-1（FDX1）——在透明细胞肾细胞癌（ccRCC）中常被下调——是铁死亡和抗肿瘤免疫的双重调节因子。FDX1的过表达会触发线粒体通透性转换孔的开放，导致线粒体DNA（mtDNA）和双链RNA（mt-dsRNA）释放到胞质中。这揭示了FDX1作为一个与线粒体应激信号相关的肿瘤内在免疫激活因子，具有一项独立的功能。这些损伤相关分子模式（DAMPs）与胞质核酸传感器——特别是cGAS和RIG-I/MDA5——相互作用，触发TBK1磷酸化和强烈的I型干扰素反应，而这一过程发生在明显的铁死亡之前。这一先天免疫级联反应通过增强MHC I/II类抗原呈递、招募CD8+ T细胞，并在原位同种移植模型中抑制肿瘤生长和转移，从而重塑肿瘤微环境。这些发现揭示了一个先前未被认识的抗肿瘤轴心，即FDX1能协同线粒体核酸释放与铁死亡过程，共同促进ccRCC中的免疫原性炎症和T细胞浸润，为靶向线粒体-免疫串扰提供了新的治疗机会。

### 第二部分 AI 大师评价

本研究旨在阐明在透明细胞肾细胞癌（ccRCC）中下调的铁硫蛋白FDX1在连接铁死亡与抗肿瘤免疫中的双重作用。研究通过FDX1过表达模型发现，FDX1能诱导线粒体DNA和双链RNA的释放，在引发铁死亡前就激活cGAS和RIG-I/MDA5介导的I型干扰素通路。这一关键发现揭示了FDX1作为肿瘤内在免疫激活因子的新功能，它将线粒体应激、先天免疫激活与程序性细胞死亡（铁死亡）联系起来，为将‘冷’肿瘤转化为‘热’肿瘤提供了新的分子靶点，在ccRCC的免疫治疗领域具有重要的转化潜力。

---

## 13. 一种基于生物学信息与视觉引导的可解释性T细胞受体-抗原表位结合预测框架

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199631](https://pubmed.ncbi.nlm.nih.gov/41199631)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41199631
**DOI：** 10.1002/advs.202512544

### 第一部分 原文与翻译

**英文原标题：** A Biologically Informed Vision-Guided Framework for Interpretable T Cell Receptor-Epitope Binding Prediction.

**英文摘要原文：**
Accurate identification of the interactions between T-cell receptors (TCRs) and antigenic epitopes presented by major histocompatibility complex (MHC) molecules is fundamental to advancing cancer immunotherapy. Nevertheless, predictive modeling of TCR-epitope binding remains challenging, as existing models struggle to generalize to unseen epitopes while often overlooking key physicochemical properties governing immune recognition. Here, a biologically informed vision-guided deep learning framework (DAISY) is proposed for robust and interpretable TCR-epitope binding prediction. DAISY integrates hierarchical physicochemical features via a biologically inspired Condition-Adaptive Fusion module, jointly modeling residue-level spatial interactions and global biochemical context. DAISY consistently outperforms state-of-the-art models across four generalization scenarios, notably improving ROC-AUC by 11% and PR-AUC by 16% over the strongest competitor in the most challenging Unseen-Pair setting. DAISY also offers intuitive interpretability by localizing interaction-relevant residues via Score-CAM visualizations. Furthermore, its computational predictions are bridged to key immunological and clinical outcomes, demonstrating utility in correlating with T-cell clonal expansion, identifying functional TCRs, and robustly forecasting patient survival. Together, DAISY can serve as a powerful tool for broad translational immunology and introduces a scalable modeling paradigm for next-generation immune modeling.

**中文摘要译文：**
准确识别T细胞受体（TCRs）与主要组织相容性复合体（MHC）分子呈递的抗原表位之间的相互作用，是推动癌症免疫治疗发展的基石。然而，TCR-抗原表位结合的预测性建模仍然充满挑战，因为现有模型难以泛化至未见过的抗原表位，并且常常忽略了决定免疫识别的关键物理化学性质。本研究提出了一种名为DAISY的、具有生物学信息和视觉引导的深度学习框架，用于实现稳健且可解释的TCR-抗原表位结合预测。DAISY通过一个受生物学启发的条件自适应融合模块，整合了层次化的物理化学特征，从而对残基水平的空间相互作用和全局生化背景进行联合建模。在四种泛化场景中，DAISY的表现始终优于当前最先进的模型，特别是在最具挑战性的“未见配对”设置下，其ROC-AUC和PR-AUC分别比最强的竞争者高出11%和16%。DAISY还通过Score-CAM可视化技术定位与相互作用相关的残基，提供了直观的可解释性。此外，该模型的计算预测结果与关键的免疫学和临床结局相关联，证明了其在关联T细胞克隆性扩增、识别功能性TCR以及稳健预测患者生存率方面的应用价值。总之，DAISY可作为广义转化免疫学的强大工具，并为下一代免疫建模引入了一种可扩展的范式。

### 第二部分 AI 大师评价

本研究旨在解决T细胞受体（TCR）-抗原表位结合预测中泛化能力差和模型“黑箱”问题。研究者为此开发了一种名为DAISY的深度学习框架，其创新性在于融合了生物学信息（如残基的物理化学性质）与视觉引导的建模策略，从而显著提升了预测的准确性和稳健性。该模型的关键优势不仅在于其卓越的性能，更在于通过可视化技术实现了可解释性，并成功将其计算预测与T细胞扩增、患者生存率等临床结局关联。DAISY为精准免疫治疗提供了强大的计算工具，并在可解释的AI免疫识别领域树立了新的范式。

---

## 14. 关于《通过RUVBL1-EEF1A1轴对翻译检查点和肿瘤进展进行表观遗传调控》一文的更正

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199425](https://pubmed.ncbi.nlm.nih.gov/41199425)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41199425
**DOI：** 10.1002/advs.202519908

### 第一部分 原文与翻译

**英文原标题：** Correction to "Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis".

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献是针对先前发表的关于“通过RUVBL1-EEF1A1轴实现翻译检查点和肿瘤进展的表观遗传调控”研究的一篇更正声明，本身不包含原创性研究内容。原文旨在探讨RUVBL1-EEF1A1信号轴如何通过表观遗传机制调控翻译检查点，进而影响肿瘤的恶性进展，这对于揭示肿瘤发生发展的分子机制具有重要意义。由于此条目为勘误信息且无摘要，无法评估其具体研究方法和发现，读者需参考原文以获取详细的研究信息。

---

## 15. SV2B通过与HERC2相互作用阻碍NF-κB亚基降解，从而促进TFE3重排型肾细胞癌的进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199339](https://pubmed.ncbi.nlm.nih.gov/41199339)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41199339
**DOI：** 10.1002/advs.202509443

### 第一部分 原文与翻译

**英文原标题：** SV2B Promotes the Progression of TFE3-Rearranged Renal Cell Carcinoma by Interacting with HERC2 to Impede the Degradation of NF-κB Subunits.

**英文摘要原文：**
TFE3-rearranged renal cell carcinoma (TFE3-RCC) represents an aggressive subtype of renal cancer characterized by a poor prognosis, yet lacking clearly defined diagnostic and therapeutic targets. Here, the study demonstrates that synaptic vesicle protein 2B (SV2B) is a potential diagnostic marker and therapeutic target for TFE3-RCC. SV2B, identified as a TFE3 target gene, is significantly upregulated in TFE3-RCC and displays high diagnostic accuracy for this subtype. Functionally, SV2B enhances the proliferation, migration, and invasion of TFE3-RCC cells. Mechanistically, SV2B competes with RELA/NFKB1 for binding to the E3 ligase HERC2, preventing their degradation and activating the NF-κB pathway. The drug padsevonil, targeting SV2B, selectively inhibits the growth of TFE3-RCC cells and organoids, similar to the NF-κB inhibitor Withaferin A. Clinically, RELA/NFKB1 expression positively correlates with SV2B levels but negatively with HERC2 expression, confirming the activation of TFE3-SV2B-NF-κB axis in TFE3-RCC. These findings establish SV2B as a novel diagnostic biomarker for TFE3-RCC and validate SV2B-NF-κB signaling as a therapeutic target, providing potential strategies for managing TFE3-RCC.

**中文摘要译文：**
TFE3重排型肾细胞癌（TFE3-RCC）是一种侵袭性的肾癌亚型，其特点是预后差，且缺乏明确的诊断和治疗靶点。本研究表明，突触囊泡蛋白2B（SV2B）是TFE3-RCC一个潜在的诊断标志物和治疗靶点。SV2B被鉴定为TFE3的靶基因，在TFE3-RCC中显著上调，并对该亚型显示出很高的诊断准确性。功能上，SV2B能增强TFE3-RCC细胞的增殖、迁移和侵袭。机制上，SV2B与RELA/NFKB1竞争性结合E3连接酶HERC2，从而阻止它们的降解并激活NF-κB通路。靶向SV2B的药物padsevonil能选择性抑制TFE3-RCC细胞和类器官的生长，其效果与NF-κB抑制剂Withaferin A相似。临床上，RELA/NFKB1的表达与SV2B水平呈正相关，但与HERC2表达呈负相关，证实了TFE3-SV2B-NF-κB轴在TFE3-RCC中的激活。这些发现确立了SV2B作为TFE3-RCC的新型诊断生物标志物，并验证了SV2B-NF-κB信号通路可作为一个治疗靶点，为TFE3-RCC的治疗提供了潜在策略。

### 第二部分 AI 大师评价

本研究旨在阐明突触囊泡蛋白2B（SV2B）在TFE3重排型肾细胞癌（TFE3-RCC）中的作用，并评估其作为诊断标志物和治疗靶点的潜力。研究通过分子生物学实验和临床样本分析，揭示了SV2B通过竞争性结合HERC2来稳定NF-κB亚基，从而激活信号通路，促进肿瘤进展。其关键发现不仅为预后不良的TFE3-RCC提供了首个特异性较高的诊断生物标志物，更创新性地验证了靶向SV2B-NF-κB轴（如使用药物padsevonil）是一种具有前景的治疗策略，具有重要的临床转化价值。

---

## 16. 更正：MiR-423-5p通过MALAT-1和线粒体相互作用调控肝细胞癌的代谢与生长

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199332](https://pubmed.ncbi.nlm.nih.gov/41199332)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41199332
**DOI：** 10.1186/s13046-025-03562-w

### 第一部分 原文与翻译

**英文原标题：** Correction: MiR-423-5p is a metabolic and growth tuner in hepatocellular carcinoma via MALAT-1 and mitochondrial interaction.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇更正启事，其本身不包含原创性研究内容。其指向的原研究探讨了微小RNA MiR-423-5p在肝细胞癌中的作用。根据标题推断，原研究揭示了MiR-423-5p通过与长链非编码RNA MALAT-1及线粒体的相互作用，调节肿瘤细胞的代谢与生长，这一发现可能为肝细胞癌的治疗提供了新的分子靶点和理论依据。

---

## 17. 利用工程化重组酶实现人类基因组的定点DNA插入

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199024](https://pubmed.ncbi.nlm.nih.gov/41199024)
**期刊：** Nature biotechnology
**PMID：** 41199024
**DOI：** 10.1038/s41587-025-02895-3

### 第一部分 原文与翻译

**英文原标题：** Site-specific DNA insertion into the human genome with engineered recombinases.

**英文摘要原文：**
Insertions of large DNA sequences into the genome are broadly enabling for research and therapeutic applications. Large serine recombinases (LSRs) can mediate direct, site-specific genomic integration of multi-kilobase DNA sequences without a pre-installed landing pad, albeit with low insertion rates and high off-target activity. Here we present an engineering roadmap for jointly optimizing their DNA recombination efficiency and specificity. We combine directed evolution, structural analysis and computational models to rapidly identify additive mutational combinations. We further enhance performance through donor DNA optimization and dCas9 fusions, enabling simultaneous target and donor recruitment. Our top engineered LSR variants, superDn29-dCas9, goldDn29-dCas9 and hifiDn29-dCas9, achieve up to 53% integration efficiency and 97% genome-wide specificity at an endogenous human locus and effectively integrate large DNA cargoes up to 12 kb for stable expression in non-dividing cells, stem cells and primary human T cells. Rational engineering of DNA recombinases enables precise and efficient single-step genome insertion for diverse applications across gene and cell therapies.

**中文摘要译文：**
大片段DNA序列的基因组插入技术广泛应用于研究和治疗领域。大丝氨酸重组酶（LSRs）可以在没有预先安装“着陆平台”的情况下，介导数千碱基对（multi-kilobase）DNA序列的直接、位点特异性基因组整合，但其插入率较低且脱靶活性较高。本研究提出了一个工程化路线图，旨在协同优化其DNA重组的效率和特异性。我们结合了定向进化、结构分析和计算模型，以快速鉴定具有累加效应的突变组合。我们通过优化供体DNA以及融合dCas9蛋白（从而能够同时招募靶点和供体）来进一步提升其性能。我们最优的工程化LSR变体，superDn29-dCas9、goldDn29-dCas9和hifiDn29-dCas9，在人类内源性基因位点上实现了高达53%的整合效率和97%的全基因组特异性，并能有效整合长达12kb的大片段DNA，在非分裂细胞、干细胞和原代人T细胞中实现稳定表达。对DNA重组酶进行理性工程化改造，能够实现精准高效的单步基因组插入，为基因和细胞治疗领域的广泛应用提供了可能。

### 第二部分 AI 大师评价

本研究旨在解决大丝氨酸重组酶（LSRs）在基因组大片段插入应用中效率低、脱靶率高的核心难题。研究团队通过结合定向进化、结构分析和dCas9融合等多种前沿技术，成功开发出新型工程化重组酶。这些新工具在人类细胞中实现了高达53%的整合效率和97%的特异性，并能高效插入长达12kb的DNA片段。该成果为基因和细胞治疗提供了一种精准、高效的“一步式”大片段基因插入工具，具有重大的临床转化潜力。

---

## 18. CRISPR活细胞成像技术揭示多个非重复位点的染色质动态及增强子相互作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199023](https://pubmed.ncbi.nlm.nih.gov/41199023)
**期刊：** Nature biotechnology
**PMID：** 41199023
**DOI：** 10.1038/s41587-025-02887-3

### 第一部分 原文与翻译

**英文原标题：** CRISPR live-cell imaging reveals chromatin dynamics and enhancer interactions at multiple non-repetitive loci.

**英文摘要原文：**
Existing methods to visualize dynamic changes in the three-dimensional genome, promoter-enhancer interactions and the influence of epigenetic modifications in non-repetitive loci are limited. Here we introduce CRISPR PRO-LiveFISH (Pooled gRNAs with Orthogonal bases LiveFISH), which combines orthogonal bases from expanded genetic alphabet technology and rational single guide RNA (sgRNA) design to efficiently label multiple non-repetitive loci in living cells. The optimized method allows simultaneous imaging of up to six genomic loci and uses as few as 10 sgRNAs for non-repetitive loci imaging without signal amplification. We demonstrate the method in diverse cell types, including primary cells, and apply it to reveal enhancer-promoter dynamics and a correlation between genomic dynamics and epigenetic states. We also show that PCDHα-enhancer interactions may persist despite spatial mobility and that BRD4 maintains super-enhancer contacts regulating MYC oncogene expression in cancer cells. CRISPR PRO-LiveFISH can be applied to diverse studies of chromatin dynamics and genome organization in living cells.

**中文摘要译文：**
现有的可视化非重复位点三维基因组动态变化、启动子-增强子相互作用以及表观遗传修饰影响的方法存在局限性。在此，我们介绍了一种名为CRISPR PRO-LiveFISH（利用正交碱基的池化gRNA LiveFISH）的新技术，该技术结合了来自扩展遗传字母技术的正交碱基和合理的单导向RNA（sgRNA）设计，从而能够高效地标记活细胞中的多个非重复位点。该优化方法可同时对多达六个基因组位点进行成像，并且在无需信号放大的情况下，仅需使用少至10个sgRNA即可实现非重复位点的成像。我们在包括原代细胞在内的多种细胞类型中验证了该方法，并应用其揭示了增强子-启动子动态以及基因组动态与表观遗传状态之间的相关性。我们还发现，尽管存在空间移动性，PCDHα-增强子的相互作用仍可能持续存在，并且在癌细胞中，BRD4蛋白维持着调控MYC癌基因表达的超级增强子接触。CRISPR PRO-LiveFISH技术可广泛应用于活细胞中染色质动态和基因组组织的各种研究。

### 第二部分 AI 大师评价

本研究介绍了一种名为CRISPR PRO-LiveFISH的新型活细胞成像技术，旨在解决同时可视化多个非重复基因组位点的难题。该方法巧妙地结合了扩展遗传字母技术和优化的sgRNA设计，实现了无需信号放大、高效率的多位点同时成像。研究不仅成功揭示了增强子-启动子的动态相互作用及其与表观遗传状态的关联，还阐明了BRD4在维持癌基因MYC表达中的关键作用，为实时研究活细胞内的基因组三维结构与调控机制提供了强有力的工具，具有重要的科研价值和广阔的应用前景。

---

## 19. MAPK-RUNX1轴对SMARCA5的时空调控区分了KRAS突变驱动的胰腺恶性肿瘤与组织再生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198969](https://pubmed.ncbi.nlm.nih.gov/41198969)
**期刊：** Nature cancer
**PMID：** 41198969
**DOI：** 10.1038/s43018-025-01065-3

### 第一部分 原文与翻译

**英文原标题：** Spatiotemporal control of SMARCA5 by a MAPK-RUNX1 axis distinguishes mutant KRAS-driven pancreatic malignancy from tissue regeneration.

**英文摘要原文：**
Acute pancreatitis-induced acinar-to-ductal metaplasia involves global chromatin remodeling and contributes to normal tissue regeneration. Oncogenic KRAS hijacks this process to promote PDAC formation. Here we show that regeneration and KRAS-driven oncogenesis can be decoupled from tissue regeneration through a chromatin remodeler, SMARCA5. We show that SMARCA5 maintains KRAS-dependent chromatin accessibility at regions specifically required for malignancy, without affecting chromatin opening that occurs during normal regeneration. Without SMARCA5, regeneration can be restored in the presence of KRAS. Mechanistically, regeneration-related or malignancy-related chromatin remodeling activities occur in a time-sensitive manner. The activity of SMARCA5 is controlled spatiotemporally by transcription factor RUNX1, which only accumulates at sufficient levels with sustained MAPK signals. We further show that inhibition of the SMARCA5-containing NoRC complex specifically inhibits the growth of PDAC organoid but not that of normal tissue derived from patients.

**中文摘要译文：**
急性胰腺炎诱导的腺泡-导管化生涉及全局染色质重塑，并有助于正常组织再生。致癌性KRAS劫持此过程以促进胰腺导管腺癌（PDAC）的形成。本研究表明，通过染色质重塑因子SMARCA5，可以将KRAS驱动的肿瘤发生从组织再生中解耦。我们发现，SMARCA5维持了恶性肿瘤特异性所需区域的KRAS依赖性染色质可及性，而不影响正常再生过程中发生的染色质开放。在缺乏SMARCA5的情况下，即使存在KRAS，组织再生仍可恢复。从机制上讲，与再生相关或与恶性肿瘤相关的染色质重塑活动是以时间敏感的方式发生的。SMARCA5的活性受到转录因子RUNX1的时空调控，而RUNX1仅在持续的MAPK信号下才能积累到足够水平。我们进一步证明，抑制含SMARCA5的NoRC复合物能特异性抑制源自患者的PDAC类器官的生长，但对正常组织来源的类器官则无影响。

### 第二部分 AI 大师评价

该研究旨在揭示KRAS突变驱动的胰腺癌发生与组织再生过程相区别的关键分子机制。研究通过对染色质重塑因子SMARCA5及其上游调控通路的研究，发现MAPK-RUNX1信号轴对SMARCA5的时空调控，是区分恶性转化与正常修复的分水岭。此项发现不仅深刻揭示了胰腺癌发生的独特表观遗传学依赖性，更重要的是，其验证了靶向SMARCA5所在的NoRC复合物能特异性杀伤肿瘤细胞而不影响正常组织，为开发高选择性、低毒性的胰腺癌新疗法提供了极具价值的分子靶点和理论依据。

---

## 20. 小生物分子对RNA结合蛋白的调控作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198869](https://pubmed.ncbi.nlm.nih.gov/41198869)
**期刊：** Nature reviews. Molecular cell biology
**PMID：** 41198869
**DOI：** 10.1038/s41580-025-00914-4

### 第一部分 原文与翻译

**英文原标题：** Regulation of RNA-binding proteins by small biomolecules.

**英文摘要原文：**
RNA-binding proteins (RBPs) are essential for post-transcriptional gene regulation, including for RNA modification such as N-methyladenosine (mA), splicing, polyadenylation, localization, translation and decay. Dysregulation of RBPs has been causally linked to a wide array of human diseases, including cancer, neurodegenerative diseases, metabolic disorders and tissue differentiation abnormalities. Although RBPs have traditionally been studied through their RNA, protein and post-translational interactions, growing evidence shows that small biomolecules (SBMs) such as sugars, nucleotides, metabolites such as S-adenosylmethionine (SAM) and NAD(P)H, and drugs can directly bind RBPs and modulate their structure, localization and RNA-binding activity. These context-dependent and concentration-dependent interactions link RBP regulation to cellular metabolism and are a key focus of current research. In this Review, we discuss the expanding landscape of SBM-binding RBPs and the functions of these RBPs in condensate formation, RNA localization, processing and translation. We highlight the molecular principles that underlie these interactions and their functional relevance to human diseases. We also examine recent advances in the identification of SBM-RBP interactions and the innovative methodologies that are driving discoveries in this rapidly advancing field. Together, these insights underscore the potential of SBMs to modulate RBPs and inform novel therapeutic strategies.

**中文摘要译文：**
RNA结合蛋白（RBPs）对转录后基因调控至关重要，包括N-甲基腺苷（mA）等RNA修饰、剪接、多聚腺苷酸化、定位、翻译和降解。RBPs的失调与多种人类疾病有因果关系，包括癌症、神经退行性疾病、代谢紊乱和组织分化异常。尽管传统上主要通过研究RBPs的RNA、蛋白质和翻译后相互作用来探索其功能，但越来越多的证据表明，糖类、核苷酸、S-腺苷甲硫氨酸（SAM）和NAD(P)H等代谢物以及药物等小生物分子（SBMs）可以直接结合RBPs，并调节其结构、定位和RNA结合活性。这些具有背景依赖性和浓度依赖性的相互作用将RBP的调控与细胞代谢联系起来，是当前研究的一个关键焦点。在这篇综述中，我们探讨了不断扩展的SBM结合RBPs领域，以及这些RBPs在凝聚体形成、RNA定位、加工和翻译中的功能。我们重点阐述了这些相互作用的分子原理及其与人类疾病的功能相关性。我们还考察了在鉴定SBM-RBP相互作用方面的最新进展，以及推动这个快速发展领域取得新发现的创新方法学。总而言之，这些见解强调了SBMs在调节RBPs方面的潜力，并为新的治疗策略提供了信息。

### 第二部分 AI 大师评价

该综述系统阐述了小生物分子（SBMs）作为RNA结合蛋白（RBPs）直接调控因子的新兴研究领域。文章深入探讨了代谢物、糖类及药物等SBMs如何通过直接结合来调节RBPs的结构与功能，进而影响RNA加工、定位及翻译等关键生命过程。此文的创新性在于揭示了细胞代谢与转录后基因调控之间的新型直接联系，不仅为理解癌症、神经退行性疾病等多种疾病的发病机制提供了新视角，也为开发靶向RBP-SBM相互作用的新型治疗策略指明了方向。

---

## 21. PRKG1在横纹肌肉瘤中阻碍生肌分化并预测AKT抑制剂ipatasertib的治疗反应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198706](https://pubmed.ncbi.nlm.nih.gov/41198706)
**期刊：** Nature communications
**PMID：** 41198706
**DOI：** 10.1038/s41467-025-64783-3

### 第一部分 原文与翻译

**英文原标题：** PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma.

**英文摘要原文：**
Rhabdomyosarcoma (RMS) is marked by a myogenesis differentiation blockade, and while the AKT/mTOR pathway is universally activated, its pharmacological inhibition has shown limited success. Here, we evaluate the activity of pan-AKT inhibitors Ipatasertib, ATP-competitive, and Miransertib, allosteric inhibitor, in RMS cell lines and fusion-positive/negative patient-derived xenografts (PDX). Unlike Miransertib, Ipatasertib show significant antitumor activity against a subset of RMS. Besides AKT, the other target of Ipatasertib, but not of Miransertib, is PRKG1, a cGMP-dependent protein kinase that shares the ATP binding pocket with AKT. We investigate the role of PRKG1 in PRKG1-depleted RMS cells and in xenograft models by transcriptomic approaches. PRKG1 silencing in RMS cells reduces tumor formation in xenograft models and induces a differentiated myogenic transcriptome. RMS show higher PRKG1 expression compared to any other developmental cancer, akin to fetal skeletal muscle. Importantly, PRKG1 expression in RMS correlates with mesodermal transcriptional signature and enhanced sensitivity to Ipatasertib, regardless of the fusion oncogene status. The antitumor activity of Ipatasertib is dose-dependent, reaching an effective intra-tumor concentration when administered at 25 mg/kg daily. This study unveils the role of PRKG1 in myogenesis and highlights the potential of PRKG1 as a clinical biomarker for Ipatasertib therapy in RMS.

**中文摘要译文：**
横纹肌肉瘤（RMS）的特征在于生肌分化受阻，尽管AKT/mTOR通路被普遍激活，但对其进行药物抑制的成功率有限。在此，我们在RMS细胞系和融合基因阳性/阴性的患者来源异种移植物（PDX）中，评估了泛AKT抑制剂Ipatasertib（一种ATP竞争性抑制剂）和Miransertib（一种变构抑制剂）的活性。与Miransertib不同，Ipatasertib对一部分RMS显示出显著的抗肿瘤活性。除AKT外，Ipatasertib的另一个靶点是PRKG1（一种cGMP依赖性蛋白激酶），而Miransertib则不作用于此靶点；PRKG1与AKT共享ATP结合口袋。我们通过转录组学方法，在PRKG1耗尽的RMS细胞和异种移植模型中研究了PRKG1的作用。在RMS细胞中沉默PRKG1可减少异种移植模型中的肿瘤形成，并诱导分化的生肌转录组。与其他任何发育性癌症相比，RMS显示出更高的PRKG1表达水平，类似于胎儿骨骼肌。重要的是，无论融合癌基因状态如何，RMS中PRKG1的表达与中胚层转录特征和对Ipatasertib敏感性增强相关。Ipatasertib的抗肿瘤活性呈剂量依赖性，当每日给药剂量为25 mg/kg时，可达到有效的肿瘤内浓度。本研究揭示了PRKG1在生肌过程中的作用，并强调了PRKG1作为RMS中Ipatasertib治疗的临床生物标志物的潜力。

### 第二部分 AI 大师评价

该研究精准切入横纹肌肉瘤（RMS）治疗中AKT抑制剂疗效不一的临床困境，通过对比两种AKT抑制剂，创新性地揭示了Ipatasertib的抗肿瘤活性不仅源于对AKT的抑制，更关键在于其对PRKG1的“脱靶”效应。研究首次阐明PRKG1是阻碍RMS生肌分化的关键因子，并证实其高表达水平可作为预测Ipatasertib疗效的精准生物标志物。这项发现不仅为理解RMS的发病机制提供了新视角，更具有重要的临床转化价值，为RMS患者的精准分层与靶向治疗策略提供了坚实的实验依据。

---

## 22. 肺腺癌中CMTR2突变改变RNA可变剪接并揭示其治疗脆弱性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198678](https://pubmed.ncbi.nlm.nih.gov/41198678)
**期刊：** Nature communications
**PMID：** 41198678
**DOI：** 10.1038/s41467-025-64821-0

### 第一部分 原文与翻译

**英文原标题：** Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities.

**英文摘要原文：**
RNA splicing dysregulation has emerged as a hallmark of cancer and a promising therapeutic target; however, its full landscape in human solid cancer remains poorly characterized. To address this, we perform alternative splicing analyses using RNA-sequencing data from 751 lung adenocarcinoma samples from our cohort integrated with 519 samples from The Cancer Genome Atlas. Visualization of splicing patterns using t-distributed stochastic neighbor embedding reveals substantial inter-tumor heterogeneity driven by distinct molecular subtypes and histological differentiation. We identify a unique molecular subtype associated with inactivating mutations in CMTR2, which encodes Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2. CMTR2 mutations are observed in 3.8% of cases and are predominantly truncating mutations, which form an isolated cluster within the splicing landscape. Intrinsic and CRISPR-Cas9-engineered CMTR2 mutations disrupt alternative splicing and sensitize cancer cells to sulfonamide-based RNA splicing modulators and immune checkpoint blockade therapy. Retrospective patient data confirm the increased sensitivity of CMTR2-deficient tumors to immune checkpoint blockade therapy. These findings uncover a previously unrecognized RNA splicing deficiency in human cancers and define a molecular subtype of lung adenocarcinoma driven by RNA splicing dysregulation, suggesting targets for therapeutic intervention in lung cancer.

**中文摘要译文：**
RNA剪接失调已成为癌症的一大标志和有潜力的治疗靶点；然而，其在人类实体瘤中的全景图谱仍不清晰。为解决此问题，我们利用来自我们队列的751例肺腺癌样本，并整合了癌症基因组图谱（TCGA）的519例样本的RNA测序数据，进行了可变剪接分析。使用t-分布随机邻域嵌入（t-SNE）对剪接模式进行可视化，结果揭示了由不同分子亚型和组织学分化驱动的显著的肿瘤间异质性。我们识别出一个与CMTR2（编码帽特异性mRNA（核苷-2'-O-）-甲基转移酶2）失活性突变相关的独特分子亚型。CMTR2突变在3.8%的病例中被观察到，且主要为截短突变，这些突变在剪接图谱中形成一个孤立的簇。内源性的和经CRISPR-Cas9工程改造的CMTR2突变均会破坏可变剪接，并使癌细胞对基于磺胺类的RNA剪接调节剂和免疫检查点阻断疗法敏感。回顾性患者数据证实了CMTR2缺陷型肿瘤对免疫检查点阻断疗法的敏感性增加。这些发现揭示了一种先前未被认识到的人类癌症中的RNA剪接缺陷，并定义了一个由RNA剪接失调驱动的肺腺癌分子亚型，为肺癌的治疗干预提出了新的靶点。

### 第二部分 AI 大师评价

本研究通过对大规模肺腺癌队列的RNA测序数据进行深度可变剪接分析，旨在描绘其剪接图谱并发现新的分子亚型。研究团队创新性地利用t-SNE可视化等方法，成功识别出一个由CMTR2基因失活性突变驱动的独特分子亚型。核心发现是，CMTR2突变不仅导致RNA剪接紊乱，还显著提升了肿瘤细胞对特定剪接调节剂及免疫检查点抑制剂的敏感性。这一发现具有重要的临床转化价值，提示CMTR2可作为预测免疫治疗疗效的潜在生物标志物，为一部分肺腺癌患者开辟了精准治疗的新策略。

---

## 23. HER3通过miR-34b-5p依赖性机制上调PHF8，促进三阴性乳腺癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198671](https://pubmed.ncbi.nlm.nih.gov/41198671)
**期刊：** Cell death & disease
**PMID：** 41198671
**DOI：** 10.1038/s41419-025-08115-9

### 第一部分 原文与翻译

**英文原标题：** HER3 promotes triple-negative breast cancer progression by upregulating PHF8 via miR-34b-5p-dependent mechanism.

**英文摘要原文：**
Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, with limited targeted treatment options and poor clinical outcomes. HER3 has recently emerged as a promising therapeutic target, with HER3-directed antibody-drug conjugates advancing to Phase III clinical trials for non-small cell lung cancer. However, the downstream molecular mechanisms by which HER3 promotes TNBC progression remain poorly defined. In this study, we uncovered a previously unrecognized HER3/miR-34b-5p/PHF8 signaling axis that drives TNBC cell proliferation and tumor growth. Mechanistically, HER3 activation suppresses the tumor-suppressive microRNA miR-34b-5p, resulting in the upregulation of the histone demethylase PHF8 (KDM7B), which in turn represses the expression of the CDK inhibitor p27 and facilitates G1-S cell cycle progression. Functional studies using shRNA-mediated knockdown and overexpression systems demonstrate that PHF8 is a critical downstream effector of HER3. PHF8 depletion phenocopied HER3 knockdown, inducing G1 arrest and suppressing colony formation and proliferation in multiple TNBC cell lines, while PHF8 overexpression rescued the inhibitory effects of HER3 loss. Furthermore, orthotopic xenograft models revealed that enforced PHF8 expression restored tumor growth suppressed by HER3 silencing in vivo. Clinically, HER3 and PHF8 expression levels were positively correlated in TNBC tissue specimens, and TCGA dataset analyses indicated that the HER3/miR-34b-5p/PHF8 axis is significantly associated with poor survival outcomes in breast cancer patients. Collectively, our findings establish a novel epigenetic regulatory circuit through which HER3 drives TNBC progression and lay the groundwork for future therapeutic strategies aimed at disrupting HER3-epigenetic crosstalk in TNBC.

**中文摘要译文：**
三阴性乳腺癌（TNBC）是乳腺癌中侵袭性最强的亚型之一，其靶向治疗选择有限，临床预后差。HER3最近已成为一个有潜力的治疗靶点，针对HER3的抗体药物偶联物已进入针对非小细胞肺癌的III期临床试验。然而，HER3促进TNBC进展的下游分子机制仍不明确。在本研究中，我们发现了一条先前未被认识的、驱动TNBC细胞增殖和肿瘤生长的HER3/miR-34b-5p/PHF8信号轴。从机制上讲，HER3的激活抑制了具有肿瘤抑制功能的microRNA miR-34b-5p，导致组蛋白去甲基化酶PHF8（KDM7B）的上调，而PHF8进而抑制CDK抑制剂p27的表达，并促进G1-S细胞周期进程。利用shRNA介导的敲降和过表达系统进行的功能性研究表明，PHF8是HER3的一个关键下游效应分子。在多种TNBC细胞系中，PHF8的耗竭表型复制了HER3敲降的效果，诱导了G1期阻滞并抑制了集落形成和增殖，而PHF8的过表达则挽救了HER3缺失所带来的抑制效应。此外，原位异种移植模型显示，在体内，强制表达PHF8能够恢复因HER3沉默而被抑制的肿瘤生长。在临床上，TNBC组织标本中HER3和PHF8的表达水平呈正相关，并且TCGA数据集分析表明，HER3/miR-34b-5p/PHF8轴与乳腺癌患者的不良生存结局显著相关。总之，我们的研究结果建立了一个新的表观遗传调控回路，HER3通过该回路驱动TNBC的进展，并为未来旨在破坏TNBC中HER3-表观遗传串扰的治疗策略奠定了基础。

### 第二部分 AI 大师评价

本研究旨在揭示HER3促进三阴性乳腺癌（TNBC）进展的下游分子机制。通过结合细胞系功能实验、动物模型验证及临床数据分析，研究团队创新性地鉴定出一条全新的“HER3/miR-34b-5p/PHF8”信号轴。该研究发现HER3通过抑制抑癌性miR-34b-5p，上调组蛋白去甲基化酶PHF8，进而促进细胞周期进程和肿瘤生长。这一发现不仅深化了对TNBC发病机制的理解，更重要的是，它揭示了HER3与表观遗传调控之间的串扰，为开发针对这一新型信号轴的TNBC靶向治疗策略提供了坚实的理论基础和潜在的新靶点。

---

## 24. 细胞内镁离子抑制人TRPV6通道的锁定机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198662](https://pubmed.ncbi.nlm.nih.gov/41198662)
**期刊：** Nature communications
**PMID：** 41198662
**DOI：** 10.1038/s41467-025-65919-1

### 第一部分 原文与翻译

**英文原标题：** The locking mechanism of human TRPV6 inhibition by intracellular magnesium.

**英文摘要原文：**
TRPV6 is a member of the vanilloid subfamily of transient receptor potential channels, which serves as the master regulator of Ca homeostasis. TRPV6 functions as a constitutively active Ca channel, and emerging evidence indicates that its overactivity underpins the progression of several human diseases, including cancer. Hence, there is a pressing need to identify TRPV6 inhibitors in conjunction with a deep mechanistic understanding of their effects on the channel activity. Here we combine cryo-electron microscopy, mutagenesis, electrophysiology and molecular dynamics modeling to decipher the molecular mechanism of TRPV6 inhibition by intracellular Mg. Mg appears to bind to four, one per subunit, sites around the intracellular entrance to the TRPV6 channel pore, contributed by the negatively charged residues, D489 in the transmembrane helix S5 and D580 in S6. When bound to the D489-D580 site, Mg prevents the α-to-π transition in the middle of S6 that accompanies channel opening, thus maintaining S6 entirely α-helical, locking the channel in the closed state and inhibiting TRPV6-mediated currents. Further exploration of this inhibitory mechanism may help to develop future strategies for the treatment of TRPV6-associated diseases.

**中文摘要译文：**
TRPV6是瞬时受体电位通道香草酸亚家族的成员，是钙稳态的主要调节因子。TRPV6作为一个组成性激活的钙通道发挥作用，并且越来越多的证据表明，其过度活跃是包括癌症在内的多种人类疾病进展的基础。因此，迫切需要在深入理解其对通道活性影响的机制基础上，寻找TRPV6的抑制剂。本研究中，我们结合了冷冻电子显微镜、定点突变、电生理学和分子动力学模拟技术，来解析细胞内镁离子抑制TRPV6的分子机制。镁离子似乎结合在TRPV6通道孔细胞内入口周围的四个位点（每个亚基一个），这些位点由跨膜螺旋S5中的D489和S6中的D580这两个带负电荷的残基构成。当与D489-D580位点结合时，镁离子会阻止伴随通道开放的S6螺旋中段发生的α-向-π螺旋构象转变，从而使S6螺旋完全保持α螺旋状态，将通道锁定在关闭状态，并抑制TRPV6介导的电流。对该抑制机制的进一步探索可能有助于为治疗TRPV6相关疾病开发未来的策略。

### 第二部分 AI 大师评价

该研究旨在阐明细胞内镁离子抑制关键钙离子通道TRPV6的分子机制。研究团队综合运用冷冻电镜、电生理学和分子动力学模拟等前沿技术，精准揭示了镁离子通过与特定位点（D489-D580）结合，阻止S6螺旋发生开放所需的构象变化，从而将通道“锁定”于关闭状态。此发现不仅在原子层面深化了对TRPV6通道门控调控的理解，更重要的是，它为开发针对癌症等TRPV6过度活跃相关疾病的新型变构抑制剂提供了关键的结构基础和理论依据。

---

## 25. p62依赖性的caspase-2激活调控肌萎缩侧索硬化症（ALS）中的TDP-43清除及神经元命运

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198658](https://pubmed.ncbi.nlm.nih.gov/41198658)
**期刊：** Cell death & disease
**PMID：** 41198658
**DOI：** 10.1038/s41419-025-08118-6

### 第一部分 原文与翻译

**英文原标题：** p62-dependent caspase-2 activation governs TDP-43 clearance and neuronal fate in ALS.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要暂缺。

### 第二部分 AI 大师评价

根据文献标题推断，本研究旨在揭示肌萎缩侧索硬化症（ALS）中神经元变性的一个关键分子机制。研究的核心发现可能在于，p62蛋白依赖性的caspase-2激活是调控病理性蛋白TDP-43清除的关键上游事件，这一过程直接决定了神经元的最终命运。该研究的创新性在于将自噬关键蛋白p62、细胞凋亡蛋白caspase-2与ALS核心病理蛋白TDP-43联系起来，为理解ALS的发病机制提供了新视角，并为开发旨在促进TDP-43清除的治疗策略提供了潜在靶点。

---

## 26. TAE684抑制Fyn：一种抑制黑色素瘤并逆转维莫非尼耐药的协同策略。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198656](https://pubmed.ncbi.nlm.nih.gov/41198656)
**期刊：** Cell death & disease
**PMID：** 41198656
**DOI：** 10.1038/s41419-025-08090-1

### 第一部分 原文与翻译

**英文原标题：** Fyn inhibition by TAE684: A synergistic strategy to suppress melanoma and reverse vemurafenib resistance.

**英文摘要原文：**
Therapies targeting BRAF can inhibit the development of melanoma with BRAF mutations and enhance survival rates, though acquired resistance inevitably arises. The non-receptor tyrosine kinase Fyn, recognized for its role in regulating tumor cell survival and drug resistance, has emerged as a promising therapeutic target in melanoma treatment. In this study, we conducted a virtual screening and identified TAE684 as a potent inhibitor of Fyn. Utilizing in vitro assays, including assessments of cell viability, reactive oxygen species (ROS) production and DNA damage, alongside an in vivo melanoma xenograft model, we demonstrated that either TAE684 treatment or Fyn knockdown resulted in increased ROS levels and DNA damage, ultimately inducing cell cycle arrest at the G2/M phase and apoptosis in melanoma cells. Significantly, the application of TAE684 in melanoma cells demonstrated a capacity to counteract vemurafenib resistance, presumably through the down-regulation of the AP-1 pathway. Furthermore, the combination of TAE684 with vemurafenib exhibits a synergistic effect, leading to decreased cell viability in melanoma cells resistant to vemurafenib treatment. These results highlight the potential of TAE684 as a dual-function agent that not only inhibits melanoma proliferation but also reverses resistance to vemurafenib by targeting Fyn, thereby establishing it as a promising candidate for melanoma therapy.

**中文摘要译文：**
靶向BRAF的疗法能够抑制携带BRAF突变的黑色素瘤的发展并提高生存率，但获得性耐药的出现不可避免。非受体酪氨酸激酶Fyn因其在调节肿瘤细胞存活和耐药性中的作用而被公认，现已成为黑色素瘤治疗中一个有前景的治疗靶点。在本研究中，我们进行了虚拟筛选，并鉴定出TAE684是Fyn的有效抑制剂。通过利用体外实验（包括细胞活力、活性氧（ROS）产生和DNA损伤的评估）以及体内黑色素瘤异种移植模型，我们证明了TAE684治疗或Fyn敲低均能导致ROS水平升高和DNA损伤增加，最终诱导黑色素瘤细胞G2/M期周期阻滞和凋亡。值得注意的是，TAE684在黑色素瘤细胞中的应用显示出逆转维莫非尼耐药的能力，这推测是通过下调AP-1通路实现的。此外，TAE684与维莫非尼联合用药表现出协同效应，导致对维莫非尼治疗耐药的黑色素瘤细胞活力下降。这些结果凸显了TAE684作为一种双功能药物的潜力，它不仅能通过靶向Fyn抑制黑色素瘤增殖，还能逆转对维莫非尼的耐药性，从而使其成为黑色素瘤治疗的一个有前景的候选药物。

### 第二部分 AI 大师评价

该研究通过虚拟筛选发现并验证了新型Fyn激酶抑制剂TAE684在黑色素瘤治疗中的潜力。研究结合体外细胞实验与体内动物模型，明确了TAE684能诱导黑色素瘤细胞凋亡，并揭示了其逆转维莫非尼耐药性的关键作用机制，可能与下调AP-1通路有关。此项工作的创新之处在于提出了靶向Fyn作为克服BRAF抑制剂耐药的新策略，TAE684与维莫非尼的协同效应为治疗耐药性黑色素瘤提供了有力的实验依据和颇具前景的临床转化方向。

---

## 27. HIRA独立于基因组区室定义早期复制起始区

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198653](https://pubmed.ncbi.nlm.nih.gov/41198653)
**期刊：** Nature communications
**PMID：** 41198653
**DOI：** 10.1038/s41467-025-65130-2

### 第一部分 原文与翻译

**英文原标题：** HIRA defines early replication initiation zones independently of their genome compartment.

**英文摘要原文：**
Chromatin states and 3D architecture have been used as proxy to identify replication initiation zones (IZs) in mammalian cells, yet their functional interconnections remain a puzzle. Here, to dissect these relationships, we focus on the histone H3.3 chaperone HIRA recently implicated in early initiation zone (IZ) definition. We monitor 3D organisation, chromatin accessibility and histone post-translational modifications (PTMs) in wild-type and HIRA knock-out cells in parallel with early replication initiation. In the absence of HIRA, compartment A loses H3.3 enrichment and gains accessibility without changes in associated histone post-translational modifications (PTMs). Furthermore, impaired early firing at HIRA-dependent IZs does not correspond to changes in chromatin accessibility or patterns of histone H3 PTMs. Additionally, a small subset of early IZs initially in compartment A switch to B and lose early initiation in the absence of HIRA. Critically, HIRA complementation restores these early IZ, and H3.3 variant enrichment, without substantial compartment reversal. Thus, while HIRA contributes to compartment A features, its role in regulating early replication initiation can be uncoupled from accessibility, histone marks and compartment organisation.

**中文摘要译文：**
在哺乳动物细胞中，染色质状态和三维结构已被用作识别复制起始区（IZs）的代理指标，但它们之间的功能性相互联系仍是一个谜。在此，为剖析这些关系，我们关注了最近被发现与早期起始区（IZ）定义有关的组蛋白H3.3伴侣HIRA。我们在野生型和HIRA敲除细胞中，同步监测了三维结构、染色质可及性和组蛋白翻译后修饰（PTMs），并与早期复制起始进行平行分析。在HIRA缺失的情况下，A区室（compartment A）失去了H3.3的富集并增加了染色质可及性，但相关的组蛋白翻译后修饰（PTMs）并未发生改变。此外，HIRA依赖性IZs的早期起始受损与染色质可及性或组蛋白H3 PTMs模式的改变并不对应。另外，在HIRA缺失时，一小部分最初位于A区室的早期IZs会转换到B区室，并丧失其早期起始能力。关键的是，HIRA的补充能够恢复这些早期IZ的功能以及H3.3变体的富集，而不会导致区室的显著逆转。因此，尽管HIRA有助于维持A区室的特征，但其在调控早期复制起始中的作用可以与染色质可及性、组蛋白标记和区室结构解耦。

### 第二部分 AI 大师评价

本研究旨在阐明组蛋白伴侣HIRA在定义早期复制起始区（IZs）中的作用，并探究其与染色质三维结构及组蛋白修饰的关系。通过对野生型和HIRA敲除细胞进行多组学比较分析，研究发现HIRA调控早期复制起始的功能可以与其在维持染色质可及性、特定组蛋白标记和基因组区室结构方面的作用相解耦。这一发现具有高度创新性，它挑战了认为染色质高级结构是复制起始唯一决定因素的传统观点，为理解DNA复制调控提供了新的分子机制视角，具有重要的基础科研价值。

---

## 28. L-2-HG在调控HIF1A信号通路及肾癌脑转移铁死亡抗性中的新作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198650](https://pubmed.ncbi.nlm.nih.gov/41198650)
**期刊：** Cell death & disease
**PMID：** 41198650
**DOI：** 10.1038/s41419-025-08068-z

### 第一部分 原文与翻译

**英文原标题：** Novel role of L-2-HG in regulating HIF1A signaling pathway and iron death resistance in renal cancer brain metastasis.

**英文摘要原文：**
L-2-hydroxyglutarate (L-2-HG) functions as a metabolite implicated in the progression of various tumors. HIF1A, a central regulator of the hypoxic response, is known to be regulated by several metabolites. This study aims to elucidate whether L-2-HG regulates the function of HIF1A through histone lactylation modification, thereby contributing to brain metastasis in renal cell carcinoma (RCC). A mouse model of RCC brain metastasis was constructed, and high-throughput metabolomics, transcriptomics, and proteomics sequencing analyses were conducted. Bioinformatics analysis revealed that L-2-HG enhanced HIF1A expression by promoting histone lactylation modification, which suppressed ferroptosis and facilitated RCC brain metastasis. In vitro cellular experiments were conducted, including cell treatment, transfection, chromatin immunoprecipitation (ChIP), malignant phenotype detection assays, Western blotting, and RT-qPCR. The results showed that L-2-HG increased the lactylation modification of HIF1A and enhanced the resistance of renal cancer cells to ferroptosis, thereby increasing cell proliferation, migration, and invasion. In vivo experiments using a nude mouse lung metastasis model demonstrated the mechanism through which L-2-HG promoted RCC brain metastasis.

**中文摘要译文：**
L-2-羟基戊二酸（L-2-HG）是一种与多种肿瘤进展相关的代谢物。作为缺氧反应的核心调节因子，HIF1A已知受多种代谢物的调控。本研究旨在阐明L-2-HG是否通过组蛋白乳酸化修饰调控HIF1A的功能，从而促进肾细胞癌（RCC）的脑转移。研究构建了RCC脑转移的小鼠模型，并进行了高通量代谢组学、转录组学和蛋白质组学测序分析。生物信息学分析显示，L-2-HG通过促进组蛋白乳酸化修饰来增强HIF1A的表达，进而抑制铁死亡并促进RCC脑转移。体外细胞实验包括细胞处理、转染、染色质免疫沉淀（ChIP）、恶性表型检测、蛋白质印迹法和实时定量PCR。结果表明，L-2-HG增加了HIF1A的乳酸化修饰，增强了肾癌细胞对铁死亡的抗性，从而促进了细胞的增殖、迁移和侵袭。采用裸鼠肺转移模型的体内实验证明了L-2-HG促进RCC脑转移的机制。

### 第二部分 AI 大师评价

本研究旨在揭示代谢物L-2-羟基戊二酸（L-2-HG）在肾细胞癌（RCC）脑转移中的具体作用机制。研究团队综合运用了多组学分析与体内外实验模型，发现L-2-HG通过促进组蛋白乳酸化修饰来上调HIF1A的表达，进而抑制铁死亡，最终增强了癌细胞的恶性表型。此项研究的创新之处在于，它清晰地串联起“代谢物-表观遗传-关键信号分子-细胞死亡模式”这一调控轴线，为理解RCC脑转移的复杂机制提供了新视角，并提示了潜在的治疗靶点。

---

## 29. 更正：肝细胞中C3G的缺失损害肝脏的完全成熟并改变葡萄糖稳态。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198631](https://pubmed.ncbi.nlm.nih.gov/41198631)
**期刊：** Cell death & disease
**PMID：** 41198631
**DOI：** 10.1038/s41419-025-08181-z

### 第一部分 原文与翻译

**英文原标题：** Correction: Deletion of C3G in hepatocytes impairs full liver maturation and alters glucose homeostasis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇更正声明，其标题直接揭示了原始研究的核心发现。该研究可能通过在肝细胞中特异性敲除C3G基因，探索了其在肝脏生理功能中的作用。关键发现指出，C3G的缺失会损害肝脏的完全成熟过程，并导致葡萄糖稳态失调。尽管本篇更正无摘要，但标题所传达的信息对于理解肝脏发育、功能维持以及相关代谢性疾病（如糖尿病）的分子机制具有重要的科研价值，提示了C3G可能是一个潜在的治疗靶点。

---

## 30. MYC依赖性lncRNA MB3通过HMGN5调控TGF-β通路抑制第3组髓母细胞瘤的细胞凋亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198629](https://pubmed.ncbi.nlm.nih.gov/41198629)
**期刊：** Cell death & disease
**PMID：** 41198629
**DOI：** 10.1038/s41419-025-08097-8

### 第一部分 原文与翻译

**英文原标题：** The MYC-dependent lncRNA MB3 inhibits apoptosis in Group 3 Medulloblastoma by regulating the TGF-β pathway via HMGN5.

**英文摘要原文：**
Group 3 (G3) is one of the most common and aggressive subtypes of the paediatric cerebellar tumour Medulloblastoma (MB), primarily driven by the MYC oncogene. The challenging targeting of MYC, coupled with gaps in understanding G3 MB molecular bases, has hindered the development of targeted therapies. The unconventional oncogenic roles of long noncoding RNAs (lncRNAs) offer opportunities to address this complexity, to provide insights and to identify novel targets. Using -omics approaches and molecular/cellular assays, we elucidate the mode-of-action of lncMB3, a MYC-dependent, anti-apoptotic lncRNA in G3 MB. LncMB3 regulates the TGF-β pathway, critically altered in G3 medulloblastomagenesis, via direct binding and translational inhibition of the mRNA for the epigenetic factor HMGN5. This regulatory axis affects apoptosis through photoreceptor lineage genes, including the G3 driver OTX2. The synergistic effects between lncMB3 targeting and cisplatin treatment underscore the relevance of this network. Additionally, we propose novel ferritin-based nanocarriers for the efficient delivery of antisense oligonucleotides against lncMB3. LncMB3 crucially links MYC amplification and apoptosis inhibition through a circuit involving RNA-based mechanisms, G3 MB key determinants and underexplored factors. This integrated framework deepens the understanding of G3 MB landscape and supports the potential for translating lncRNA research into future applications.

**中文摘要译文：**
第3组（G3）是儿童小脑肿瘤髓母细胞瘤（MB）最常见且最具侵袭性的亚型之一，主要由MYC癌基因驱动。MYC靶向治疗的挑战性，加上对G3型髓母细胞瘤分子基础的理解不足，阻碍了靶向疗法的发展。长链非编码RNA（lncRNA）的非传统致癌作用为解决这一复杂问题、提供新见解和发现新靶点提供了机会。我们利用组学方法和分子/细胞实验，阐明了G3型髓母细胞瘤中一种MYC依赖性、抗凋亡的lncRNA——lncMB3的作用模式。LncMB3通过直接结合并抑制表观遗传因子HMGN5的mRNA翻译，调控在G3型髓母细胞瘤发生中被关键性改变的TGF-β通路。这一调控轴通过包括G3型驱动基因OTX2在内的感光细胞谱系基因影响细胞凋亡。靶向lncMB3与顺铂治疗之间的协同效应凸显了该调控网络的重要性。此外，我们提出了一种新型的基于铁蛋白的纳米载体，用于高效递送针对lncMB3的反义寡核苷酸。LncMB3通过一个涉及RNA层面机制、G3型髓母细胞瘤关键决定因素及未充分探索因素的回路，将MYC扩增与细胞凋亡抑制关键性地联系起来。这一整合性框架加深了对G3型髓母细胞瘤分子图景的理解，并支持将lncRNA研究转化为未来应用的潜力。

### 第二部分 AI 大师评价

本研究旨在揭示MYC驱动的第3组髓母细胞瘤（G3 MB）中长链非编码RNA lncMB3的功能和作用机制。研究者综合运用组学分析与分子细胞实验，发现lncMB3通过直接结合并抑制HMGN5 mRNA的翻译，进而调控TGF-β通路及下游关键基因（如OTX2），最终抑制肿瘤细胞凋亡。该研究的创新性在于阐明了一条全新的“MYC-lncMB3-HMGN5-TGF-β”调控轴，为难以直接靶向的MYC癌基因找到了一个可行的间接干预靶点，并提出了基于纳米载体的递送策略，极具临床转化潜力。

---

## 31. 在单克隆B细胞淋巴细胞增多症（MBL）个体中，CHIP会增加淋巴系统恶性肿瘤的风险。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198626](https://pubmed.ncbi.nlm.nih.gov/41198626)
**期刊：** Blood cancer journal
**PMID：** 41198626
**DOI：** 10.1038/s41408-025-01385-8

### 第一部分 原文与翻译

**英文原标题：** CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL).

**英文摘要原文：**
Monoclonal B-cell lymphocytosis (MBL) and clonal hematopoiesis of indeterminate potential (CHIP) are prevalent clonal precursors associated with increased risk of lymphoid malignancies. However, the relationship between MBL and CHIP and their combined impact on lymphoid malignancy risk remains poorly understood. We screened participants from the Mayo Clinic Biobank to identify MBL using eight-color flow cytometry; CHIP was detected using whole-exome sequencing of whole-blood DNA in 291 genes related to myeloid or lymphoid malignancies. Incident myeloid or lymphoid hematological malignancies were identified using ICD codes and confirmed via medical record review. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Cox regression was used to estimate hazard ratios (HR). Analyses were adjusted for age and sex. In 10,067 participants, 15% had MBL, and 9% had CHIP. No evidence of an association between MBL and CHIP (OR = 1.00; 95% CI: 0.82-1.20) was observed. With a median follow-up of 5.4 years, 138 participants developed hematological malignancies (94 lymphoid). MBL (HR = 3.48; 95% CI: 2.27-5.34; P < 0.001) and CHIP (HR = 1.89; 95% CI: 1.10-3.27; P = 0.022) were each associated with incident lymphoid malignancy. Compared to individuals with no precursors, the combined presence of MBL and CHIP significantly amplified lymphoma risk (HR = 7.18; 95% CI: 3.33-15.47; P < 0.001), more than doubling the risk among individuals with MBL alone (HR = 3.30; 95% CI: 2.06-5.30; P < 0.001). In contrast, the risk associated with CHIP alone was attenuated and no longer statistically significant (HR = 1.63; 95% CI: 0.77-3.47; P = 0.20). MBL and CHIP are independent hematological precursor conditions. While their combined presence amplifies the risk of lymphoid malignancy, CHIP alone may not be a strong independent risk factor.

**中文摘要译文：**
单克隆B细胞淋巴细胞增多症（MBL）和意义不明确的克隆性造血（CHIP）是常见的克隆性前驱状态，与淋巴系统恶性肿瘤风险增加相关。然而，MBL与CHIP之间的关系及其对淋巴系统恶性肿瘤风险的共同影响仍不清楚。我们筛选了梅奥诊所生物样本库的参与者，使用八色流式细胞术鉴定MBL；通过对291个与髓系或淋巴系恶性肿瘤相关的基因进行全血DNA全外显子测序来检测CHIP。新发的髓系或淋巴系血液系统恶性肿瘤通过国际疾病分类（ICD）编码进行识别，并通过病历审查进行确认。使用逻辑回归分析估算比值比（OR）和95%置信区间（CI）。使用Cox回归分析估算风险比（HR）。分析对年龄和性别进行了校正。在10,067名参与者中，15%患有MBL，9%患有CHIP。未观察到MBL与CHIP之间存在关联的证据（OR = 1.00; 95% CI: 0.82-1.20）。中位随访5.4年后，138名参与者发展为血液系统恶性肿瘤（其中94例为淋巴系）。MBL（HR = 3.48; 95% CI: 2.27-5.34; P < 0.001）和CHIP（HR = 1.89; 95% CI: 1.10-3.27; P = 0.022）均与新发淋巴系统恶性肿瘤相关。与无前驱状态的个体相比，MBL和CHIP的共同存在显著放大了淋巴瘤风险（HR = 7.18; 95% CI: 3.33-15.47; P < 0.001），这一风险是单独患有MBL个体（HR = 3.30; 95% CI: 2.06-5.30; P < 0.001）的两倍以上。相比之下，单独存在CHIP所带来的风险则减弱且不再具有统计学显著性（HR = 1.63; 95% CI: 0.77-3.47; P = 0.20）。MBL和CHIP是两种独立的血液系统前驱状态。尽管它们的共同存在会放大淋巴系统恶性肿瘤的风险，但单独的CHIP可能并非一个强有力的独立风险因素。

### 第二部分 AI 大师评价

本研究旨在阐明两种常见克隆前驱状态——单克隆B细胞淋巴细胞增多症（MBL）与意义不明确的克隆性造血（CHIP）——之间的关系及其对淋巴系统恶性肿瘤风险的协同影响。研究团队利用大规模生物样本库，结合流式细胞术和全外显子测序等先进技术，发现MBL与CHIP是相互独立的，但二者共存会使淋巴瘤风险放大至七倍以上，远超单一前驱状态的风险。这一发现具有重要的临床价值，提示对于MBL患者，检测CHIP状态可能有助于进行更精准的风险分层和监测，为恶性肿瘤的早期预警提供了新的分子标志物。

---

## 32. Setd2确保在小鼠造血干/祖细胞中建立精确的基础炎症状态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198622](https://pubmed.ncbi.nlm.nih.gov/41198622)
**期刊：** Cell death & disease
**PMID：** 41198622
**DOI：** 10.1038/s41419-025-08110-0

### 第一部分 原文与翻译

**英文原标题：** Setd2 ensures the establishment of a precise basal inflammatory state within murine hematopoietic stem/progenitor cells.

**英文摘要原文：**
The maintenance of a basal immunoinflammatory signature in hematopoietic stem/progenitor cells (HSPCs) constitutes a fundamental regulatory axis governing hematopoietic competence and immune effector generation. While epigenetic repressors constrain this inflammatory phenotype, the molecular amplifiers that preserve this critical state remain undefined. Through integrated single-cell transcriptomic/epigenomic profiling and functional interrogation, we identify Setd2-mediated H3K36me3 as an indispensable epigenetic amplifier sustaining baseline inflammation in murine HSPCs. Setd2 ablation specifically eliminated interferon (IFN)-enriched HSPC subpopulations and attenuated inflammatory signaling cascades. Functionally, Setd2-deficient HSPCs exhibited impaired IFNγ responsiveness, compromised B-lymphopoiesis, and diminished reconstitution capacity due to Linc-KitSca1 cell depletion. Paradoxically, Setd2 loss conferred resistance to IFNγ-induced HSPCs exhaustion, which may contribute to the maintenance of Setd2-deficient HSPCs in our myelodysplastic syndrome (MDS) model under the inflammatory milieu. Mechanistically, Setd2 sustained chromatin accessibility and enhancer (H3K27ac) activity at inflammatory gene loci. This work delineates a critical link between Setd2-mediated chromatin regulation, baseline inflammation, HSPC function, and immune competence, providing insights into inflammatory dysregulation in hematopoietic malignancies like MDS.

**中文摘要译文：**
造血干/祖细胞（HSPCs）中基础免疫炎症印记的维持，是调控造血能力和免疫效应细胞生成的关键调节轴。虽然表观遗传抑制因子限制了这种炎症表型，但维持这一关键状态的分子放大器仍不明确。通过整合单细胞转录组学/表观基因组学分析和功能探究，我们发现Setd2介导的H3K36me3是维持小鼠HSPCs基线炎症不可或缺的表观遗传放大器。Setd2的缺失特异性地清除了富含干扰素（IFN）的HSPC亚群，并减弱了炎症信号级联反应。在功能上，由于Linc-KitSca1细胞的耗竭，Setd2缺陷的HSPCs表现出IFNγ反应性受损、B淋巴细胞生成受损以及重建能力下降。矛盾的是，Setd2的缺失赋予了细胞对IFNγ诱导的HSPCs耗竭的抵抗力，这可能有助于在炎症环境下我们骨髓增生异常综合征（MDS）模型中Setd2缺陷HSPCs的维持。从机制上看，Setd2维持了炎症基因位点的染色质开放性和增强子（H3K27ac）活性。这项工作描绘了Setd2介导的染色质调控、基线炎症、HSPC功能和免疫能力之间的关键联系，为理解MDS等造血系统恶性肿瘤中的炎症失调提供了新见解。

### 第二部分 AI 大师评价

本研究旨在阐明表观遗传调控因子Setd2在维持小鼠造血干/祖细胞（HSPCs）基础炎症状态中的关键作用。研究人员综合运用单细胞转录组与表观基因组学分析、功能实验及MDS疾病模型，发现Setd2作为一种表观遗传放大器，通过H3K36me3修饰维持HSPCs的基线炎症。该研究的创新之处在于揭示了Setd2在调控炎症中的“放大器”角色，而非传统认知中的抑制作用，并阐明了其在正常造血与MDS病理状态下的双重功能。这一发现不仅加深了对造血免疫表观调控的理解，也为探索MDS等血液肿瘤的炎症失调机制和潜在治疗靶点提供了重要线索。

---

## 33. 靶向FAM134B-DDX3X轴抑制肝细胞癌的AKT信号传导

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198618](https://pubmed.ncbi.nlm.nih.gov/41198618)
**期刊：** Cell death & disease
**PMID：** 41198618
**DOI：** 10.1038/s41419-025-08080-3

### 第一部分 原文与翻译

**英文原标题：** Targeting FAM134B-DDX3X axis inhibiting AKT signaling in hepatocellular carcinoma.

**英文摘要原文：**
Family with sequence similarity 134, member B (FAM134B), known for its role as an ER-phagy receptor, has been implicated in the promotion of hepatocellular carcinoma (HCC) progression through the activation of the AKT signaling pathway. However, the precise mechanism underlying FAM134B's activation of AKT signaling remains to be elucidated. This study aimed to investigate the interaction between FAM134B and DEAD-box helicase 3 X-linked (DDX3X) and its implications for HCC. We found that FAM134B interacts with DDX3X, preventing its proteasomal degradation by reducing K48-linked polyubiquitination and enhancing K63-linked polyubiquitination. This stabilization of DDX3X is crucial for AKT signaling activation, as DDX3X is known to promote the transcription of Rac Family Small GTPase 1 (Rac1), a key activator of the AKT pathway. Our results confirmed that FAM134B activates AKT signaling through the DDX3X-Rac1-AKT axis in HCC. Furthermore, we observed that DDX3X is upregulated in HCC and contributes to tumor progression. Interestingly, DDX3X not only activates AKT signaling but also increases FAM134B expression by enhancing its transcriptional activity, suggesting a positive feedback loop between these two proteins in HCC. Lastly, we explored the therapeutic potential of combining the DDX3X inhibitor RK-33 with FAM134B knockdown in HCC treatment. Our findings indicate that this synergistic approach may offer a promising strategy for HCC therapy.

**中文摘要译文：**
序列相似性家族134成员B（FAM134B）以其作为内质网自噬受体的作用而闻名，并被认为通过激活AKT信号通路促进肝细胞癌（HCC）的进展。然而，FAM134B激活AKT信号通路的精确机制仍有待阐明。本研究旨在探讨FAM134B与X连锁DEAD-box解旋酶3（DDX3X）之间的相互作用及其对HCC的影响。我们发现，FAM134B与DDX3X相互作用，通过减少K48连接的多聚泛素化并增强K63连接的多聚泛素化，来阻止DDX3X的蛋白酶体降解。DDX3X的这种稳定性对于AKT信号的激活至关重要，因为已知DDX3X能促进AKT通路关键激活因子——Rac家族小GTP酶1（Rac1）的转录。我们的研究结果证实，在HCC中，FAM134B通过DDX3X-Rac1-AKT轴激活AKT信号通路。此外，我们观察到DDX3X在HCC中表达上调，并促进肿瘤进展。有趣的是，DDX3X不仅激活AKT信号通路，还通过增强FAM134B的转录活性来增加其表达，这表明这两种蛋白在HCC中存在一个正反馈循环。最后，我们探讨了在HCC治疗中，联合使用DDX3X抑制剂RK-33与FAM134B敲降的治疗潜力。我们的研究结果表明，这种协同方法可能为HCC治疗提供一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在揭示FAM134B在肝细胞癌（HCC）中激活AKT信号通路的具体分子机制。研究团队发现，FAM134B通过与DDX3X相互作用并调控其泛素化，进而稳定DDX3X蛋白，最终经由Rac1激活AKT通路。该研究的创新之处在于首次阐明了FAM134B-DDX3X这一关键调控轴，并发现二者之间存在正反馈循环，为理解HCC的进展提供了新视角。更重要的是，研究验证了联合靶向FAM134B和DDX3X的协同抗肿瘤效应，为HCC的治疗提出了具有转化潜力的联合用药新策略。

---

## 34. KAT2A驱动的SRSF11琥珀酰化通过强化剪接体介导的RAD52剪接，促进肝细胞癌的同源重组与放疗抵抗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198615](https://pubmed.ncbi.nlm.nih.gov/41198615)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41198615
**DOI：** 10.1038/s41392-025-02458-7

### 第一部分 原文与翻译

**英文原标题：** KAT2A-driven succinylation of SRSF11 enforces spliceosome-mediated RAD52 splicing to promote homologous recombination and radioresistance in hepatocellular carcinoma.

**英文摘要原文：**
Posttranslational modification succinylation plays a pivotal role in tumorigenesis across malignancies, yet its mechanistic contributions to hepatocellular carcinoma (HCC) pathogenesis and therapeutic resistance remain poorly characterized. In this study, we systematically demonstrated that the splicing factor SRSF11 undergoes functional consequential succinylation in HCC progression. Mechanistically, lysine acetyltransferase 2 A (KAT2A) directly interacts with SRSF11 to catalyze its succinylation at lysine 419 (K419), thereby enhancing DNA damage repair capacity in both in vitro and in vivo HCC models. Structural and functional analyses revealed that K419 succinylation stabilizes SRSF11-spliceosome interactions, which promote the inclusion of exon 10 of RAD52 through enhanced pre-mRNAs binding. This exon-specific splicing event preserves the RAD51-binding domain essential for homologous recombination (HR) repair, ultimately facilitating RAD52-RAD51 dimer assembly and HR-mediated genomic stabilization. Clinically, elevated SRSF11 expression is correlated with increased HR activity, radioresistance, and reduced survival in HCC patients. Notably, genetic disruption of the KAT2A-SRSF11 axis sensitizes HCC cells to radiation-induced apoptosis. Our findings establish succinylation as a novel regulatory mechanism linking alternative splicing to DNA repair fidelity in HCC, while proposing therapeutic targeting of this pathway to overcome radioresistance in advanced HCC.

**中文摘要译文：**
翻译后修饰琥珀酰化在多种恶性肿瘤的发生发展中扮演着关键角色，但其在肝细胞癌（HCC）发病机制和治疗抵抗中的作用机制仍不明确。在本研究中，我们系统性地证明了剪接因子SRSF11在HCC进展过程中发生了具有功能性后果的琥珀酰化。机制上，赖氨酸乙酰转移酶2A（KAT2A）直接与SRSF11相互作用，催化其在赖氨酸419位点（K419）的琥珀酰化，从而在体外和体内HCC模型中增强了DNA损伤修复能力。结构和功能分析显示，K419位点的琥珀酰化稳定了SRSF11与剪接体的相互作用，通过增强与pre-mRNA的结合，促进了RAD52外显子10的包含。这一外显子特异性剪接事件保留了对同源重组（HR）修复至关重要的RAD51结合域，最终促进了RAD52-RAD51二聚体的组装和HR介导的基因组稳定。临床上，SRSF11的高表达与HCC患者的HR活性增加、放疗抵抗以及生存期缩短相关。值得注意的是，基因层面破坏KAT2A-SRSF11轴可使HCC细胞对放射线诱导的凋亡敏感。我们的研究结果确立了琥珀酰化作为一种新的调控机制，将可变剪接与HCC中的DNA修复保真性联系起来，同时提出靶向该通路可能成为克服晚期HCC放疗抵抗的治疗策略。

### 第二部分 AI 大师评价

该研究旨在阐明琥珀酰化修饰在肝细胞癌（HCC）放疗抵抗中的具体作用机制。研究团队通过体内外实验、结构功能分析及临床数据验证，揭示了KAT2A介导的剪接因子SRSF11琥珀酰化是关键一环。其核心发现是，此修饰通过稳定SRSF11与剪接体的互作，促进了RAD52基因的特定剪接，进而增强同源重组修复能力，最终导致放疗抵抗。这项工作创新性地将蛋白质翻译后修饰、可变剪接与DNA损伤修复三者联系起来，不仅深化了对HCC放疗抵抗机制的理解，也为晚期HCC的治疗提供了靶向KAT2A-SRSF11轴这一极具潜力的新策略。

---

## 35. Zelenectide Pevedotin在晚期实体瘤患者中的首次人体I/II期剂量爬坡与扩展研究：来自单药治疗剂量爬坡的结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41197088](https://pubmed.ncbi.nlm.nih.gov/41197088)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41197088
**DOI：** 10.1200/JCO-25-00559

### 第一部分 原文与翻译

**英文原标题：** First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

**英文摘要原文：**
PURPOSE: Zelenectide pevedotin (BT8009) is a Bicycle Drug Conjugate comprising a highly selective Nectin-4-targeting Bicycle peptide, linked to monomethyl auristatin E. We report monotherapy dose-escalation results from Duravelo-1 (Phase I/II; ClinicalTrials.gov identifier: NCT04561362).

METHODS: Adults with advanced/metastatic solid tumors associated with Nectin-4 expression received zelenectide pevedotin intravenously at 2.5, 5.0, or 7.5 mg/m once weekly on a 28-day cycle; or 7.5 mg/m on days 1 and 8 of a 21-day cycle; or 7.5 or 10.0 mg/m once every 2 weeks on a 28-day cycle. Primary objectives were to evaluate safety and tolerability; antitumor activity and pharmacokinetic characterization were secondary objectives.

RESULTS: Forty-nine patients, most with urothelial carcinoma (UC; 25 of 49), received three previous lines of therapy (median). Common treatment-related adverse events (TRAEs) included nausea (49% [grade 3/4 2%]), likely because of a lack of prophylactic antiemetics during the dose-limiting toxicity period, and fatigue (39% [grade 3/4 6%]). The most common TRAEs of clinical interest were peripheral neuropathy (33% [grade 3/4 2%]), neutropenia (22% [grade 3/4 16%]), and skin reactions (22% [grade 3/4 2%]). The maximum tolerated dose was 7.5 mg/m once every 2 weeks; the recommended phase 2 doses were 5.0 mg/m once weekly and 7.5 mg/m on days 1 and 8 of a 21-day cycle. Across doses (efficacy-evaluable; all tumor types), the objective response rate (ORR) was 24% and the clinical benefit rate (CBR) was 48% (n = 10 of 42; 95% CI, 12.1 to 39.5); the ORR was 38% and the CBR was 57% for patients with UC (n = 8 of 21; 95% CI, 18.1 to 61.6). The median duration of response and the median follow-up for all patients were 11.1 and 7.4 months, respectively.

CONCLUSION: Zelenectide pevedotin monotherapy demonstrated a generally well-tolerated safety profile and preliminary efficacy, particularly in UC, supporting investigation of UC and non-UC populations in the expansion phase.

**中文摘要译文：**
目的：Zelenectide pevedotin (BT8009)是一种自行车药物偶联物（Bicycle Drug Conjugate），由一个高选择性Nectin-4靶向的Bicycle肽与单甲基澳瑞他汀E连接而成。本研究报告了Duravelo-1研究（I/II期；ClinicalTrials.gov注册号：NCT04561362）中单药治疗剂量爬坡的结果。

方法：Nectin-4表达相关的晚期/转移性实体瘤成年患者，接受了Zelenectide pevedotin静脉注射，方案包括：2.5、5.0或7.5 mg/m²每周一次（28天一周期）；或7.5 mg/m²在第1天和第8天给药（21天一周期）；或7.5或10.0 mg/m²每两周一次（28天一周期）。主要研究终点是评估安全性与耐受性；次要终点为抗肿瘤活性和药代动力学特征。

结果：共49例患者入组，其中多数为尿路上皮癌（UC；25/49），中位既往治疗线数为3线。常见的治疗相关不良事件（TRAEs）包括恶心（49%[3/4级 2%]），这可能与剂量限制性毒性评估期间未使用预防性止吐药有关，以及疲劳（39%[3/4级 6%]）。临床关注的最常见TRAEs为外周神经病变（33%[3/4级 2%]）、中性粒细胞减少（22%[3/4级 16%]）和皮肤反应（22%[3/4级 2%]）。最大耐受剂量为7.5 mg/m²每两周一次；推荐的II期剂量为5.0 mg/m²每周一次以及7.5 mg/m²在21天周期的第1天和第8天给药。在所有剂量组中（可评估疗效；所有肿瘤类型），客观缓解率（ORR）为24%，临床获益率（CBR）为48%（n=10/42；95% CI, 12.1-39.5）；在UC患者中，ORR为38%，CBR为57%（n=8/21；95% CI, 18.1-61.6）。所有患者的中位缓解持续时间为11.1个月，中位随访时间为7.4个月。

结论：Zelenectide pevedotin单药治疗展现了总体良好的安全性特征和初步疗效，尤其是在尿路上皮癌中，这支持了在扩展阶段对UC和非UC人群进行进一步研究。

### 第二部分 AI 大师评价

本研究是一项关于新型Nectin-4靶向自行车药物偶联物（Bicycle Drug Conjugate）Zelenectide pevedotin的首次人体I/II期临床试验。研究通过剂量爬坡设计，成功确定了该药物在晚期实体瘤患者中的最大耐受剂量和II期推荐剂量，并验证了其总体可控的安全性。该研究的关键发现是在经多线治疗的晚期尿路上皮癌患者中展现出令人鼓舞的抗肿瘤活性（ORR达38%），为这一难治性患者群体提供了新的潜在治疗选择。这项研究的创新性在于验证了一种全新药物分子形式的临床潜力，其初步的积极结果为后续关键性临床试验的开展奠定了坚实基础。

---

## 36. DNA双链断裂的修复会给基因组功能留下可遗传的损伤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196998](https://pubmed.ncbi.nlm.nih.gov/41196998)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196998
**DOI：** 10.1126/science.adk6662

### 第一部分 原文与翻译

**英文原标题：** Repair of DNA double-strand breaks leaves heritable impairment to genome function.

**英文摘要原文：**
Upon DNA breakage, a genomic locus undergoes alterations in three-dimensional chromatin architecture to facilitate signaling and repair. Although cells possess mechanisms to repair damaged DNA, it is unknown whether the surrounding chromatin is restored to its naïve state. We show that a single DNA double-strand break (DSB) within a topologically associated domain (TAD) harboring conformation-sensitive genes causes lasting chromatin alterations, which persist after completion of DNA repair and feature topological rearrangements and loss of local RNA species. These newly acquired features of postrepair chromatin are transmitted to daughter cells and manifest as heritable impairments of gene expression. These findings uncover a hitherto concealed dimension of DNA breakage, which we term postrepair chromatin fatigue and which confers heritable impairment of gene function beyond DNA repair.

**中文摘要译文：**
DNA断裂后，基因组位点会发生三维染色质结构的改变，以促进信号传导和修复。尽管细胞拥有修复受损DNA的机制，但周围的染色质是否能恢复到其初始状态尚不清楚。我们发现，在包含构象敏感基因的拓扑关联结构域（TAD）内发生的单次DNA双链断裂（DSB），会引起持久的染色质改变，这些改变在DNA修复完成后依然存在，并表现为拓扑重排和局部RNA种类的丢失。这些修复后染色质的新获得特征会遗传给子代细胞，并表现为可遗传的基因表达损伤。这些发现揭示了DNA断裂一个迄今为止被隐藏的层面，我们称之为“修复后染色质疲劳”（postrepair chromatin fatigue），它导致了超越DNA修复本身的可遗传性基因功能损伤。

### 第二部分 AI 大师评价

该研究聚焦于DNA修复后染色质状态的恢复问题，通过精巧的实验设计揭示了一个重要发现：即使DNA序列被成功修复，其所在区域的染色质三维结构仍会留下持久性的“伤疤”。这项研究首次提出了“修复后染色质疲劳”这一创新概念，指出这种染色质层面的改变是可遗传的，并会导致基因表达功能受损，从而为理解DNA损伤的长期生物学效应（如细胞衰老和癌症发生）提供了全新的表观遗传学视角。其发现不仅加深了对基因组稳定性的认识，也为相关疾病的干预提供了潜在的新靶点。

---

## 37. 神经架构的无偏探索

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196997](https://pubmed.ncbi.nlm.nih.gov/41196997)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196997
**DOI：** 10.1126/science.adx6741

### 第一部分 原文与翻译

**英文原标题：** Unbiased discovery of neuronal architectures.

**英文摘要原文：**
Comparative whole-brain and single-cell analyses identify neurons orchestrating neurological functions.

**中文摘要译文：**
比较性全脑和单细胞分析可识别出调控神经功能的神经元。

### 第二部分 AI 大师评价

该研究旨在通过一种无偏见的方法来揭示调控神经功能的关键神经元及其组织结构。研究者创新性地结合了比较性全脑分析与单细胞分析技术，从而能够系统性地识别出在特定神经功能中发挥核心调控作用的神经元。这一发现为理解复杂神经回路的工作原理提供了全新的视角，不仅在基础神经科学研究中具有重要价值，也为未来针对神经系统疾病的精准干预提供了潜在靶点。该研究方法代表了从数据驱动角度探索大脑功能的先进范式。

---

## 38. 脂肪生成素通过结合十二聚体seipin复合物促进脂滴的发育

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196993](https://pubmed.ncbi.nlm.nih.gov/41196993)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196993
**DOI：** 10.1126/science.adr9755

### 第一部分 原文与翻译

**英文原标题：** Adipogenin promotes the development of lipid droplets by binding a dodecameric seipin complex.

**英文摘要原文：**
The microprotein adipogenin (Adig) is predominantly expressed in adipose tissues. Here, we found that Adig interacts with seipin to form a stable, rigid complex. We present the structure of the seipin-Adig complex at an overall resolution of ~3.0 angstroms. The structure revealed that mammalian seipin assembles into two distinct oligomeric forms: undecamers and dodecamers. Adig selectively bound to the dodecameric form and enhanced seipin assembly by bridging and stabilizing adjacent subunits. Functionally, this complex promoted lipid droplet development at both early and late stages. In transgenic mice, adipocyte-specific overexpression of Adig increased fat mass and enlarged lipid droplets, whereas Adig deletion disrupted triglyceride accumulation in brown adipose tissues. Thus, Adig can modulate lipid storage through its structural and functional interactions with seipin.

**中文摘要译文：**
微蛋白脂肪生成素（Adig）主要在脂肪组织中表达。本研究中，我们发现Adig与seipin相互作用，形成一个稳定且刚性的复合物。我们解析了seipin-Adig复合物的结构，总体分辨率约为3.0埃。该结构揭示，哺乳动物的seipin会组装成两种不同的寡聚体形式：十一聚体和十二聚体。Adig选择性地与十二聚体形式结合，并通过桥接和稳定相邻的亚基来增强seipin的组装。在功能上，该复合物在脂滴发育的早期和晚期阶段均起到促进作用。在转基因小鼠中，脂肪细胞特异性过表达Adig会增加脂肪量并使脂滴增大，而Adig的缺失则会破坏棕色脂肪组织中的甘油三酯积累。因此，Adig可以通过其与seipin在结构和功能上的相互作用来调节脂质储存。

### 第二部分 AI 大师评价

本研究旨在阐明微蛋白脂肪生成素（Adig）在脂滴发育中的作用机制。研究团队综合运用结构生物学和转基因小鼠模型，关键性地发现Adig通过选择性结合并稳定十二聚体的seipin复合物，从而促进脂滴的形成与甘油三酯的积累。这项工作不仅揭示了Adig作为脂质储存关键调节因子的新功能，还为其与seipin相互作用的分子基础提供了高分辨率的结构见解，为理解脂滴生物合成及相关代谢性疾病开辟了新的研究方向。

---

## 39. 论建立全球合作以关注人类神经类器官及组装体研究的必要性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196981](https://pubmed.ncbi.nlm.nih.gov/41196981)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196981
**DOI：** 10.1126/science.aeb1510

### 第一部分 原文与翻译

**英文原标题：** The need for a global effort to attend to human neural organoid and assembloid research.

**英文摘要原文：**
A continuing international process is needed to monitor and advise this rapidly progressing field.

**中文摘要译文：**
有必要建立一个持续的国际程序，以监测这个快速发展的领域并为其提供建议。

### 第二部分 AI 大师评价

该文献是一篇前瞻性述评，明确指出了在全球范围内协调人类神经类器官与组装体研究的紧迫性与必要性。作者的核心论点是，鉴于该领域的飞速进步，必须建立一个持续的国际性流程来对其进行监督和指导。此文的价值在于，它前瞻性地探讨了这一前沿技术背后复杂的伦理、法律和社会议题，而非局限于技术本身。通过倡导建立统一的国际监督与咨询机制，该文旨在推动该领域的负责任创新，确保这一颠覆性技术的长期健康发展。

---

## 40. Nudix水解酶5在抑制嘌呤从头合成中的非酶促作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196952](https://pubmed.ncbi.nlm.nih.gov/41196952)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196952
**DOI：** 10.1126/science.adv4257

### 第一部分 原文与翻译

**英文原标题：** A non-enzymatic role of Nudix hydrolase 5 in repressing purine de novo synthesis.

**英文摘要原文：**
Folate metabolism is intricately linked to purine de novo synthesis through the incorporation of folate-derived one-carbon units into the purine scaffold. By investigating chemical and genetic dependencies caused by mutations in methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 (MTHFD1), we discovered a key role for Nudix hydrolase 5 (NUDT5) in regulating purine de novo synthesis. Genetic depletion and selective chemical degradation showed that a scaffolding role, rather than NUDT5 enzymatic activity, was causing this phenotype. NUDT5 interacted with phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme of purine de novo synthesis, to repress the pathway in response to increased purine abundance. Through this mechanism, loss of NUDT5 mediates resistance to purine analogs in cancer treatment and prevents adenosine toxicity in MTHFD1 deficiency.

**中文摘要译文：**
叶酸代谢通过将叶酸来源的单碳单位整合到嘌呤骨架中，与嘌呤的从头合成紧密相连。通过研究由亚甲基四氢叶酸脱氢酶、环化水解酶和甲酰四氢叶酸合成酶1（MTHFD1）突变引起的化学和遗传依赖性，我们发现了Nudix水解酶5（NUDT5）在调节嘌呤从头合成中的关键作用。遗传耗竭和选择性化学降解表明，是NUDT5的支架作用而非其酶活性导致了这一表型。NUDT5与嘌呤从头合成的限速酶——磷酸核糖焦磷酸酰胺转移酶（PPAT）相互作用，以响应嘌呤丰度的增加来抑制该通路。通过这一机制，NUDT5的缺失介导了对癌症治疗中嘌呤类似物的耐药性，并防止了MTHFD1缺陷中的腺苷毒性。

### 第二部分 AI 大师评价

本研究旨在探索嘌呤从头合成通路新的调控机制。研究团队运用遗传耗竭和化学降解等方法，创新性地揭示了Nudix水解酶5（NUDT5）的一个非酶促功能。关键发现是NUDT5作为支架蛋白与该通路的限速酶PPAT相互作用，从而抑制嘌呤合成。这一发现不仅深化了我们对细胞代谢调控网络的理解，也为解释嘌呤类似物耐药机制及MTHFD1缺陷相关疾病提供了新的分子靶点，具有重要的科研和临床转化潜力。

---

## 41. 肝细胞癌的起源取决于代谢分区

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196951](https://pubmed.ncbi.nlm.nih.gov/41196951)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196951
**DOI：** 10.1126/science.adv7129

### 第一部分 原文与翻译

**英文原标题：** The origin of hepatocellular carcinoma depends on metabolic zonation.

**英文摘要原文：**
The origin of cancer is poorly understood because premalignant cells are rarely followed in their native environments. While the spatial compartmentalization of metabolic functions is critical for proper liver function, it is unknown if cancers arise from some zones but not others, and if there are metabolic determinants of cancer risk. Zone-specific, mosaic introduction of Ctnnb1 and Nfe2l2 mutations, commonly co-mutated genes in hepatocellular carcinoma (HCC), showed that position and metabolic context determine clone fates. Ctnnb1-driven cancers were much more likely to arise in zone 3. The zone 3 genes Gstm1 and Gstm2 were required for efficient HCC initiation, in part through inhibition of ferroptosis. In the liver, the zonal determinants of HCC development can reveal metabolic vulnerabilities of cancer.

**中文摘要译文：**
由于癌前细胞很少在其原生环境中被追踪，因此癌症的起源尚不清楚。尽管代谢功能的空间区室化对正常的肝功能至关重要，但目前尚不清楚癌症是否起源于某些特定区域而非其他区域，以及是否存在决定癌症风险的代谢因素。通过在特定肝区以嵌合方式引入肝细胞癌（HCC）中常见的共突变基因Ctnnb1和Nfe2l2的突变，研究表明克隆的位置和代谢背景决定了其命运。由Ctnnb1驱动的癌症更可能起源于肝小叶3区。肝小叶3区的基因Gstm1和Gstm2是有效启动HCC所必需的，其部分机制是通过抑制铁死亡。在肝脏中，HCC发展的区域决定因素可以揭示癌症的代谢脆弱性。

### 第二部分 AI 大师评价

本研究旨在探讨肝脏代谢分区（metabolic zonation）如何影响肝细胞癌（HCC）的起源。研究者通过在小鼠肝脏特定区域嵌合式引入致癌突变，创新性地揭示了HCC的发生具有明显的区域选择性，主要起源于肝小叶3区。该研究不仅发现了驱动癌症发生的关键基因，还阐明了其通过抑制铁死亡发挥作用的机制，深刻揭示了肿瘤细胞的“起源位置”与其代谢微环境之间的密切关系。这一发现为理解肿瘤异质性提供了新视角，并为开发靶向肿瘤代谢脆弱性的新疗法指明了方向。

---

## 42. 冷冻电镜可视化揭示XRCC3-RAD51C-RAD51D-XRCC2复合物对RAD51蛋白丝的组装与末端加帽作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196948](https://pubmed.ncbi.nlm.nih.gov/41196948)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196948
**DOI：** 10.1126/science.aea1546

### 第一部分 原文与翻译

**英文原标题：** Cryo-electron microscopy visualization of RAD51 filament assembly and end-capping by XRCC3-RAD51C-RAD51D-XRCC2.

**英文摘要原文：**
Homologous recombination repairs DNA double strand breaks and protects stalled replication forks, but how the five RAD51 paralogs contribute to these processes remains unclear. Mutations in the RAD51 paralogs are linked to heritable breast and ovarian cancers and the cancer-prone disease Fanconi anemia. In this work, we show that the RAD51 paralogs assemble into two distinct heterotetrameric complexes, RAD51B-RAD51C-RAD51D-XRCC2 (RAD51B complex) and XRCC3-RAD51C-RAD51D-XRCC2 (XRCC3 complex). The RAD51B complex promotes dynamic adenosine triphosphate hydrolysis-dependent assembly of RAD51 filaments, whereas the XRCC3 complex stably caps the 5'-termini of RAD51 filaments to promote homologous pairing, as visualized by cryo-electron microscopy. Highly conserved across evolution, these complexes reveal insights into RAD51 filament formation and capping during DNA repair and replication fork stabilization.

**中文摘要译文：**
同源重组修复DNA双链断裂并保护停滞的复制叉，但五种RAD51旁系同源蛋白如何参与这些过程尚不清楚。RAD51旁系同源蛋白的突变与遗传性乳腺癌、卵巢癌以及易患癌症的范可尼贫血症有关。在这项工作中，我们发现RAD51旁系同源蛋白组装成两种不同的异源四聚体复合物：RAD51B-RAD51C-RAD51D-XRCC2（RAD51B复合物）和XRCC3-RAD51C-RAD51D-XRCC2（XRCC3复合物）。RAD51B复合物促进依赖于三磷酸腺苷水解的RAD51蛋白丝的动态组装，而XRCC3复合物则稳定地为RAD51蛋白丝的5'末端加上“帽子”，以促进同源配对，这一过程通过冷冻电子显微镜得以可视化。这些复合物在进化过程中高度保守，为我们深入了解DNA修复和复制叉稳定化过程中的RAD51蛋白丝形成与加帽机制提供了新的见解。

### 第二部分 AI 大师评价

该研究旨在阐明RAD51旁系同源蛋白在同源重组中的具体作用机制。研究团队创新性地运用冷冻电子显微镜技术，首次直观揭示了两种不同的RAD51旁系同源蛋白复合物（RAD51B复合物与XRCC3复合物）的功能分工：前者促进RAD51蛋白丝的动态组装，而后者则稳定其末端。这一发现不仅深化了对DNA损伤修复和基因组稳定性维持机理的理解，也为解析相关遗传性癌症（如乳腺癌）和范可尼贫血症的致病机理提供了关键的结构生物学基础，具有重要的科研价值和潜在的临床意义。

---

## 43. 三阴性乳腺癌中耐药持续细胞的特征鉴定：揭示一种跨越不同疗法与患者的共同持续程序

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196808](https://pubmed.ncbi.nlm.nih.gov/41196808)
**期刊：** Cancer research
**PMID：** 41196808
**DOI：** 10.1158/0008-5472.CAN-25-0995

### 第一部分 原文与翻译

**英文原标题：** Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.

**英文摘要原文：**
Acquisition of resistance to anti-cancer therapies is a multistep process initiated by the survival of drug-tolerant persister cells. Accessibility of drug-tolerant persister cells in patients is limited, which has hindered understanding the mechanisms driving their emergence. Here, using multiple patient-derived models to isolate persister cells, we showed that these cells are transcriptionally plastic in vivo and return to a common treatment naïve-like state upon relapse, regardless of treatment. Hallmarks of the persister state in TNBC across treatment modalities included high expression of basal keratins together with activation of stress response and inflammation pathways. These hallmarks were also activated in HER2+ breast and lung cancer cells in response to targeted therapies. Analysis of gene regulatory networks identified AP-1, NF-κB and IRF/STAT as the key drivers of this hallmark persister state. Functionally, FOSL1, an AP-1 member, drove cells to the persister state by binding enhancers and reprogramming the transcriptome of cancer cells. On the contrary, cancer cells without FOSL1 had a decreased ability to reach the persister state. By defining hallmarks of TNBC persistence on multiple therapies, this study provides a resource to design effective combination therapeutic strategies that limit resistance.

**中文摘要译文：**
对抗癌疗法的耐药性获得是一个多步骤过程，起始于耐药持续细胞的存活。在患者体内获取耐药持续细胞的机会有限，这阻碍了对其出现机制的理解。本研究利用多种源自患者的模型分离出持续细胞，结果表明，这些细胞在体内具有转录可塑性，并且在复发时会回到一种与治疗前相似的共同状态，无论接受何种治疗。在不同治疗模式下，三阴性乳腺癌持续状态的标志性特征包括基底角蛋白的高表达，以及应激反应和炎症通路的激活。这些标志性特征在HER2阳性乳腺癌和肺癌细胞中，在对靶向治疗产生应答时同样被激活。基因调控网络分析确定了AP-1、NF-κB和IRF/STAT是这种标志性持续状态的关键驱动因素。在功能上，AP-1成员FOSL1通过结合增强子和重编程癌细胞的转录组，驱动细胞进入持续状态。相反，缺乏FOSL1的癌细胞进入持续状态的能力降低。通过明确三阴性乳腺癌在多种疗法下的持续性标志，本研究为设计限制耐药性的有效联合治疗策略提供了资源。

### 第二部分 AI 大师评价

本研究旨在揭示三阴性乳腺癌（TNBC）中耐药持续细胞的核心特征，并寻找跨越不同治疗方法的共同耐药机制。研究团队利用多种患者来源模型，创新性地发现这些细胞存在一个共同的“持续程序”，其标志是基底角蛋白高表达、应激与炎症通路激活，且该程序由AP-1/NF-κB/IRF/STAT等信号通路驱动。该研究不仅深化了对肿瘤耐药初始阶段的理解，更通过锁定关键驱动因子FOSL1，为开发旨在根除持续细胞、预防复发的联合治疗策略提供了极具价值的新靶点和理论基础。

---

## 44. 放射治疗诱导树突状细胞中的YTHDF2，从而损害交叉递呈和T细胞功能。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196643](https://pubmed.ncbi.nlm.nih.gov/41196643)
**期刊：** The Journal of experimental medicine
**PMID：** 41196643
**DOI：** 10.1084/jem.20250641

### 第一部分 原文与翻译

**英文原标题：** Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function.

**英文摘要原文：**
Metastatic progression is a major cause of radiotherapy (RT) failure, yet the mechanisms linking RT to immune suppression and metastasis remain unclear. Here, we identify YTHDF2 as a radiation-induced immune checkpoint in dendritic cells (DCs). By analyzing patient biopsies from a clinical trial (NCT03223155), we discover that increased YTHDF2 expression in DCs after RT correlates with treatment failure after RT. Mechanistically, ionizing radiation induces SPI1, which drives transcription of Ythdf2 in DCs. Upregulated YTHDF2 promotes m6A-mediated degradation of Notch pathway regulators (Mfng, Aph1b, Aph1c), impairing MHC-I cross-presentation and CD8+ T cell activation, thereby facilitating tumor immune evasion and metastatic spread. Crucially, targeting YTHDF2 restores DC immunogenicity, enhances RT-induced tumor control, and improves DC-based cancer vaccines when combined with RT, providing a clinically actionable strategy to overcome RT resistance and metastasis.

**中文摘要译文：**
转移性进展是放射治疗（RT）失败的主要原因，但连接放疗与免疫抑制及转移的机制仍不清楚。在此，我们将YTHDF2鉴定为树突状细胞（DCs）中一种由辐射诱导的免疫检查点。通过分析一项临床试验（NCT03223155）中的患者活检样本，我们发现放疗后树突状细胞中YTHDF2表达的增加与治疗失败相关。从机制上讲，电离辐射会诱导SPI1，而SPI1驱动树突状细胞中Ythdf2的转录。上调的YTHDF2通过m6A介导的方式促进Notch通路调节因子（Mfng, Aph1b, Aph1c）的降解，从而损害MHC-I的交叉递呈和CD8+ T细胞的活化，进而促进了肿瘤的免疫逃逸和转移扩散。关键的是，靶向YTHDF2能够恢复树突状细胞的免疫原性，增强放疗诱导的肿瘤控制效果，并且在与放疗联合使用时能改善基于树突状细胞的癌症疫苗的效力，这为克服放疗抵抗和转移提供了一种具有临床可行性的策略。

### 第二部分 AI 大师评价

本研究旨在揭示放射治疗（RT）导致免疫抑制和肿瘤转移的关键机制。研究通过分析临床试验样本及机制探究，创新性地发现放疗能诱导树突状细胞（DC）中YTHDF2蛋白的表达，后者通过m6A依赖性途径降解Notch通路关键分子，最终损害了DC的抗原交叉递呈能力和T细胞的激活，促进了肿瘤免疫逃逸。这一发现不仅阐明了放疗抵抗的一个新机制，更提出了靶向YTHDF2作为增效放疗、改善DC疫苗效果的临床转化策略，具有重要的科研价值和应用前景。

---

## 45. 移植后环磷酰胺对比常规预防方案：无血缘关系供者年龄对受者结局的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196629](https://pubmed.ncbi.nlm.nih.gov/41196629)
**期刊：** JAMA oncology
**PMID：** 41196629
**DOI：** 10.1001/jamaoncol.2025.4551

### 第一部分 原文与翻译

**英文原标题：** Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis.

**英文摘要原文：**
IMPORTANCE: Advanced age in unrelated donors (URDs) is a well-established risk factor in allogeneic hematopoietic cell transplant (HCT), leading registries to prioritize younger donors. However, this paradigm relevance is uncertain in the era of posttransplant cyclophosphamide (PTCy) for graft-vs-host disease (GVHD) prophylaxis, a strategy increasingly adopted for its effectiveness. Clarifying this association is crucial for optimizing donor selection and potentially expanding the donor pool.

OBJECTIVE: To determine whether the association of older URD age with overall survival differs between patients receiving PTCy-based vs conventional calcineurin inhibitor (CNI)-based GVHD prophylaxis.

DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter cohort study using registry data from the Center for International Blood and Marrow Transplant Research for January 2017 through June 2021. Eligible participants were adult patients with acute leukemia or myelodysplastic syndrome who underwent an allogeneic HCT from a URD who was fully matched for 8 of 8 human leukocyte antigen loci (MUD) or mismatched for 7 of 8 human leukocyte antigen loci (MMUD). Data were analyzed from January to June 2025.

EXPOSURES: GVHD prophylaxis regimen (PTCy-based vs CNI-based) and donor age (analyzed continuously and categorically).

MAIN OUTCOMES AND MEASURES: Overall survival was the primary outcome, with associations assessed using a multipronged approach including least absolute shrinkage and selection operator (LASSO)-penalized Cox proportional hazards models, inverse probability of treatment weighting (IPTW), and XGBoost machine learning.

RESULTS: The study analysis included 10 025 patients (mean [SD] age, 56.5 [14.4] years; 4379 female [43.7%] and 5646 male [56.3%] individuals) among whom 7272 (72.5%) had received MUD-CNI; 1681 (16.8%%) MUD-PTCy; 613 (6.1%) MMUD-PTCy; and 459 (4.6%) MMUD-CNI. Increasing donor age was associated with worse OS in CNI-based MUD (hazard ratio [HR], 1.004-1.009 per year increase) and MMUD (HR, 1.022-1.034) cohorts. Conversely, this association was not observed in the combined PTCy cohort (HR, 1.001-1.007). These findings were robust across standard and overlap weighted IPTW, LASSO-penalized models, and XGBoost analyses. The attenuated association in the PTCy cohort was primarily driven by a lack of association between donor age and nonrelapse mortality.

CONCLUSIONS AND RELEVANCE: The findings of this cohort study indicate that the association of donor age with URD HCT outcomes appears to be mitigated in the PTCy setting, suggesting that PTCy may counteract some of the adverse effects associated with increased unrelated donor age. This observation challenges existing paradigms and warrants validation in independent cohorts, and if validated, could substantially expand the donor pool.

**中文摘要译文：**
重要性：在无关供者（URD）异基因造血细胞移植（HCT）中，供者高龄是一个公认的风险因素，这导致骨髓库优先选择年轻供者。然而，在采用移植后环磷酰胺（PTCy）预防移植物抗宿主病（GVHD）的时代，这一范式的相关性尚不确定，而PTCy策略因其有效性而日益普及。阐明这种关联对于优化供者选择和可能扩大供者库至关重要。

目的：旨在确定在接受基于PTCy与基于常规钙调磷酸酶抑制剂（CNI）的GVHD预防方案的患者中，高龄URD与总生存期的关联是否存在差异。

设计、地点与参与者：这是一项多中心队列研究，使用了国际血液与骨髓移植研究中心从2017年1月至2021年6月的注册数据。合格的参与者为患有急性白血病或骨髓增生异常综合征的成年患者，他们接受了来自8/8人类白细胞抗原位点完全匹配（MUD）或7/8人类白细胞抗原位点不匹配（MMUD）的URD的异基因HCT。数据分析时间为2025年1月至6月。

暴露因素：GVHD预防方案（基于PTCy vs 基于CNI）和供者年龄（作为连续变量和分类变量进行分析）。

主要结局与测量指标：总生存期是主要结局，其关联性通过多管齐下的方法进行评估，包括最小绝对收缩和选择算子（LASSO）惩罚的Cox比例风险模型、治疗加权的反向概率（IPTW）以及XGBoost机器学习。

结果：该研究分析共纳入10025名患者（平均[SD]年龄，56.5 [14.4]岁；4379名女性[43.7%]和5646名男性[56.3%]），其中7272名（72.5%）接受了MUD-CNI方案；1681名（16.8%）接受了MUD-PTCy方案；613名（6.1%）接受了MMUD-PTCy方案；459名（4.6%）接受了MMUD-CNI方案。在基于CNI的MUD（风险比[HR]，每年龄增长为1.004-1.009）和MMUD（HR，1.022-1.034）队列中，供者年龄的增长与更差的总生存期相关。相反，在联合的PTCy队列中未观察到此关联（HR，1.001-1.007）。这些发现在标准和重叠加权的IPTW、LASSO惩罚模型及XGBoost分析中均表现稳健。PTCy队列中关联性的减弱主要是由于供者年龄与非复发死亡率之间缺乏关联所驱动。

结论与相关性：这项队列研究的结果表明，在PTCy背景下，供者年龄与URD HCT结局的关联似乎得到了缓解，这提示PTCy可能抵消了与无关供者年龄增长相关的部分不良影响。这一观察结果挑战了现有范式，有待在独立队列中进行验证，若经验证，可能极大地扩大供者库。

### 第二部分 AI 大师评价

本研究聚焦于异基因造血干细胞移植领域的核心议题——供者年龄选择。通过对CIBMTR注册中心的大样本数据进行多重复杂统计模型（包括机器学习）分析，研究创新性地探讨了移植后环磷酰胺（PTCy）方案是否能改变高龄无关供者对受者生存的不利影响。其关键发现——PTCy方案可有效缓解高龄供者带来的生存劣势——直接挑战了“优先选择年轻供者”的传统观念。这项研究具有重大的临床指导价值，若经进一步验证，有望显著扩大供者库，为更多患者带来移植机会。

---

## 46. 双重打击模糊之敌：精准靶向BCL11B

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196623](https://pubmed.ncbi.nlm.nih.gov/41196623)
**期刊：** Blood
**PMID：** 41196623
**DOI：** 10.1182/blood.2025030748

### 第一部分 原文与翻译

**英文原标题：** Double trouble for a blurry foe: precision strike on BCL11B.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献标题极富启发性，暗示其内容可能是一篇关于靶向B细胞淋巴瘤/白血病11B（BCL11B）的创新性评论或前沿观点。文章可能聚焦于一种新型的“双重打击”精准治疗策略，用以对抗以往难以明确靶向（“模糊之敌”）的BCL11B相关疾病，如T细胞急性淋巴细胞白血病。鉴于其发表在血液学顶级期刊《Blood》，该文所评述的研究很可能具有重大突破，为开发针对该关键转录因子的新疗法提供了重要思路和临床转化潜力。

---

## 47. 具有印戒细胞形态、酷似腺癌的经典型霍奇金淋巴瘤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196619](https://pubmed.ncbi.nlm.nih.gov/41196619)
**期刊：** Blood
**PMID：** 41196619
**DOI：** 10.1182/blood.2025029949

### 第一部分 原文与翻译

**英文原标题：** Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献（可能为病例报告）揭示了一种经典型霍奇金淋巴瘤的罕见形态学变异，即出现酷似腺癌的印戒细胞样形态。此发现极具临床病理诊断价值，因为它指出了一个潜在的诊断陷阱——这种非典型表现可能导致其被误诊为转移性腺癌。文章强调了在遇到印戒细胞形态的肿瘤时，需拓宽鉴别诊断思路，并依赖免疫组织化学染色进行精确诊断的重要性。尽管可能仅为个案报道，但该发现对于提醒病理医生警惕这一罕见现象、避免误诊误治具有重要意义。

---

## 48. 新兴人工智能技术在急性髓系白血病风险评估与管理中的应用：一篇综述

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196612](https://pubmed.ncbi.nlm.nih.gov/41196612)
**期刊：** JAMA oncology
**PMID：** 41196612
**DOI：** 10.1001/jamaoncol.2025.3601

### 第一部分 原文与翻译

**英文原标题：** Emerging Artificial Intelligence Technologies for Risk Assessment and Management in Acute Myeloid Leukemia: A Review.

**英文摘要原文：**
IMPORTANCE: Acute myeloid leukemia (AML) is a severe hematologic cancer with complex genetic heterogeneity necessitating personalized treatment approaches. Artificial intelligence (AI) technologies may revolutionize risk stratification, diagnosis enhancement, and treatment planning in addressing critical gaps in AML management, particularly in low-resource health care environments.

OBSERVATIONS: This narrative review synthesizes existing AI applications in 3 primary areas of AML management. Machine learning algorithms integrating clinical, cytogenetic, and molecular data demonstrate greater prognostic accuracy than conventional European LeukemiaNet (ELN) guidelines. Deep learning approaches to image analysis yield excellent results for AML subtype identification from bone marrow smears (area under the receiver operating characteristic curve [AUROC]: 0.97) and genetic variant prediction (eg, NPM1 status [AUROC: 0.92]). AI-driven genomic analysis reveals novel prognostic signatures and therapeutic targets through advanced pattern recognition, with high-dimensional machine learning achieving greater than 99% accuracy in AML classification from transcriptomic data. Explainable AI models overcome the black box limitation through interpretable algorithms with Shapley Additive Explanations values and local interpretable model-agnostic explanation techniques. Federated learning approaches enable multi-institutional collaboration with protection of patient privacy, with 96.5% accuracy in leukemia classification on heterogeneous datasets.

CONCLUSIONS AND RELEVANCE: AI technologies hold potential to improve AML treatment through enhanced risk stratification, early detection capabilities, and individualized treatment optimization. The transition toward explainable AI models is essential to clinical readiness, with federated learning architectures resolving data scarcity concerns. Seamless integration requires harmonized data standards, robust regulatory frameworks, and equitable access to technology to fully realize the transformative potential of AI in improving outcomes for patients with AML globally.

**中文摘要译文：**
重要性：急性髓系白血病（AML）是一种严重的血液系统恶性肿瘤，具有复杂的遗传异质性，需要个体化的治疗方法。人工智能（AI）技术有望在风险分层、诊断增强和治疗规划方面带来革命性变化，以解决AML管理中的关键空白，尤其是在资源匮乏的医疗环境中。

观察结果：本篇叙述性综述综合了AI在AML管理三个主要领域的现有应用。集成临床、细胞遗传学和分子数据的机器学习算法，在预后准确性方面表现出比传统欧洲白血病网（ELN）指南更高的水平。深度学习方法在图像分析中取得了优异成果，可用于从骨髓涂片中识别AML亚型（受试者工作特征曲线下面积[AUROC]：0.97）和预测遗传变异（例如，NPM1状态[AUROC]：0.92）。AI驱动的基因组分析通过先进的模式识别揭示了新的预后特征和治疗靶点，其中高维机器学习从转录组数据中分类AML的准确率超过99%。可解释性AI模型通过使用Shapley可加性解释（Shapley Additive Explanations）值和局部可解释模型无关解释（local interpretable model-agnostic explanation）等技术的可解释算法，克服了“黑箱”限制。联邦学习方法在保护患者隐私的同时，实现了多机构协作，在异构数据集上对白血病分类的准确率达到96.5%。

结论与相关性：AI技术有潜力通过增强风险分层、早期检测能力和个体化治疗优化来改善AML的治疗。向可解释性AI模型的过渡对于临床准备至关重要，而联邦学习架构则解决了数据稀缺的问题。无缝集成需要统一的数据标准、健全的监管框架以及技术的可及性公平，从而在全球范围内充分实现AI在改善AML患者预后方面的变革性潜力。

### 第二部分 AI 大师评价

本篇综述系统总结了人工智能（AI）在急性髓系白血病（AML）风险评估与管理中的前沿应用。文章重点介绍了机器学习与深度学习模型如何超越传统指南，在整合多维数据以提升预后预测、图像分析和基因变异检测方面的卓越表现。该综述的创新价值在于不仅展示了AI的强大能力，还深入探讨了可解释性AI和联邦学习等技术在克服“黑箱”问题与数据隐私方面的关键作用，为AI在AML领域的临床转化提供了清晰的路线图和未来展望。

---

## 49. 移植后环磷酰胺在GVHD预防领域再创佳绩？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196611](https://pubmed.ncbi.nlm.nih.gov/41196611)
**期刊：** JAMA oncology
**PMID：** 41196611
**DOI：** 10.1001/jamaoncol.2025.4603

### 第一部分 原文与翻译

**英文原标题：** Another Feather In The Cap for Posttransplant Cyclophosphamide GVHD Prophylaxis?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题判断，本文可能是一篇针对移植后环磷酰胺（PTCy）预防移植物抗宿主病（GVHD）最新研究进展的述评或社论，而非原创性研究。文章标题以“再创佳绩？”的设问形式，暗示了PTCy方案在临床应用中又取得了新的突破性成果，可能是在特定移植类型或患者群体中展示了优越性。该文的核心价值在于对现有证据的解读与评论，旨在探讨PTCy在不断变化的造血干细胞移植领域中的地位及其未来的发展方向。

---

## 50. 远程医疗及在线认知行为疗法用于治疗高影响性慢性疼痛

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196589](https://pubmed.ncbi.nlm.nih.gov/41196589)
**期刊：** JAMA
**PMID：** 41196589
**DOI：** 10.1001/jama.2025.17420

### 第一部分 原文与翻译

**英文原标题：** Telehealth and Online Cognitive Behavioral Therapy-Based Treatments for High-Impact Chronic Pain.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本文聚焦于利用远程医疗及在线认知行为疗法（CBT）治疗高影响性慢性疼痛这一前沿课题。从标题推断，该文可能探讨了这类数字化干预措施在提升治疗可及性、改善患者功能及生活质量方面的潜力与挑战。尽管缺乏摘要信息，该主题本身具有重要的临床意义和科研价值，尤其是在后疫情时代，探索高效、便捷的慢性疼痛管理新模式是医疗领域的一大热点，此文可能为相关临床实践和未来研究提供重要参考。

---

## 51. 伴有既存癌症的肥胖患者中司美格鲁肽与替尔泊肽的处方分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196576](https://pubmed.ncbi.nlm.nih.gov/41196576)
**期刊：** JAMA oncology
**PMID：** 41196576
**DOI：** 10.1001/jamaoncol.2025.4560

### 第一部分 原文与翻译

**英文原标题：** Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于一个重要的临床问题：在合并癌症病史的肥胖患者中，司美格鲁肽（Semaglutide）和替尔泊肽（Tirzepatide）这两种新型减肥药物的处方现状。由于原文无摘要，推测这可能是一篇研究信函或简报，通过分析真实世界数据，旨在揭示这些药物在该特殊人群中的使用趋势。本研究的价值在于，它关注了关键临床试验通常会排除的复杂患者群体，为评估GLP-1类药物在肿瘤患者中的安全性提供了初步的现实世界证据，对指导临床实践和未来的前瞻性研究具有重要参考价值。

---

## 52. 肌肉量、衰弱、体重减轻与癌症治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196575](https://pubmed.ncbi.nlm.nih.gov/41196575)
**期刊：** JAMA oncology
**PMID：** 41196575
**DOI：** 10.1001/jamaoncol.2025.4521

### 第一部分 原文与翻译

**英文原标题：** Muscle Mass, Fragility, Weight Loss, and Cancer Treatment.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文标题揭示了其核心议题，即探讨肌肉量、衰弱和体重减轻这三个关键生理指标与癌症治疗之间的相互关系。由于缺乏摘要，此文可能是一篇社论、综述或观点性文章，旨在强调对癌症患者进行全面的身体成分和功能状态评估的重要性。其临床价值在于提醒医生，在制定治疗方案时，应将患者的营养状况和身体机能纳入考量，这对于优化治疗耐受性、降低并发症风险及改善患者预后至关重要。

---

## 53. 肺神经内分泌肿瘤的表型图谱：基于OTP/ASCL1表达的亚型分类及其与组织学、激素和结局的相关性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196447](https://pubmed.ncbi.nlm.nih.gov/41196447)
**期刊：** Endocrine pathology
**PMID：** 41196447
**DOI：** 10.1007/s12022-025-09882-z

### 第一部分 原文与翻译

**英文原标题：** Phenotypic Landscape of Pulmonary Neuroendocrine Tumors: Subtyped by OTP/ASCL1 Expression Correlated with Histology, Hormones and Outcome.

**英文摘要原文：**
Recent studies have shown that pulmonary neuroendocrine tumor (NET) subgroups, defined by the transcription factors OTP and ASCL1, correlate with age, sex, and tumor location. Their relationships with histology and hormone production, however, remain unclear. We analyzed 170 pulmonary NETs classified by OTP (O) and ASCL1 (A) expression into four groups: O + /A + , O + /A-, O-/A + , and O-/A-. Subgroups were assessed for histology, hormone expression, therapy-related markers, outcomes, and matched metastases. Among 152 resected primaries, O + /A + tumors (38%) were most frequent, occurring mainly in females (median age 72 years), and typically showed central or peripheral location, solid/spindle morphology with diffuse gastrin-releasing peptide (GRP), and focal ACTH/calcitonin. They also showed strong DLL3 expression and pronounced neuroendocrine cell hyperplasia. O + /A- tumors (23%) occurred predominantly in females (median age 56 years) with solid/trabecular patterns, occasional/ACTH, and strong SSTR2A/5 expression. O-/A- tumors (25%) were more common in males (median age 70 years), often central with solid/trabecular or oncocytic histology, serotonin expression (24%), and frequently SSTR2A-positivity. O-/A + tumors (14%) occurred across both sexes (median age 58 years), were centrally located, and solid, sometimes oncocytic features with moderate DLL3/SSTR2A expression. Metastases mirrored their primaries in transcription factor and hormone profiles. In the univariate analysis, OTP-negative tumors were associated with poorer disease-free survival (DFS). However, the multivariate analysis identified Ki67-based WHO grades (G1-G3) as the only independent prognostic factors. In conclusion, integrating OTP and ASCL1 refines pulmonary NET classification into four histologically and biologically distinct subgroups, providing additional insight into tumor heterogeneity. O + /A + tumors showed solid-spindle features and diffuse GRP and frequent ACTH expression, trabecular patterns characterized ASCL1-negative tumors, while oncocytic histology predominated in OTP-negative tumors, highlighting their role in defining tumor heterogeneity.

**中文摘要译文：**
近期的研究表明，由转录因子OTP和ASCL1定义的肺神经内分泌肿瘤（NET）亚组与年龄、性别和肿瘤位置相关。然而，它们与组织学和激素产生之间的关系仍不清楚。我们分析了170例肺NET，根据OTP（O）和ASCL1（A）的表达将其分为四组：O+/A+、O+/A-、O-/A+和O-/A-。我们对各亚组的组织学、激素表达、治疗相关标志物、结局以及匹配的转移灶进行了评估。在152例切除的原发灶中，O+/A+型肿瘤（38%）最为常见，主要发生于女性（中位年龄72岁），通常位于中央或外周，呈实性/梭形形态，伴有弥漫性胃泌素释放肽（GRP）和局灶性ACTH/降钙素表达。它们还表现出强烈的DLL3表达和显著的神经内分泌细胞增生。O+/A-型肿瘤（23%）主要发生于女性（中位年龄56岁），呈实性/梁状模式，偶见ACTH表达，并有强烈的SSTR2A/5表达。O-/A-型肿瘤（25%）在男性中更为常见（中位年龄70岁），常位于中央，具有实性/梁状或嗜酸细胞样组织学特征，24%表达血清素，且常为SSTR2A阳性。O-/A+型肿瘤（14%）在两性中均有发生（中位年龄58岁），位于中央，呈实性，有时具有嗜酸细胞样特征，并有中等程度的DLL3/SSTR2A表达。转移灶的转录因子和激素谱与其原发灶一致。在单变量分析中，OTP阴性肿瘤与较差的无病生存期（DFS）相关。然而，多变量分析确定，基于Ki67的WHO分级（G1-G3）是唯一的独立预后因素。总之，整合OTP和ASCL1可将肺NET分类细化为四个在组织学和生物学上截然不同的亚组，为理解肿瘤异质性提供了新的视角。O+/A+型肿瘤表现为实性-梭形特征、弥漫性GRP和频繁的ACTH表达，梁状模式是ASCL1阴性肿瘤的特征，而嗜酸细胞样组织学则在OTP阴性肿瘤中占主导，这凸显了这些转录因子在定义肿瘤异质性中的作用。

### 第二部分 AI 大师评价

该研究创新性地运用转录因子OTP和ASCL1的表达，对肺神经内分泌肿瘤（NETs）进行了新的分子亚型划分。通过对170例样本的综合分析，研究揭示了四个亚型在组织学、激素表达谱和临床特征上存在显著差异，深化了我们对肺NETs异质性的理解。尽管该分型在多变量分析中未显示出独立的预后价值（WHO分级仍是唯一独立预后因素），但它为探索不同亚型的生物学行为和潜在治疗靶点（如DLL3、SSTR2A）提供了坚实的理论基础和新的研究方向。

---

## 54. 伊诺泽替尼：一种选择性、高脑通透性的EGFR抑制剂，用于治疗携带EGFR 20号外显子及非典型突变的非小细胞肺癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196054](https://pubmed.ncbi.nlm.nih.gov/41196054)
**期刊：** Cancer research
**PMID：** 41196054
**DOI：** 10.1158/0008-5472.CAN-25-3502

### 第一部分 原文与翻译

**英文原标题：** Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

**英文摘要原文：**
EGFR mutations are common oncogenic drivers in non-small cell lung cancer (NSCLC), and around one-third of patients develop brain metastases over the course of their disease. Patients with non-classical EGFR mutations, such as insertions in exon 20, are a high unmet need with a worse prognosis compared to patients with classical EGFR mutations. Here, we describe the discovery and development of enozertinib (formerly ORIC-114), a highly brain-penetrant, orally bioavailable, irreversible inhibitor that targets EGFR exon 20 mutations with unparalleled kinome selectivity. Preclinical studies revealed strong potency and tumor regressions driven by enozertinib across a broad range of atypical EGFR mutant models. In a phase I clinical trial of enozertinib in patients with advanced NSCLC bearing atypical mutations in EGFR, a patient with harboring an EGFR exon 20 insertion experienced sustained complete response of all systemic and brain metastases. Together, these findings identify enozertinib as a promising investigational inhibitor to meet the unmet need for brain-penetrant therapies for NSCLC with EGFR exon 20 insertions or other atypical mutations.

**中文摘要译文：**
EGFR突变是非小细胞肺癌（NSCLC）中常见的致癌驱动因素，约三分之一的患者在病程中会发生脑转移。与携带经典EGFR突变的患者相比，携带非经典EGFR突变（如20号外显子插入突变）的患者预后更差，存在高度未被满足的医疗需求。本文中，我们描述了enozertinib（曾用名ORIC-114）的发现与开发过程，它是一种具有高血脑屏障通透性、可口服、不可逆的抑制剂，以无与伦比的激酶组选择性靶向EGFR 20号外显子突变。临床前研究显示，在多种EGFR非典型突变模型中，enozertinib均表现出强大的效力并能驱动肿瘤消退。在一项针对携带EGFR非典型突变的晚期NSCLC患者的I期临床试验中，一名携带EGFR 20号外显子插入突变的患者其所有全身及脑部转移灶均获得了持续的完全缓解。综上，这些研究结果表明，enozertinib是一种极具前景的在研抑制剂，有望满足携带EGFR 20号外显子插入或其他非典型突变的NSCLC患者对高脑通透性疗法的未竟需求。

### 第二部分 AI 大师评价

本研究旨在介绍新型EGFR抑制剂enozertinib的研发与特性，该药物主要针对携带EGFR 20号外显子插入及其他非典型突变的非小细胞肺癌（NSCLC）。研究结合了临床前模型验证与I期临床试验，系统评估了其药效、激酶选择性及临床活性。核心发现是enozertinib具有出色的激酶选择性和高血脑屏障通透性，不仅在临床前模型中展现强大抗肿瘤效果，更在一名伴有脑转移的患者中实现了全身病灶的持续完全缓解。该研究的创新性与临床价值巨大，为这类预后差、特别是伴有脑转移的NSCLC患者提供了一种极具潜力的治疗新选择，有望填补当前治疗领域的空白。

---

## 55. USP20驱动的胆固醇代谢连接胰腺癌的炎症信号、恶性进展及基质协同进化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196022](https://pubmed.ncbi.nlm.nih.gov/41196022)
**期刊：** Cancer research
**PMID：** 41196022
**DOI：** 10.1158/0008-5472.CAN-25-1228

### 第一部分 原文与翻译

**英文原标题：** USP20-Driven Cholesterol Metabolism Links Inflammatory Signaling to Malignancy and Stromal Co-evolution in Pancreatic Cancer.

**英文摘要原文：**
Inflammatory signaling, metabolic reprogramming, and stromal complexity have emerged as core hallmarks of pancreatic ductal adenocarcinoma (PDAC). Crosstalk between these programs could represent potential targets to concurrently perturb multiple tumor-promoting processes. By integrating multi-omics data from clinical cohorts, patient-derived organoids, and autochthonous models, we uncovered tumor-intrinsic inflammatory cascades in PDAC as master regulators of mevalonate pathway hijacking, which drove both malignant progression and stromal co-evolution. TNFSF13B+ tumor-associated macrophages activated STAT3 signaling in neoplastic epithelia, leading to the transcriptional upregulation of USP20. This deubiquitinase stabilized HMGCR to potentiate mevalonate flux, resulting in cholesterol and geranylgeranyl pyrophosphate overproduction. Stimulation of YAP/TAZ signaling induced by the USP20-mediated metabolic alterations promoted tumor cell proliferation and triggered the activation of cancer-associated fibroblasts (CAFs). Genetic ablation or pharmacological inhibition of USP20 using a selective inhibitor reversed tumor metabolic dysregulation, suppressing both tumor growth and stromal desmoplasia. Furthermore, the combination of USP20 inhibition and anti-PD-1/anti-CTLA-4 immunotherapy resulted in enhanced anti-tumor efficacy. These findings reveal the STAT3-USP20-HMGCR axis as a central coordinator of PDAC malignancy and position USP20 inhibition as a strategy to suppress oncogenic signaling, perturb metabolic reprogramming, and reverse microenvironmental remodeling.

**中文摘要译文：**
炎症信号、代谢重编程和基质复杂性已成为胰腺导管腺癌（PDAC）的核心标志。这些程序之间的串扰可能代表了可同时干扰多个促瘤进程的潜在靶点。通过整合来自临床队列、患者源性类器官和原位模型的的多组学数据，我们揭示了PDAC中肿瘤内在的炎症级联反应是甲羟戊酸途径劫持的主要调控者，该过程驱动了恶性进展和基质协同进化。TNFSF13B+的肿瘤相关巨噬细胞激活了肿瘤上皮细胞中的STAT3信号通路，导致USP20的转录上调。这种去泛素化酶通过稳定HMGCR来增强甲羟戊酸途径的流量，导致胆固醇和香叶基香叶基焦磷酸的过量产生。由USP20介导的代谢改变所诱导的YAP/TAZ信号通路的激活，促进了肿瘤细胞的增殖并触发了癌症相关成纤维细胞（CAFs）的活化。使用选择性抑制剂对USP20进行基因敲除或药理学抑制，可逆转肿瘤的代谢失调，从而抑制肿瘤生长和基质纤维增生。此外，USP20抑制剂与抗PD-1/抗CTLA-4免疫疗法的联合使用，增强了抗肿瘤效果。这些发现揭示了STAT3-USP20-HMGCR轴是PDAC恶性进展的核心协调者，并将抑制USP20定位为一种可抑制致癌信号、干扰代谢重编程并逆转微环境重塑的策略。

### 第二部分 AI 大师评价

本研究旨在揭示胰腺癌（PDAC）中炎症信号、代谢重编程与基质微环境协同进化的内在联系。研究综合运用多组学分析、类器官及动物模型，精准描绘出一条“炎症-STAT3-USP20-HMGCR”信号轴如何劫持胆固醇代谢，从而驱动肿瘤增殖和基质活化。其关键创新在于将USP20确立为连接上述三大致癌特征的核心节点，并证实靶向USP20不仅能抑制肿瘤，还能改善基质环境，甚至增敏免疫治疗。这项工作为恶性程度极高的胰腺癌提供了一个极具潜力的“一石三鸟”式治疗新靶点，具有重要的临床转化价值。

---

## 56. 肿瘤相关巨噬细胞通过产生PGE2促进CD8+ T细胞耗竭，从而驱动微卫星稳定型结直肠癌对PD-L1阻断的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196020](https://pubmed.ncbi.nlm.nih.gov/41196020)
**期刊：** Cancer research
**PMID：** 41196020
**DOI：** 10.1158/0008-5472.CAN-25-0079

### 第一部分 原文与翻译

**英文原标题：** Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal Cancer.

**英文摘要原文：**
Immune checkpoint blockade treatment is highly effective in microsatellite instable (MSI) colorectal cancer (CRC). However, microsatellite stable (MSS) tumors, are intrinsically resistant to immunotherapy. Here, we sought to better understand the mechanisms of resistance to anti-PD-L1 therapy in CRC by characterizing the immune profiles of MSS and MSI tumor models. While both tumor types presented intratumoral CD8+ T cell and PD-L1 expression, the exhausted CD8+ T cell phenotypes differed. In the MSS tumors, exhausted CD8+ T cells co-expressed PD-1 and TIGIT and exhibited a terminal exhausted profile with low cytokine secretion and limited cytotoxic function. In contrast, PD-1+ CD8+ T cells in MSI tumors did not express TIGIT and displayed higher cytokine and cytotoxic activities. Interestingly, immunosuppressive M2-like tumor-associated macrophages (TAM) accumulated in MSI tumors and positively correlated with PD-1+ TIGIT+ CD8+ T cell frequency. M2-like TAM depletion reduced TIGIT expression, increased CD8+ T cell function, and improved efficacy of PD-L1 blockade. Transcriptomic analysis revealed elevated COX1/2 expression in TAMs in MSS tumors compared to MSI tumors. COX2 and prostaglandin E2 receptor inhibition impeded TIGIT expression and restored CD8+ T cell activity, while PGE2 triggered TIGIT upregulation in CD8+ T cells. Single-cell, spatial, and bulk transcriptomic data from CRC patients substantiated the correlation between elevated TIGIT in CD8+ T cell and COX1/2 in TAMs. Together, these data uncover the role of the TAM axis in inhibiting PD-L1 efficacy in MSS CRC and support the utility of combining anti-PD-L1 therapy with TIGIT blockade, PGE2 treatment, or M2-like TAM inhibition in CRC.

**中文摘要译文：**
免疫检查点阻断疗法在微卫星不稳定型（MSI）结直肠癌（CRC）中高度有效。然而，微卫星稳定型（MSS）肿瘤对免疫疗法具有内在耐药性。本研究旨在通过描绘MSS和MSI肿瘤模型的免疫图谱，以更深入地理解CRC对PD-L1抑制剂治疗产生耐药性的机制。尽管两种肿瘤类型均存在肿瘤内CD8+ T细胞浸润和PD-L1表达，但其耗竭性CD8+ T细胞的表型有所不同。在MSS肿瘤中，耗竭的CD8+ T细胞共表达PD-1和TIGIT，并呈现出一种终末耗竭表型，其特征是细胞因子分泌水平低且细胞毒性功能受限。相反，MSI肿瘤中的PD-1+ CD8+ T细胞不表达TIGIT，并表现出更高的细胞因子水平和细胞毒性活性。有趣的是，免疫抑制性的M2样肿瘤相关巨噬细胞（TAM）在MSS肿瘤中富集，并与PD-1+ TIGIT+ CD8+ T细胞的频率呈正相关。清除M2样TAM可降低TIGIT的表达，增强CD8+ T细胞的功能，并提高PD-L1阻断疗法的疗效。转录组学分析显示，与MSI肿瘤相比，MSS肿瘤中TAM的COX1/2表达水平升高。抑制COX2和前列腺素E2受体可阻碍TIGIT的表达并恢复CD8+ T细胞的活性，而PGE2则会诱导CD8+ T细胞上TIGIT的表达上调。来自CRC患者的单细胞、空间和批量转录组学数据证实了CD8+ T细胞中TIGIT表达升高与TAM中COX1/2表达升高之间的相关性。综上所述，这些数据揭示了TAM轴在抑制PD-L1疗法对MSS型CRC疗效中的作用，并为在CRC治疗中联合应用抗PD-L1疗法与TIGIT阻断、PGE2通路抑制或M2样TAM抑制提供了理论支持。

### 第二部分 AI 大师评价

本研究旨在阐明微卫星稳定型（MSS）结直肠癌对PD-L1阻断疗法耐药的关键机制。研究综合运用了肿瘤模型、多组学分析及功能实验，精准揭示了肿瘤相关巨噬细胞（TAMs）通过COX/PGE2通路诱导CD8+ T细胞上TIGIT表达，导致T细胞终末耗竭的核心环节。该发现不仅深刻揭示了MSS结直腸癌的免疫抑制微环境，更重要的是为临床提供了极具价值的联合治疗新策略，即PD-L1抑制剂联合TIGIT阻断剂或COX2抑制剂，为攻克这一免疫治疗“冷”肿瘤开辟了新路径。

---

## 57. 打破机械罗盘：通过破坏硬度趋向性来阻止纤维化和转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196016](https://pubmed.ncbi.nlm.nih.gov/41196016)
**期刊：** Cancer research
**PMID：** 41196016
**DOI：** 10.1158/0008-5472.CAN-25-4947

### 第一部分 原文与翻译

**英文原标题：** Breaking the Mechanical Compass: Disrupting Durotaxis to Halt Fibrosis and Metastasis.

**英文摘要原文：**
Durotaxis is the directed migration of cells along tissue stiffness gradients, and is emerging as a fundamental mechanobiological process orchestrating progression in diseases such as fibrosis and cancer. Despite compelling in vitro evidence demonstrating durotactic behaviour across multiple cell types, translating these findings to in vivo contexts has remained challenging due to the inherent complexity of isolating biomechanical cues from the myriad biochemical and architectural features that collectively define tissue properties. In their recent Nature Cell Biology study, Al-Hilal and colleagues address this translational gap through innovative bioengineering approaches combined with genetic models. Using high-resolution atomic force microscopy and intravital two-photon imaging, the authors demonstrate that pathological stiffness gradients drive fibroblast recruitment and activation in bleomycin-induced lung fibrosis, whilst simultaneously promoting quasi-mesenchymal pancreatic cancer cell dissemination. Critically, they identify the FAK-paxillin signalling axis as the mechanosensory machinery underpinning durotactic behaviour in both contexts. Pharmacological inhibition of this pathway using JP-153, or genetic disruption of tumour cell durotaxis, significantly attenuates fibrosis and metastatic burden without affecting primary tumour growth. These findings establish durotaxis as a therapeutically tractable mechanism in fibrotic and neoplastic disease, introducing a paradigm shift whereby targeting biomechanical sensing pathways may offer precise therapeutic intervention whilst preserving developmental and homeostatic processes dependent on functional mechanosensing.

**中文摘要译文：**
硬度趋向性是细胞沿组织硬度梯度进行的定向迁移，它正成为一个调控纤维化和癌症等疾病进展的基础性力学生物学过程。尽管大量体外证据表明多种细胞类型均存在硬度趋向性行为，但由于从共同定义组织特性的众多生化和结构特征中分离出生物力学线索本身具有复杂性，将这些发现在体内环境中进行转化仍然充满挑战。在他们最近发表于《自然-细胞生物学》的研究中，Al-Hilal及其同事通过创新的生物工程方法结合遗传模型，解决了这一转化难题。作者们利用高分辨率原子力显微镜和活体双光子成像技术证明，病理性硬度梯度在博来霉素诱导的肺纤维化中驱动成纤维细胞的招募和活化，同时促进了准间质型胰腺癌细胞的播散。关键的是，他们确定了FAK-paxillin信号轴是支撑这两种情况下硬度趋向性行为的力学传感机制。使用JP-153对该通路进行药理学抑制，或通过基因手段破坏肿瘤细胞的硬度趋向性，均能显著减轻纤维化和转移负荷，且不影响原发肿瘤的生长。这些发现将硬度趋向性确立为纤维化和肿瘤性疾病中一个具有治疗可行性的靶点机制，引入了一种范式转变，即靶向生物力学传感通路有望提供精准的治疗干预，同时保留依赖于功能性力学感应的发育和稳态过程。

### 第二部分 AI 大师评价

该研究旨在阐明硬度趋向性在体内纤维化和癌症转移中的关键作用，并探索将其作为治疗靶点的可行性。研究者巧妙地结合了高分辨率原子力显微镜、活体成像与基因模型，首次在活体层面证实了病理性组织硬度梯度能驱动成纤维细胞招募和癌细胞扩散，并锁定了FAK-paxillin信号轴为此过程的核心力学传感机制。此项工作的重大创新在于，它不仅填补了硬度趋向性从体外到体内研究的空白，更揭示了一个全新的、可精准干预的治疗靶点，即通过抑制细胞的“机械罗盘”来遏制疾病进展，为抗纤维化和抗肿瘤转移治疗开辟了颠覆性的新思路。

---

## 58. 美国癌症研究协会（AACR）关于支持联邦限制可燃烟草尼古丁含量以保护公众健康的政策声明

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41195890](https://pubmed.ncbi.nlm.nih.gov/41195890)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41195890
**DOI：** 10.1158/1078-0432.CCR-25-2182

### 第一部分 原文与翻译

**英文原标题：** An AACR Policy Statement to Support a Federal Limit on Nicotine in Combustible Tobacco and Protect Public Health.

**英文摘要原文：**
Chronic tobacco use is the leading preventable cause of 18 cancer types, heart and pulmonary disease, and premature death in the United States. The average cigarette contains approximately 10-15 milligrams of nicotine, a highly addictive chemical and the primary driver of chronic tobacco use. High-quality clinical trials have repeatedly shown that reducing nicotine content in cigarettes by approximately 95 percent lowers exposure to toxicants and carcinogens by decreasing the number of cigarettes smoked and increasing quit attempts and cessation. It is estimated that limiting nicotine in combustible cigarettes to such minimally addictive levels would result in nearly 13 million additional Americans quitting smoking within one year, powerfully benefiting public health. Therefore, we urge the United States Food and Drug Administration (FDA) to move forward in finalizing the recently proposed nicotine product standard limiting nicotine concentration to 0.7 mg/g within combustible cigarettes and other selected combustible tobacco products. Specific populations may benefit disproportionally from a limit on nicotine levels, and it is important to consider such impacts. Therefore, it is vital that FDA and other federal and local health agencies engage with broad stakeholders to ensure that all Americans benefit equally. Additionally, increased support for evidence-based smoking cessation therapies and education surrounding the continuum of risk of nicotine products will be essential for supporting individuals who want to quit and maximizing the public health benefits of the nicotine product standard. If implemented, this policy would constitute one of the most impactful cancer prevention, anti-addiction, and anti-chronic disease policies in American history.

**中文摘要译文：**
在美国，长期使用烟草是导致18种癌症、心肺疾病和过早死亡的首要可预防原因。平均每支香烟含有约10-15毫克尼古丁，这是一种高度成瘾的化学物质，也是导致长期使用烟草的主要驱动因素。高质量的临床试验反复表明，将香烟中的尼古丁含量降低约95%，可以通过减少吸烟数量、增加戒烟尝试和成功戒烟，从而降低使用者接触有毒物和致癌物的水平。据估计，将可燃香烟中的尼古丁限制在最低成瘾水平，将促使近1300万美国人在一年内戒烟，从而极大地有益于公众健康。因此，我们敦促美国食品药品监督管理局（FDA）尽快完成近期提出的尼古丁产品标准，该标准旨在将可燃香烟及其他特定可燃烟草产品中的尼古丁浓度限制在0.7毫克/克以内。特定人群可能会从尼古丁含量限制中获益更多，因此考虑这些影响至关重要。因此，FDA及其他联邦和地方卫生机构必须与广泛的利益相关者进行沟通，以确保所有美国人都能平等受益。此外，增加对循证戒烟疗法的支持，并加强关于尼古丁产品风险连续谱的教育，对于帮助希望戒烟的个人以及最大化尼古丁产品标准的公共健康效益至关重要。如果该政策得以实施，将构成美国历史上最具影响力的癌症预防、反成瘾和抗慢性病政策之一。

### 第二部分 AI 大师评价

本文是美国癌症研究协会（AACR）发布的一份重要政策声明，其核心目标是敦促美国食品药品监督管理局（FDA）最终确定并实施一项联邦法规，以大幅降低可燃烟草产品中的尼古丁含量。该声明并非原创性研究，而是基于大量高质量临床试验证据，论证了将尼古丁含量降至最低成瘾水平的巨大公共卫生效益，包括减少吸烟量、提高戒烟成功率，从而降低癌症等多种慢病风险。其突出价值在于，作为顶级癌症研究机构的官方立场，它为控烟政策提供了强有力的科学背书和伦理支持，有望推动美国历史上最具影响力的癌症预防政策之一的落地，对全球控烟策略亦有深远的示范意义。

---

## 59. 蛋白质基因组学特征分析揭示结直肠癌肝转移中的代谢脆弱性与异常磷酸化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41195591](https://pubmed.ncbi.nlm.nih.gov/41195591)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41195591
**DOI：** 10.1002/advs.202511744

### 第一部分 原文与翻译

**英文原标题：** Proteogenomic Characterization Reveals Metabolic Vulnerabilities and Aberrant Phosphorylation in Colorectal Metastasis to Liver.

**英文摘要原文：**
Colorectal liver metastasis (CRLM) is one of the leading death causes among colorectal cancer (CRC) patients, yet its underlying molecular events remain poorly understood, particularly at the proteomic and phosphoproteomic levels. A proteogenomic analysis combining genomics, transcriptomics, proteomics, and phosphoproteomics is performed on 102 samples from 34 treatment-naïve CRLM patients, including primary CRC, adjacent normal colorectal, and matched liver metastasis tissues. CRC cell lines, organoids, mouse models, and an independent patient cohort are used to validate the findings. Proteomics and phosphoproteomics show profoundly dysregulated pathways in liver metastasis tissues, notably disruptions in carbon metabolism. Functional validation using CRC organoids and mouse models demonstrates that the one-carbon metabolism enzyme SHMT1 promotes CRC tumorigenesis and metastasis via formate-mediated AMPK inhibition, whereas PIM kinase-dependent NDRG1 Ser330 phosphorylation exacerbates liver metastasis by promoting ubiquitin-dependent degradation of NDRG1. Unsupervised clustering identifies two proteomic subtypes of liver metastasis samples with distinct clinical outcomes: a poor-prognosis C1 (metabolism) subtype and a better-prognosis C2 (RNA function) subtype. Considering expression frequency, specificity, and functional relevance, FTCD, GPD1, SOD2, and EIF4B Ser422 phosphorylation are further identified and validated as subtype prognostic biomarkers. This study provides critical insights into the molecular mechanisms underlying CRLM and offers resources for high-risk metastatic CRC.

**中文摘要译文：**
结直肠癌肝转移（CRLM）是导致结直肠癌（CRC）患者死亡的主要原因之一，然而其潜在的分子事件，尤其是在蛋白质组学和磷酸化蛋白质组学层面的机制，仍有待阐明。本研究对34例初治CRLM患者的102份样本（包括原发性CRC、癌旁正常结直肠组织及配对的肝转移组织）进行了一项结合了基因组学、转录组学、蛋白质组学和磷酸化蛋白质组学的蛋白质基因组学分析。研究人员利用CRC细胞系、类器官、小鼠模型以及一个独立的患者队列对研究发现进行了验证。蛋白质组学和磷酸化蛋白质组学分析显示，肝转移组织中存在显著失调的信号通路，特别是碳代谢的紊乱。通过CRC类器官和小鼠模型进行的功能验证表明，单碳代谢酶SHMT1通过甲酸介导的AMPK抑制来促进CRC的肿瘤发生和转移，而PIM激酶依赖性的NDRG1 Ser330磷酸化则通过促进NDRG1的泛素依赖性降解来加剧肝转移。无监督聚类分析识别出两种具有不同临床结局的肝转移样本蛋白质组学亚型：预后较差的C1（代谢）亚型和预后较好的C2（RNA功能）亚型。综合考虑表达频率、特异性和功能相关性，研究进一步确定并验证了FTCD、GPD1、SOD2以及EIF4B Ser422磷酸化可作为亚型预后生物标志物。该研究为理解CRLM的潜在分子机制提供了关键见解，并为高风险转移性CRC的研究提供了宝贵资源。

### 第二部分 AI 大师评价

本研究通过一项全面的蛋白质基因组学多组学分析，系统地探究了结直肠癌肝转移（CRLM）的分子机制。研究的创新之处在于，它不仅揭示了碳代谢重编程（如SHMT1通路）和异常磷酸化（如NDRG1 Ser330磷酸化）在驱动转移中的关键作用，还首次基于蛋白质组学特征将肝转移分为两种具有显著预后差异的亚型。这些发现不仅深化了我们对CRLM生物学的理解，还为高风险患者的精准分层和治疗靶点开发提供了极具价值的生物标志物和理论依据。

---

## 60. 在接受依布替尼治疗的慢性淋巴细胞白血病患者中加用Ianalumab (VAY736)：一项Ib期研究的结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41194375](https://pubmed.ncbi.nlm.nih.gov/41194375)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41194375
**DOI：** 10.1158/1078-0432.CCR-25-0210

### 第一部分 原文与翻译

**英文原标题：** Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

**英文摘要原文：**
PURPOSE: This phase Ib dose-escalation/expansion trial (NCT03400176) enrolled patients with CLL who did not achieve a complete response (CR) with ibrutinib or had developed resistance mutations. Ianalumab (VAY736), an anti-B cell-activating factor receptor monoclonal antibody, combined with ibrutinib significantly improved survival and reduced tumor burden in preclinical chronic lymphocytic leukemia (CLL) models.

PATIENTS AND METHODS: Patients received intravenous ianalumab (escalation: 0.3-9.0 mg/kg; expansion: 3.0 mg/kg) once every 2 weeks and continued ibrutinib (420 mg) once daily for up to eight cycles of 28 days. The study aimed to evaluate the safety, tolerability, recommended dose, and antitumor activity of this combination.

RESULTS: Thirty-nine patients were treated (escalation: n = 15; expansion: n = 24). No dose-limiting toxicities were observed. Of the 39 patients, 38.5% were in CR or CR with incomplete marrow recovery at cycle 9 (C9). At C9 day 1, 17 patients (43.6%) achieved undetectable measurable residual disease in blood or bone marrow. Grade ≥3 adverse events occurred in 16 patients (41.0%), which were treatment-related in nine (23.1%). No on-treatment deaths were reported; one patient died because of COVID-19 during the posttreatment period. Seventeen patients (43.6%) discontinued ibrutinib at or after C9 day 1 and remained off therapy for 12.1 to 24.5 months. Preliminary RNA sequencing and flow cytometry data support both NK- and T-cell activation with ianalumab.

CONCLUSIONS: The combination was well tolerated, with 43.6% of patients discontinuing ibrutinib therapy. Biomarker data suggest that ianalumab increased NK- and T-cell activation. These data support further evaluations of ianalumab in combination with Bruton tyrosine kinase inhibitors for patients with CLL.

**中文摘要译文：**
目的：这项Ib期剂量递增/扩展试验（NCT03400176）招募了使用依布替尼未能达到完全缓解（CR）或已产生耐药突变的慢性淋巴细胞白血病（CLL）患者。Ianalumab（VAY736）是一种抗B细胞活化因子受体的单克隆抗体，在临床前慢性淋巴细胞白血病（CLL）模型中，其与依布替尼联合使用可显著改善生存并减少肿瘤负荷。

患者与方法：患者每两周接受一次静脉注射ianalumab（剂量递增阶段：0.3-9.0 mg/kg；扩展阶段：3.0 mg/kg），并继续每日一次口服依布替尼（420 mg），治疗周期为28天，最多进行八个周期。该研究旨在评估此联合方案的安全性、耐受性、推荐剂量及抗肿瘤活性。

结果：共计39名患者接受了治疗（剂量递增阶段：n = 15；扩展阶段：n = 24）。未观察到剂量限制性毒性。在这39名患者中，38.5%在第9周期（C9）时达到了完全缓解或骨髓未完全恢复的完全缓解。在第9周期第1天，17名患者（43.6%）在外周血或骨髓中实现了不可测量的微小残留病。16名患者（41.0%）发生了≥3级的不良事件，其中9名（23.1%）与治疗相关。治疗期间无死亡病例报告；一名患者在治疗后期间因COVID-19死亡。17名患者（43.6%）在第9周期第1天或之后停止了依布替尼治疗，并维持停药状态12.1至24.5个月。初步的RNA测序和流式细胞术数据支持ianalumab可同时激活NK细胞和T细胞。

结论：该联合方案耐受性良好，43.6%的患者能够停止依布替尼治疗。生物标志物数据表明，ianalumab增强了NK细胞和T细胞的活化。这些数据支持在CLL患者中进一步评估ianalumab与布鲁顿酪氨酸激酶抑制剂的联合应用。

### 第二部分 AI 大师评价

本研究旨在评估新型抗体药物Ianalumab联合依布替尼对于依布替尼疗效不佳或耐药的慢性淋巴细胞白血病患者的安全性和有效性。研究通过一项Ib期临床试验证实，该联合方案耐受性良好，并且取得了令人鼓舞的抗肿瘤效果，近四成患者达到了完全缓解，超过四成的患者实现了微小残留病灶阴性并得以停止依布替尼治疗。此研究的创新之处在于探索了BAFF受体和BTK双重抑制的新策略，其促使患者实现“无治疗缓解”的潜力，为CLL的治疗提供了极具价值的新方向，并为后续更大规模的临床试验奠定了坚实基础。

---

## 61. CDK与MEK双重抑制通过诱导高突变负荷头颈癌细胞焦亡，增强CD8+ T细胞介导的抗肿瘤免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41194215](https://pubmed.ncbi.nlm.nih.gov/41194215)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41194215
**DOI：** 10.1186/s13046-025-03557-7

### 第一部分 原文与翻译

**英文原标题：** Dual CDK and MEK Inhibition potentiates CD8 T cell-mediated antitumor immunity by inducing pyroptotic cell death in high-mutational head and neck cancer.

**英文摘要原文：**
BACKGROUND: HPV-negative (-) head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous cancer characterized by high mutational burden, an immunosuppressive microenvironment, and poor response to standard therapies. These features highlight the urgent need for novel and more effective treatment strategies.

METHODS: Drug sensitivity prediction was performed using integrated datasets from TCGA, GDSC, and CCLE. To assess the therapeutic potential and underlying mechanisms of combining the CDK inhibitor AZD5438 with the MEK1/2 inhibitor PD0325901, we employed a comprehensive panel of HNSCC models, including established cell lines, orthotopic mouse tumor models, and patient-derived organoids (PDOs). Lipid nanoparticles (LNPs) were engineered to co-deliver both agents into the same cancer cell populations. The tumor secretome was profiled using biotinylation coupled with liquid chromatography-mass spectrometry (LC-MS). Molecular alterations were examined by immunofluorescence, immunohistochemistry, ELISA, flow cytometry, and Western blot.

RESULTS: Our bioinformatics analysis identified AZD5438 and PD0325901 as two of thirteen candidate drugs whose sensitivity is consistently associated with the five most frequently mutated genes in HPV (-) HNSCC. Notably, among these candidates, AZD5438 and PD0325901 exhibited the lowest correlation in their sensitivity profiles, suggesting complementary mechanisms of action. In experimental models, the combination of AZD5438 and PD0325901 not only outperformed either monotherapy in suppressing tumor growth but also augmented CD8⁺ T cell-mediated antitumor immunity by promoting caspase-8/gasdermin E-dependent pyroptosis. Furthermore, in both orthotopic tumor-bearing mice and PDOs, the LNP-encapsulated drug combination produced significantly greater therapeutic efficacy compared with the free drug formulation.

CONCLUSIONS: Our findings indicate that the combination of AZD5438 and PD0325901 holds therapeutic potential for the treatment of HPV (-) HNSCC, particularly in tumors with a high mutational burden. By targeting complementary pathways, this combination may improve treatment outcomes in this aggressive cancer subtype.

**中文摘要译文：**
背景：HPV阴性（-）头颈部鳞状细胞癌（HNSCC）是一种高度异质性的癌症，其特点是高突变负荷、免疫抑制性微环境以及对标准疗法反应不佳。这些特征凸显了开发新型、更有效治疗策略的迫切需求。

方法：研究使用来自TCGA、GDSC和CCLE的整合数据集进行药物敏感性预测。为评估CDK抑制剂AZD5438与MEK1/2抑制剂PD0325901联合应用的治疗潜力及其潜在机制，我们采用了一系列全面的HNSCC模型，包括已建立的细胞系、原位小鼠肿瘤模型和患者来源的类器官（PDOs）。研究设计了脂质纳米颗粒（LNPs）以将两种药物共同递送至相同的癌细胞群体。采用生物素化偶联液相色谱-质谱联用技术（LC-MS）对肿瘤分泌蛋白组进行了分析。通过免疫荧光、免疫组织化学、ELISA、流式细胞术和Western blot检测分子水平的改变。

结果：我们的生物信息学分析从13种候选药物中筛选出AZD5438和PD0325901，这两种药物的敏感性与HPV（-）HNSCC中五个最常见突变基因持续相关。值得注意的是，在这些候选药物中，AZD5438和PD0325901的敏感性谱相关性最低，表明它们可能具有互补的作用机制。在实验模型中，AZD5438和PD0325901的联合应用在抑制肿瘤生长方面不仅优于任何一种单药治疗，还通过促进caspase-8/gasdermin E依赖性细胞焦亡，增强了CD8⁺ T细胞介导的抗肿瘤免疫。此外，在原位荷瘤小鼠和PDOs中，与游离药物制剂相比，LNP包裹的联合药物显示出显著更强的治疗效果。

结论：我们的研究结果表明，AZD5438与PD0325901的联合应用在治疗HPV（-）HNSCC方面具有治疗潜力，尤其是在高突变负荷的肿瘤中。通过靶向互补的通路，这种联合疗法有望改善这种侵袭性癌症亚型的治疗结局。

### 第二部分 AI 大师评价

本研究旨在为治疗效果不佳的HPV阴性头颈癌寻找新的联合治疗策略。研究通过生物信息学筛选出CDK抑制剂与MEK抑制剂的组合，并利用细胞、动物及患者来源的类器官模型进行了全面验证。其核心发现是，该联合疗法能诱导肿瘤细胞发生焦亡，从而激活CD8+ T细胞的抗肿瘤免疫，这一机制的阐明是本研究的关键创新点。此外，研究采用脂质纳米颗粒（LNP）递送系统提高了疗效，为该方案向临床转化提供了坚实的实验依据和巨大潜力。

---

## 62. 幽门螺杆菌相关胃癌中癌症相关成纤维细胞介导的免疫调控的空间与功能解析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41194113](https://pubmed.ncbi.nlm.nih.gov/41194113)
**期刊：** Molecular cancer
**PMID：** 41194113
**DOI：** 10.1186/s12943-025-02490-9

### 第一部分 原文与翻译

**英文原标题：** Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer.

**英文摘要原文：**
BACKGROUND: Cancer-associated fibroblasts (CAFs) are key regulators of the tumor microenvironment, yet their spatial organization and immunomodulatory functions in H. pylori-associated gastric cancer (GC) remain incompletely understood.

METHODS: We profiled formalin-fixed paraffin-embedded (FFPE) tumors from 71 GC patients using spatial transcriptomics and integrated single-cell RNA-seq from three independent cohorts (China, USA, and Singapore). CAF-immune cell colocalization was quantified by neighborhood enrichment and aggregation index score. Ligand-receptor inference and trajectory analysis resolved CAF signaling and state transitions. To delineate post-transcriptional control, ARE-motif scanning and expression correlations were combined with laser-assisted crosslinking and immunoprecipitation sequencing (LACE-seq) to nominate ZFP36 targets. Immune contexture and prognostic associations were evaluated using CIBERSORT-ABS and Kaplan-Meier analyses in The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) cohorts.

RESULTS: We first defined the spatial distributions of the four CAF subtypes reported in prior studies and found that their immune associations varied across histologic and infection-defined GC subtypes. In H. pylori-positive tumors, THBS1⁺ CAFs were spatially enriched near regulatory T cells (Tregs) and were associated with local immunosuppression through WNT5-FZD interactions. In parallel, ZFP36 bound AU-rich elements within the FN1 3' untranslated region (3'UTR), destabilizing FN1 mRNA and thereby diminishing FN1⁺ CAF-mediated cytotoxic T lymphocyte (CTL) activation. Together, these axes promoted Treg accumulation and suppression of CTL activation.

CONCLUSIONS: These findings reveal infection-associated stromal programs that shape the immune landscape in GC and highlight CAF-directed pathways as potential therapeutic targets in H. pylori-associated GC.

**中文摘要译文：**
背景：癌症相关成纤维细胞（CAFs）是肿瘤微环境的关键调节者，然而其在幽门螺杆菌（H. pylori）相关胃癌（GC）中的空间组织结构和免疫调节功能仍未被完全阐明。

方法：我们利用空间转录组学技术对71例胃癌患者的福尔马林固定石蜡包埋（FFPE）肿瘤进行了分析，并整合了来自三个独立队列（中国、美国和新加坡）的单细胞RNA测序数据。通过邻域富集和聚集指数评分对CAF与免疫细胞的共定位进行量化。配体-受体推断和轨迹分析解析了CAF的信号传导和状态转变。为描绘转录后调控，我们将ARE基序扫描和表达相关性分析与激光辅助交联免疫沉淀测序（LACE-seq）相结合，以提名ZFP36的靶点。利用CIBERSORT-ABS和Kaplan-Meier分析在癌症基因组图谱（TCGA）和亚洲癌症研究组（ACRG）队列中评估了免疫背景和预后关联。

结果：我们首先确定了先前研究报道的四种CAF亚型的空间分布，并发现它们的免疫关联性在不同组织学和感染定义的胃癌亚型中存在差异。在幽门螺杆菌阳性的肿瘤中，THBS1⁺ CAFs在空间上富集于调节性T细胞（Tregs）附近，并通过WNT5-FZD相互作用与局部免疫抑制相关。与此同时，ZFP36与FN1 3'非翻译区（3'UTR）内的富含AU的元件结合，从而破坏FN1 mRNA的稳定性，进而减弱FN1⁺ CAF介导的细胞毒性T淋巴细胞（CTL）的活化。这两个轴共同促进了Treg的积聚并抑制了CTL的活化。

结论：这些发现揭示了在胃癌中塑造免疫景观的感染相关基质程序，并强调了以CAF为导向的通路可作为幽门螺杆菌相关胃癌的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究通过整合空间转录组学与单细胞测序技术，精细解析了幽门螺杆菌相关胃癌中癌症相关成纤维细胞（CAFs）的空间分布及其免疫调节功能。研究的关键发现揭示了两种并行的免疫抑制机制：THBS1⁺ CAFs通过WNT5信号通路促进调节性T细胞富集，同时ZFP36介导的FN1 mRNA降解抑制了细胞毒性T细胞的活化。这项工作不仅在空间维度上深化了对肿瘤微环境复杂性的理解，更精准地指出了针对特定CAF亚型及其调控轴作为治疗幽门螺杆菌相关胃癌的潜在新靶点，具有重要的临床转化价值。

---

## 63. CDK7靶向治疗可有效阻断头颈癌的细胞周期进程和致癌信号传导。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41193441](https://pubmed.ncbi.nlm.nih.gov/41193441)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41193441
**DOI：** 10.1038/s41392-025-02452-z

### 第一部分 原文与翻译

**英文原标题：** CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer.

**英文摘要原文：**
Head and neck squamous cell carcinoma (HNSCC) remains a prevalent and aggressive malignancy, characterized by a lack of targeted therapies and limited clinical benefits. Here, we conducted an optimized whole-genome CRISPR screen across five HNSCC cell lines aimed at identifying actionable genetic vulnerabilities for rapid preclinical evaluation as novel targeted therapies. Given their critical role in cancer, cyclin-dependent kinases (CDKs) were prioritized for further investigation. Among these, CDK7 was identified as an essential and targetable gene across all five cell lines, prompting its selection for in-depth functional and molecular characterization. Genetic and pharmacological inhibition of CDK7 significantly and consistently reduced tumor cell proliferation due to generalized cell cycle arrest and apoptosis induction. Additionally, CDK7 knockout (KO) and selective inhibitors (YKL-5-124 and samuraciclib) demonstrated potent antitumor activity, effectively suppressing tumor growth in HNSCC patient-derived organoids (PDOs), as well as in both cell line- and patient-derived xenograft (PDX) mouse models with minimal toxicity. Mechanistically, CDK7 inhibition led to a broad downregulation of gene sets related to cell cycle progression and DNA repair, and significantly reduced the transcription of essential genes and untargetable vulnerabilities identified by our CRISPR screen. These findings highlight CDK7 as a promising therapeutic target for HNSCC. Our study provides strong evidence of the robust antitumor activity of CDK7-selective inhibition in disease-relevant preclinical models, strongly supporting its progression to clinical testing.

**中文摘要译文：**
头颈部鳞状细胞癌（HNSCC）是一种常见且具有高侵袭性的恶性肿瘤，其特点是缺乏靶向治疗方法且临床获益有限。在本研究中，我们对五种HNSCC细胞系进行了优化的全基因组CRISPR筛选，旨在鉴定出可作为新型靶向疗法进行快速临床前评估的潜在遗传脆弱性。鉴于细胞周期蛋白依赖性激酶（CDKs）在癌症中的关键作用，我们优先对其进行了深入研究。在这些激酶中，CDK7在所有五种细胞系中均被鉴定为一个关键且可靶向的基因，因此我们选择对其进行深入的功能和分子特性研究。通过遗传学和药理学方法抑制CDK7，能够引起广泛的细胞周期停滞和细胞凋亡，从而显著且持续地减少肿瘤细胞的增殖。此外，CDK7基因敲除（KO）以及其选择性抑制剂（YKL-5-124和samuraciclib）在头颈癌患者来源的类器官（PDOs）、细胞系来源和患者来源的异种移植（PDX）小鼠模型中均显示出强大的抗肿瘤活性，有效抑制了肿瘤生长，且毒性极小。从机制上看，抑制CDK7导致与细胞周期进程和DNA修复相关的基因集广泛下调，并显著降低了我们通过CRISPR筛选发现的关键基因和不可靶向脆弱性基因的转录水平。这些发现凸显了CDK7作为HNSCC的一个极具潜力的治疗靶点。我们的研究为CDK7选择性抑制在疾病相关临床前模型中的强大抗肿瘤活性提供了有力证据，强烈支持将其推进到临床试验阶段。

### 第二部分 AI 大师评价

本研究通过全基因组CRISPR筛选技术，创新性地锁定了头颈部鳞状细胞癌（HNSCC）的一个关键治疗靶点——CDK7。研究团队运用基因敲除和选择性抑制剂，在细胞系、患者来源的类器官及异种移植模型中全面验证了抑制CDK7的强大抗肿瘤效果。该研究不仅揭示了CDK7在调控细胞周期和致癌信号中的核心作用，更为重要的是，它为缺乏有效靶向药的HNSCC提供了坚实的临床前证据，有力推动了CDK7抑制剂进入临床试验，具有重要的转化医学价值。

---

## 64. 关于Vepdegestrant用于晚期乳腺癌的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41191951](https://pubmed.ncbi.nlm.nih.gov/41191951)
**期刊：** The New England journal of medicine
**PMID：** 41191951
**DOI：** 10.1056/NEJMc2512877

### 第一部分 原文与翻译

**英文原标题：** Vepdegestrant in Advanced Breast Cancer. Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献并非一篇原创性研究论文，而是一篇“回复”或“读者来信”。其核心目的很可能是对先前发表的关于Vepdegestrant治疗晚期乳腺癌研究的评论或质疑进行回应。此类文献虽不提供新的主要研究数据，但在促进学术讨论、澄清研究细节以及完善科学结论方面扮演着重要角色。它的价值在于展现了科学研究的同行评议和深入探讨过程，有助于读者更全面地理解原始研究的背景和细节。

---

## 65. Vepdegestrant在晚期乳腺癌中的应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41191950](https://pubmed.ncbi.nlm.nih.gov/41191950)
**期刊：** The New England journal of medicine
**PMID：** 41191950
**DOI：** 10.1056/NEJMc2512877

### 第一部分 原文与翻译

**英文原标题：** Vepdegestrant in Advanced Breast Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题明确指出，其核心内容是关于新型药物Vepdegestrant在晚期乳腺癌治疗中的应用。作为发表在顶尖期刊《新英格兰医学杂志》上的文章，这通常预示着一项可能改变临床实践的重要研究。然而，由于原文缺少摘要，我们无法获知该研究的具体设计、关键发现或统计数据，也无法评估其方法的创新性与研究的潜在局限性。尽管如此，该标题本身就揭示了一个内分泌治疗领域的前沿方向，提示Vepdegestrant可能为晚期乳腺癌患者带来新的治疗选择，具有重要的临床关注价值。

---

## 66. Vepdegestrant治疗晚期乳腺癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41191949](https://pubmed.ncbi.nlm.nih.gov/41191949)
**期刊：** The New England journal of medicine
**PMID：** 41191949
**DOI：** 10.1056/NEJMc2512877

### 第一部分 原文与翻译

**英文原标题：** Vepdegestrant in Advanced Breast Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文标题表明其内容聚焦于一种名为Vepdegestrant的新型药物在晚期乳腺癌治疗中的应用。发表于《新英格兰医学杂志》这一顶级期刊，预示着该主题具有重要的临床关注度。然而，由于文献缺乏摘要，无法就其具体研究设计、关键发现或创新性进行深入评价，但其标题本身已突显了在内分泌治疗领域的潜在进展。

---

## 67. 乳腺癌乳房切除术后省略胸壁放疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41191945](https://pubmed.ncbi.nlm.nih.gov/41191945)
**期刊：** The New England journal of medicine
**PMID：** 41191945
**DOI：** 10.1056/NEJMe2512077

### 第一部分 原文与翻译

**英文原标题：** Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

基于文献标题和其发表于《新英格兰医学杂志》（NEJM）这一顶级期刊，可以推断该文很可能是一篇重要的编辑评论或观点文章。该文的核心议题是探讨乳腺癌患者在接受乳房切除术后，是否可以安全地省略胸壁放射治疗。此类研究旨在优化治疗方案，通过精准识别低复发风险患者，在不牺牲疗效的前提下，帮助其避免放疗带来的短期及长期毒副作用，从而改善生活质量。这篇文章的发表标志着乳腺癌局部治疗策略正在向更个体化、更精简化的方向发展，对临床实践具有重要的指导意义。

---

## 68. 乳腺癌乳房切除术后胸壁放疗的十年生存分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41191939](https://pubmed.ncbi.nlm.nih.gov/41191939)
**期刊：** The New England journal of medicine
**PMID：** 41191939
**DOI：** 10.1056/NEJMoa2412225

### 第一部分 原文与翻译

**英文原标题：** Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.

**英文摘要原文：**
BACKGROUND: The role of postmastectomy chest-wall irradiation in patients with breast cancer classified as pN1 (with involvement of one to three axillary nodes) or pN0 (pathologically node negative) with additional risk factors is uncertain.

METHODS: In this international, phase 3, randomized trial, we evaluated the omission of chest-wall irradiation in women with "intermediate-risk" breast cancer - defined as cancer that was stage pT1N1, pT2N1, or pT3N0 or stage pT2N0 with a histologic grade of 3, lymphovascular invasion, or both (tumor size: T1, ≤2 cm; T2, >2 cm to 5 cm; or T3, >5 cm) - that was treated with mastectomy, an axillary procedure, and systemic therapy. Patients were assigned to undergo chest-wall irradiation (40 to 50 Gy; the irradiation group) or not to undergo chest-wall irradiation (the no-irradiation group). The primary end point was overall survival, with 10 years of follow-up. Chest-wall recurrence, regional recurrence, disease-free survival, distant metastasis-free survival, causes of death, and radiation-related adverse events were also assessed.

RESULTS: The intention-to-treat population included 808 patients in the irradiation group and 799 in the no-irradiation group. The median follow up was 9.6 years. Overall survival was 81.4% with chest-wall irradiation and 81.9% with no chest-wall irradiation according to 10-year Kaplan-Meier estimates (hazard ratio for death, 1.04; 95% confidence interval [CI], 0.82 to 1.30; P = 0.80). A total of 29 patients had a chest-wall recurrence - 9 (1.1%) in the irradiation group and 20 (2.5%) in the no-irradiation group (between-group difference, <2 percentage points; hazard ratio, 0.45; 95% CI, 0.20 to 0.99). Disease-free survival was 76.2% in the irradiation group and 75.5% in the no-irradiation group (hazard ratio for recurrence or death, 0.97; 95% CI, 0.79 to 1.18), and distant metastasis-free survival was 78.2% and 79.2%, respectively (hazard ratio for distant metastasis or death, 1.06; 95% CI, 0.86 to 1.31).

CONCLUSIONS: In this trial, chest-wall irradiation did not result in higher overall survival than no chest-wall irradiation among patients with intermediate-risk, early breast cancer treated with mastectomy and contemporary adjuvant systemic therapy. (Funded by the Medical Research Council and others; SUPREMO ISRCTN Clinical Study Registry number, 61145589.).

**中文摘要译文：**
背景：对于伴有其他风险因素、分期为pN1（1-3个腋窝淋巴结受累）或pN0（病理学淋巴结阴性）的乳腺癌患者，乳房切除术后胸壁放疗的作用尚不确定。

方法：在这项国际性、3期、随机试验中，我们评估了对接受乳房切除术、腋窝处理和全身性治疗的“中等风险”乳腺癌女性省略胸壁放疗的效果。中等风险定义为分期为pT1N1、pT2N1、pT3N0，或分期为pT2N0且组织学分级为3级、存在淋巴血管侵犯或两者兼有（肿瘤大小：T1, ≤2 cm; T2, >2 cm至5 cm; 或T3, >5 cm）。患者被分配接受胸壁放疗（40至50 Gy；放疗组）或不接受胸壁放疗（无放疗组）。主要终点是总生存期，随访时间为10年。同时，我们还评估了胸壁复发、区域复发、无病生存期、无远处转移生存期、死亡原因以及与放疗相关的不良事件。

结果：意向治疗人群包括放疗组的808名患者和无放疗组的799名患者。中位随访时间为9.6年。根据10年Kaplan-Meier估计，放疗组的总生存率为81.4%，无放疗组为81.9%（死亡风险比为1.04；95%置信区间[CI]为0.82至1.30；P=0.80）。共有29名患者出现胸壁复发——放疗组9名（1.1%），无放疗组20名（2.5%）（组间差异<2个百分点；风险比为0.45；95% CI为0.20至0.99）。放疗组的无病生存率为76.2%，无放疗组为75.5%（复发或死亡的风险比为0.97；95% CI为0.79至1.18）；两组的无远处转移生存率分别为78.2%和79.2%（远处转移或死亡的风险比为1.06；95% CI为0.86至1.31）。

结论：在本试验中，对于接受乳房切除术和现代辅助全身性治疗的中等风险早期乳腺癌患者，与不进行胸壁放疗相比，进行胸壁放疗并未带来更高的总生存率。（由医学研究理事会等资助；SUPREMO ISRCTN临床研究注册号：61145589）。

### 第二部分 AI 大师评价

本研究是一项发表于《新英格兰医学杂志》的大规模国际3期随机对照试验，旨在明确对于接受了乳房切除术和现代全身治疗的中等风险早期乳腺癌患者，省略术后胸壁放疗是否会影响其长期生存。研究关键发现，经过近十年的随访，与不放疗相比，胸壁放疗虽然降低了局部复发风险，但并未改善患者的总生存率、无病生存率或无远处转移生存率。该研究结果具有重大的临床实践指导意义，为特定患者群体的治疗“降阶梯”提供了高级别证据，可能改变临床指南，使部分患者免于不必要的放疗及其带来的毒副作用和经济负担，是乳腺癌精准治疗领域的又一重要进展。

---

## 69. 人工智能在血液学领域的应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40845137](https://pubmed.ncbi.nlm.nih.gov/40845137)
**期刊：** Blood
**PMID：** 40845137
**DOI：** 10.1182/blood.2025029876

### 第一部分 原文与翻译

**英文原标题：** Artificial intelligence in hematology.

**英文摘要原文：**
Artificial intelligence (AI) and its subdiscipline, machine learning (ML), have the potential to revolutionize health care, including hematology. The diagnosis and treatment of hematologic disorders depend on the integration of diverse data sources, such as imaging, pathology, omics, and laboratory parameters. The increasing volume and complexity of patient data have made clinical decision-making more challenging. AI/ML hold significant potential for enhancing diagnostic accuracy, risk stratification, and treatment response prediction through advanced modeling techniques. Generative AI, a recent advancement within the broader field of AI, is poised to have a profound impact on health care and hematology. Generative AI can enhance the development of novel therapeutic strategies, improve diagnostic workflows by generating high-fidelity images or pathology reports, and facilitate more personalized approaches to patient management. Its ability to augment clinical decision-making and streamline research represents a significant leap forward in the field. However, despite this potential, few AI/ML tools have been fully implemented in clinical practice due to challenges related to data quality, equity, advanced infrastructure, and the establishment of robust evaluation metrics. Despite its promise, AI implementation in hematology faces critical challenges, including bias, data quality issues, and a lack of regulatory frameworks and safety standards that keep pace with rapid technological advancements. In this review, we provide an overview of the current state of AI/ML in hematology as of 2025, identify existing gaps, and offer insights into future developments.

**中文摘要译文：**
人工智能（AI）及其子学科机器学习（ML）具有彻底改变医疗保健（包括血液学）的潜力。血液系统疾病的诊断和治疗有赖于对影像学、病理学、组学和实验室参数等多种数据源的整合。日益增长的患者数据量和复杂性使得临床决策变得更具挑战性。通过先进的建模技术，AI/ML在提高诊断准确性、风险分层和治疗反应预测方面拥有巨大潜力。生成式AI作为AI领域的最新进展，势必将对医疗保健和血液学产生深远影响。生成式AI能够通过生成高保真图像或病理报告来促进新治疗策略的开发、改善诊断流程，并推动更个性化的患者管理方法。其增强临床决策和简化研究的能力代表了该领域的一次重大飞跃。然而，尽管潜力巨大，但由于数据质量、公平性、先进基础设施以及稳健评估指标建立等方面的挑战，很少有AI/ML工具在临床实践中得到全面实施。尽管前景广阔，AI在血液学领域的实施仍面临严峻挑战，包括偏见、数据质量问题，以及缺乏与技术快速发展同步的监管框架和安全标准。在这篇综述中，我们概述了截至2025年AI/ML在血液学领域的应用现状，指出了存在的差距，并对未来发展提出了见解。

### 第二部分 AI 大师评价

本研究是一篇前瞻性综述，旨在系统总结截至2025年人工智能（AI）及机器学习（ML）在血液学领域的应用现状、关键进展与未来方向。文章重点阐述了AI技术，特别是生成式AI，在整合多源数据以提升诊断精度、风险分层及治疗预测方面的巨大潜力。同时，该综述也深刻指出了数据质量、算法偏见及监管缺失等阻碍技术临床转化的核心挑战，为该领域的未来研究和实践提供了重要的参考框架和前瞻性思考。

---

## 70. 多组学分析揭示高危型NK细胞型慢性活动性EBV感染的遗传与表观遗传特征

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40737598](https://pubmed.ncbi.nlm.nih.gov/40737598)
**期刊：** Blood
**PMID：** 40737598
**DOI：** 10.1182/blood.2024026805

### 第一部分 原文与翻译

**英文原标题：** Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.

**英文摘要原文：**
Chronic active Epstein-Barr virus (EBV) infection (CAEBV) is an orphan disease characterized by the proliferation and infiltration of EBV-infected T/natural killer (NK) cells into multiple organs. Although CAEBV is a heterogeneous disease with diverse clinical courses, its pathogenesis remains poorly understood. In this study, we explored the molecular mechanisms underlying CAEBV by performing a comprehensive multiomics analysis, including genome, transcriptome, epigenome, and single-cell transcriptome and surface proteome analyses, of 65 patients with CAEBV. Methylation analysis identified 2 distinct subtypes of NK cell-type CAEBV based on the CpG island methylator phenotype (CIMP). In CIMP-positive CAEBV, regions associated with enhancer of zeste homolog 2 binding sites and histone H3 lysine 27 trimethylation exhibited increased DNA hypermethylation, resulting in downregulation of tumor suppressor and antiherpesvirus genes. CIMP-positive CAEBV had a particularly poor prognosis and displayed a "neoplastic" phenotype with a DNA methylation pattern similar to that of extranodal NK/T-cell lymphoma, a higher tumor mutation burden, and frequent copy number alterations. In addition, both in vitro and in vivo functional assays demonstrated that 5-azacytidine, a hypomethylating agent, was a potentially effective agent for high-risk CIMP-positive CAEBV. Finally, we established a method to effectively detect EBV-infected cells in single-cell analysis, suggesting that EBV-infected NK cells have tissue-resident properties and that innate and adaptive immunity to EBV is compromised in patients with CAEBV. The present findings provide insight into the complex molecular features of CAEBV and suggest potential molecular therapies.

**中文摘要译文：**
慢性活动性爱泼斯坦-巴尔病毒（EBV）感染（CAEBV）是一种罕见病，其特征是EBV感染的T/自然杀伤（NK）细胞增殖并浸润至多个器官。尽管CAEBV是一种具有多种临床病程的异质性疾病，但其发病机制仍知之甚少。在本研究中，我们对65例CAEBV患者进行了全面的多组学分析，包括基因组、转录组、表观基因组以及单细胞转录组和表面蛋白质组分析，以探索CAEBV的潜在分子机制。甲基化分析根据CpG岛甲基化表型（CIMP）确定了NK细胞型CAEBV的两种不同亚型。在CIMP阳性CAEBV中，与zeste同源物增强子2结合位点和组蛋白H3赖氨酸27三甲基化相关的区域表现出DNA高甲基化增强，导致肿瘤抑制基因和抗疱疹病毒基因的下调。CIMP阳性CAEBV的预后尤其差，并表现出一种“肿瘤性”表型，其DNA甲基化模式与结外NK/T细胞淋巴瘤相似，具有更高的肿瘤突变负荷和频繁的拷贝数变异。此外，体外和体内功能性试验均表明，去甲基化药物5-氮杂胞苷是治疗高危CIMP阳性CAEBV的潜在有效药物。最后，我们建立了一种在单细胞分析中有效检测EBV感染细胞的方法，表明EBV感染的NK细胞具有组织驻留特性，并且CAEBV患者对EBV的先天性和适应性免疫功能受损。本研究结果为了解CAEBV复杂的分子特征提供了新见解，并提示了潜在的分子治疗方法。

### 第二部分 AI 大师评价

本研究采用前沿的多组学整合分析方法，系统性地揭示了高危型NK细胞型慢性活动性EBV感染（CAEBV）的遗传与表观遗传全景。其核心创新在于，首次通过甲基化分析将该疾病划分为两种具有显著预后差异的亚型（CIMP阳性与阴性），并阐明了CIMP阳性亚型高风险的表观遗传机制。更重要的是，研究不仅发现了该亚型与淋巴瘤的分子相似性，还通过功能实验验证了去甲基化药物的潜在疗效，为临床治疗提供了新的靶点和策略，具有重要的转化医学价值。

---

## 71. 疾病风险而非缓解状态决定AML的移植结局：ASAP试验的长期结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40737595](https://pubmed.ncbi.nlm.nih.gov/40737595)
**期刊：** Blood
**PMID：** 40737595
**DOI：** 10.1182/blood.2025028730

### 第一部分 原文与翻译

**英文原标题：** Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

**英文摘要原文：**
Attempting to induce a complete remission before allogeneic hematopoietic cell transplant (alloHCT) is current practice in patients with acute myeloid leukemia (AML). However, benefit of remission induction strategy (RIST) before alloHCT has never been proven in a prospective trial. Potent conditioning regimens exist that allow for successful alloHCT in patients with active AML. Therefore, the ASAP trial was conducted to test RIST by salvage chemotherapy before alloHCT against immediate transplant after intensified conditioning. In total, 281 patients with AML with poor response after first induction or untreated first relapse were randomized 1:1 to RIST with high-dose cytarabine plus mitoxantrone vs immediate alloHCT with sequential conditioning after nonintensive disease control (DisC) measures, preferentially watchful waiting only. Overall survival at 5 years from randomization analyzed according to intention-to-treat was 46.1% for DisC vs 47.5% for RIST (P = .82). In multivariable Cox regression analysis, genetic AML risk according to European LeukemiaNet criteria (P < .0001), age (P = .001), and comorbidities (P = .046) predicted survival, but not treatment arm (hazard ratio, 1.08 for DisC vs RIST; P = .67). In conclusion, long-term follow-up of the ASAP trial showed no survival advantage for standard salvage chemotherapy before alloHCT as opposed to immediate alloHCT. The trial results question the general concept of RIST with intensive standard salvage therapy before alloHCT for all patients, because immediate alloHCT may reduce time in hospital and health care expenses. Novel bridging therapies that are well tolerated, and posttransplant maintenance with targeted drugs are urgently warranted, especially for adverse-risk AML, to improve outcomes after alloHCT. This trial was registered at www.ClinicalTrials.gov as #NCT02461537.

**中文摘要译文：**
在急性髓系白血病（AML）患者中，异基因造血细胞移植（alloHCT）前诱导完全缓解是当前的标准实践。然而，alloHCT前采用缓解诱导策略（RIST）的获益从未在前瞻性试验中得到证实。现有的强效预处理方案使得对活动性AML患者成功进行alloHCT成为可能。因此，开展了ASAP试验，旨在比较alloHCT前的挽救性化疗诱导缓解策略（RIST）与强化预处理后立即进行移植的策略。总共281名首次诱导治疗反应不佳或未经治疗的首次复发的AML患者，被1:1随机分配至接受大剂量阿糖胞苷联合米托蒽醌的RIST组，或在采取非强化疾病控制（DisC）措施（优先选择仅观察等待）后，接受序贯预处理并立即进行alloHCT的组。根据意向性治疗分析，自随机化起的5年总生存率，DisC组为46.1%，RIST组为47.5%（P = .82）。在多变量Cox回归分析中，根据欧洲白血病网（European LeukemiaNet）标准的AML遗传学风险（P < .0001）、年龄（P = .001）和合并症（P = .046）可预测生存，但治疗分组并非预测因素（DisC组 vs RIST组的风险比为1.08；P = .67）。总之，ASAP试验的长期随访结果显示，与立即进行alloHCT相比，alloHCT前进行标准挽救性化疗并无生存优势。该试验结果对所有患者在alloHCT前都采用强化标准挽救治疗进行RIST的普适性概念提出了质疑，因为立即进行alloHCT或许能减少住院时间和医疗开销。迫切需要耐受性良好的新型桥接疗法以及移植后使用靶向药物的维持治疗，特别是对于高危风险AML，以改善alloHCT后的结局。该试验已在www.ClinicalTrials.gov注册，注册号为 #NCT02461537。

### 第二部分 AI 大师评价

本研究通过一项前瞻性随机对照试验（ASAP试验），旨在挑战急性髓系白血病（AML）治疗中的一个核心常规：即在异基因移植前必须先通过挽救化疗诱导缓解。研究关键发现，对于首次诱导无效或首次复发的AML患者，直接进行移植与先进行挽救化疗的5年总生存率并无显著差异。此项研究的长期随访结果具有重大的临床指导意义，它表明患者的遗传学风险而非移植前的缓解状态是决定预后的关键因素，提示对于部分患者，直接移植或是一种更优的策略，有望缩短住院时间并降低医疗成本。

---

## 72. BCMA-mRNA疫苗：一种有前景的多发性骨髓瘤治疗方法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40700574](https://pubmed.ncbi.nlm.nih.gov/40700574)
**期刊：** Blood
**PMID：** 40700574
**DOI：** 10.1182/blood.2025028597

### 第一部分 原文与翻译

**英文原标题：** A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.

**英文摘要原文：**
Cancer vaccines are emerging as promising therapies to not only prevent cancer but to treat cancer. Here, we developed a therapeutic vaccine for multiple myeloma (MM) using B-cell maturation antigen (BCMA) protein as a target. Given the remarkable efficacy of COVID-19 messenger RNA (mRNA) vaccines, we first packaged sequence- and base-optimized BCMA mRNA into lipid nanoparticles (LNPs) using next-generation ionizable lipid, enhancing their accumulation in the spleen. A toll-like receptor 3 agonist, polyinosinic:polycytidylic acid [poly(I:C)], was also encapsulated in LNPs to further elicit BCMA-specific immune response. BCMA-mRNA LNPs were internalized by dendritic cells (DCs) in vitro, triggering proliferation and activation of BCMA-specific CD8+ cytolytic T cells (CTLs). Importantly, these CTLs lysed BCMA+ U266 MM cells and CD138+ patient MM cells, without affecting BCMA-knockout U266 or CD138- patient-derived bone marrow cells. Vaccination of C57BL/6J mice with BCMA-mRNA LNPs activated splenic DCs and induced BCMA-specific CTLs, assessed by tetramer staining, which selectively killed murine 5TGM1 BCMA overexpressing MM cells. Finally, vaccination of C57BL/KaLwRijHsd mice bearing BCMA-overexpressing 5TGM1 cells inhibited tumor growth associated with BCMA-specific CD8+ T-cell responses. The combination treatment with poly(I:C) further triggered the immune response induced by BCMA-mRNA LNPs in all instances. Our findings provide the framework for clinical evaluation of BCMA-mRNA LNP vaccines to improve patient outcome in MM.

**中文摘要译文：**
癌症疫苗正作为一种有前景的疗法崭露头角，其不仅能预防癌症，还能治疗癌症。在此，我们以B细胞成熟抗原（BCMA）蛋白为靶点，开发了一种用于治疗多发性骨髓瘤（MM）的治疗性疫苗。鉴于COVID-19信使RNA（mRNA）疫苗的出色疗效，我们首先采用新一代可电离脂质，将序列和碱基优化后的BCMA mRNA包装入脂质纳米颗粒（LNP）中，以增强其在脾脏中的蓄积。同时，我们将Toll样受体3激动剂聚肌苷酸：聚胞苷酸[poly(I:C)]也封装在LNP中，以进一步激发BCMA特异性的免疫反应。在体外实验中，BCMA-mRNA LNP能被树突状细胞（DC）内吞，从而触发BCMA特异性CD8+细胞毒性T淋巴细胞（CTL）的增殖和活化。重要的是，这些CTL能够裂解BCMA阳性的U266 MM细胞和CD138阳性的患者MM细胞，而对BCMA基因敲除的U266细胞或CD138阴性的患者来源骨髓细胞无影响。为C57BL/6J小鼠接种BCMA-mRNA LNP疫苗后，激活了其脾脏DC并诱导产生了BCMA特异性的CTL（经四聚体染色评估），这些CTL能选择性地杀伤过表达BCMA的鼠源5TGM1 MM细胞。最后，在荷载过表达BCMA的5TGM1细胞的C57BL/KaLwRijHsd小鼠模型中，疫苗接种抑制了肿瘤生长，并与BCMA特异性的CD8+ T细胞反应相关。在所有实验中，与poly(I:C)联合治疗均能进一步增强BCMA-mRNA LNP诱导的免疫反应。我们的研究结果为BCMA-mRNA LNP疫苗的临床评估提供了框架，旨在改善MM患者的预后。

### 第二部分 AI 大师评价

本研究旨在开发一种靶向B细胞成熟抗原（BCMA）的mRNA治疗性疫苗，用于治疗多发性骨髓瘤。研究人员巧妙地运用了先进的mRNA-脂质纳米颗粒(LNP)技术，并联用免疫佐剂以增强疫苗效果。研究结果表明，该疫苗能成功诱导机体产生特异性T细胞，有效识别并杀伤多发性骨髓瘤细胞，最终在动物模型中抑制了肿瘤生长。此项研究将成熟的mRNA疫苗技术创新性地应用于多发性骨髓瘤治疗，为开发新型、高效的肿瘤免疫疗法提供了强有力的临床前证据和理论基础。

---

速递结束，祝您工作愉快！